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Summary
DHEA is an adrenal derived hormone with a unique secretory pattern with highest serum 
concentrations observed in middle age. Individuals with adrenal insufficiency exhibit 
gross DHEA deficiency though its replacement in this context is not commonplace. 
DHEA is known to behave as a pro-hormone with the ability to be converted into either 
androgenic or oestrogenic terminal hormones; whether this is its sole physiological role 
still remains unclear.
Various animal and in vitro studies have suggested that treatment with DHEA can 
precipitate improvements in body fat, adipocytokine profiles, insulin resistance and 
estimates of vascular disease. Human studies have demonstrated inconsistent results and 
have tended to focus on the physiological deficiency of DHEA associated with normal 
aging and not the pathological DHEA deficiency seen in adrenal insufficiency.
The aims of this thesis were: (1) To determine the effect of DHEA on preadipocyte (cell 
line and primary) proliferation and differentiation and to examine the mechanisms behind 
any observed effects. (2) To evaluate the effect of replacing DHEA on vascular function 
and body composition in subjects with primary and secondary adrenal insufficiency.
(1) DHEA inhibited proliferation in all preadipocytes examined secondary, at least in 
part, to cell cycle blockade. DHEA inhibited adipogenesis in omental but not 
subcutaneous derived preadiocytes. (2) Arterial stiffness and endothelial function was not 
affected the total population but stratification by study group showed that DHEA 
replacement reduced central blood pressure in patients with secondary adrenal 
insufficiency. Body composition was not affected in either subject group.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 Dehydroepiandrosterone
1.1.1 Overview
Dehydroepiandrosterone (DHEA) is a precursor sex steroid which, in common with all 
adrenal steroids, is derived from the parent molecule cholesterol. It was first identified in 
its sulphated form, dehydroepiandrosterone sulphate (DHEAS), in 1954 by Migeon and 
Plager [1] and was the first hormone with androgenic activity to be isolated from human 
plasma. Subsequent studies have shown that DHEA and DHEAS are present in the 
human and higher primate circulation in higher concentrations than any other steroid 
hormone [2], though levels decline dramatically after middle age [3,4]. This age-related 
fall in concentration has led to speculation as to whether this physiological reduction in 
DHEA is causally related to disease processes normally associated with aging. This in 
turn has driven a market in sales of DHEA, particularly in the USA and on the internet 
where it is easily available as a food supplement. However, the precise physiological role 
of DHEA remains uncertain despite a variety of epidemiological studies demonstrating an 
inverse correlation with some features of the metabolic syndrome (obesity [5, 6 ], insulin 
resistance [7]) as well as cardiovascular morbidity and mortality [8 , 9]. Furthermore, 
interventional studies in women (postmenopausal and those with hypoadrenalism) have 
demonstrated improvements in insulin sensitivity following DHEA therapy [10, 11]. 
Currently however, the somewhat limited evidence base for DHEA use in the clinical 
setting is largely confined to females with adrenal insufficiency in whom there is a failure 
to achieve adequate quality of life with or without reduced libido, despite optimal 
glucocorticoid and mineralocorticoid replacement [12, 13]. Nevertheless a plethora of
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other uses have been suggested for DHEA in a diverse variety of conditions, ranging 
from infectious diseases to Alzheimer’s disease [14-22].
1.1.2 DHEA Structure
All adrenal steroids which are derived from cholesterol share the same basic structure 
comprising a cylcopentenophenanthrene nucleus made up of three six-carbon rings 
(A, B, C) and one five-carbon ring (D). The rings are fused in the trans position to 
produce a planar structure with a hydrophobic side chain (Fig 1.1).
O
CH
CH
HO
A B C D
HO -  hydroxyl group 
CH3 -  methyl group
Fig 1.1 Structure of DHEA
Each DHEA molecule contains a double bond in ring B and a hydroxyl group in ring A. 
This hydroxyl group is substituted for a sulphate group to produce DHEAS and this small
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change in the structure reduces membranous transport potential. Changes within the side 
chain located on ring D occur with the generation of different terminal hormones. Again, 
small changes here can provoke profound effects on activity and potency.
1.1.3 Synthesis of DHE A
Various enzymatically controlled pathways are involved in the generation of steroid 
hormones [23] .Cholesterol is the common precursor to all adrenal steroids. The primary 
and rate-limiting step in the conversion of cholesterol into functioning steroids involves 
the cleavage of a 6 -carbon group. This reaction is governed by the mitochondrial enzyme 
P450-linked side chain cleaving enzyme (P450-LSCCE) also known as cholesterol 
desmolase or CYP11A which is only found in significant quantities in steroid-producing 
cells. Regulation of this enzyme occurs in two distinct ways: short-term regulation is 
governed by cyclic adenosine monophosphate (cAMP) which, via stimulation of cAMP- 
dependent protein kinase A (PKA), leads to phosphorylation of cholesterol-ester esterase 
and increases cholesterol concentrations, the primary reaction substrate. Long-term 
regulation occurs at the level of the P450-LSCCE gene whose promoter contains a cAMP 
response element. Binding of cAMP here increases transcription of P450-LSCCE. The 
system also possesses a negative feedback loop, whereby cholesterol inhibits the enzyme 
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG CoA reductase). This enzyme 
catalyses the first step in the cholesterol production pathway and is also the target 
element for the Statin group of pharmacological agents. Activity of the P450-LSCCE 
produces pregnenolone which is the common precursor to glucocorticoids, 
mineralocorticoids and adrenal androgens. Once generated, pregnenolone passes into the
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cytosol of cells within the zona reticularis of the adrenal cortex (Fig 1.2). The steroid- 
producing cells located in this zone possess CYP17 (17, 20 Lyase/17a- 
hydroxylase/P450cl7) located at the endoplasmic reticulum. Firstly this enzyme catalyses 
the 17a-hydroxylation of pregnenolone producing pregnenolone sulphate then cleaves 2  
carbon atoms to produced the 19 carbon ring structure of DHEA.
CHOLESTEROL
ZONA RETICULARIS
Mitochondria CYP11A
PREGNENOLONE
CYP17
17-OH Pregnenolone
CYP17
DEHYDROEPIANDROSTERONE
Fig 1.2 Synthesis pathway of DHEA
Once synthesised, DHEA is exposed to the enzyme 3p-hydroxysteroid dehydrogenase to 
generate androstenedione (Fig 1.3). Cells located within the other zones of the adrenal
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cortex contain enzyme cascades that generate the terminal hormones aldosterone and 
cortisol.
Pregnenolone
17a-OH Pregnenolone
DHEA
Progesterone
B
17a-OH Progesterone
C
Androstenedione H
19-OH
Androstenedione
DHEAS TestosteroneAndrostenediol
A. 3p-hydroxysteroid dehydrogenase
B. 17-hydroxylase
C. C1(M9desm olase/Lyase
0 . Steroid sulphatase
E. Steroid sulphotransferase
F. 17p-hydroxysteriod dehydrogenase
G. 5a-reductase
H. 19-hydroxylase
1. Aromatase
Di hydrotestosterone
l/H
Oestrone
Oestradiol
Fig 1.3 Metabolism of DHEA
1.1.4 Interconversion of DHEA and DHEAS
DHEAS, the sulphated conjugate of DHEA is quantitatively the most important androgen 
secreted by the adrenal cortex and is almost exclusively produced in the adrenal gland. 
DHEAS can be considered the hydrophilic circulating form whereas DHEA is lipophylic 
and can undergo membranous transport. DHEAS may be produced either from sulphation 
of DHEA or directly from pregnenolone sulphate [24, 25]. DHEA and DHEAS have been 
demonstrated to have androgenic activity relative to testosterone; DHEA exhibiting
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relatively more androgenic activity than DHEAS [26]. There is continual flux between 
DHEA and DHEAS under the influence of converting enzymes. DHEA is converted to 
DHEAS by the activity of Sulphotransferase which replaces the terminal hydroxyl group 
with a sulphate group. Identical sulphotransferases have been identified in both human 
adult and foetal adrenal tissue [27]. Furthermore , DHEAS has been located in 
supernatants from human liver and jejunal cultures [28]. The opposite reaction (DHEAS 
to DHEA) is controlled by Steroid sulphatase (Fig 1.4) which has been identified in 
human adrenal, testicular and ovarian tissue [29] as well as on human lymphocytes [30], 
in pulmonary tissue and the pulmonary vasculature [31]; hence many cells within the 
body contain the metabolic machinery to bring about DHEA to DHEAS conversion and 
vice versa.
DHEA
CH
CH
HO
DHEAS CH3
sulphotransferase
c h 3
Steroid sulphatase
SO4
Fig 1.4 Interconversion of DHEA to DHEAS 
However, recent evidence suggests that DHEAS is less readily converted back into active 
DHEA, hence DHEA/DHEAS ratios will vary predominantly according to 
Sulphotransferase activity [32].
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DHEAS is routinely assayed during endocrinological assessment of androgenic status in 
females; approximately 20% of Caucasian and up to 30% of black females with a 
diagnosis of polycystic ovarian syndrome have elevated serum concentrations [33].
1.1.5 Protein binding
DHEA exists in the circulation mostly bound to albumin [34] with a smaller portion 
bound to sex hormone binding globulin (SHBG) (Fig 1.5), in contrast to testosterone and 
oestradiol which are bound principally to SHBG. More DHEA is found bound to SHBG 
in females particulary during pregnancy when SHBG levels rise. Furthermore, a larger 
percentage of DHEA exists in the circulation in the unbound state compared to 
testosterone and oestrogen. All three hormones are similar in that very little binding 
occurs with cortisol binding globulin [35].
Male Female (Follicular)
4.13%
Unbound
92.4%
ALBUMIN
SHBG
CBG
3 .93%
Unbound
88.1%
Fig 1.5 Transport of DHEA as a percentage concentration in each fraction (SHBG -  sex 
hormone binding globulin, CBG - cortisol binding globulin) adapted from Dunn et al [35]
1.1.6 Metabolism
Once in the intracellular compartment DHEA can be converted enzymatically into either 
androgenic or oestrogenic terminal hormones. DHEA is converted to androstenedione by 
3p-hydroxysteroid dehydrogenase (3p-HSD). The structure of this membrane bound 
enzyme was only determined in 1989 [36] and its expression has since been confirmed in 
skin, adipose tissue, breast, lung, endometrium, prostate, liver, kidney, epididymis and 
brain tissue as well as in placental, adrenal, ovarian and testicular sites [37-40]. This once 
more indicates that there is widespread peripheral utilisation of DHEA. Because of its 
position upstream of oestradiol formation, inhibition of 3P-HSD has been proposed as a 
potential treatment for oestrogen sensitive malignancies [41, 42]. Androstenedione can 
be converted to testosterone by 17p-hydroxysteroid dehydrogenase (17-pHSD). A 
number of different types of 17P-HSD have been identified, some catalysing the forward 
or reduction reaction (types 1, 3, 5, 12 and 13) and others the reverse or oxidative 
reaction (types 2, 4, 6  and 8 ) [43-46]. Testosterone can in turn be converted to 
dihydrotestosterone through the action of 5a-reductase. 5a-reductase exists in 2 isoforms, 
called type 1 and type 2, with type 1 being predominantly expressed in skin [47] and a 
deficiency in type 2 being a recognised cause of male undermasculinisation [48]. 
Androstenedione is converted to 19-OH androstenedione by 19-hydroxylase before 
undergoing aromatisation to oestrone. Testosterone is converted directly to oestradiol, 
again through aromatisation. Oestrone can also be converted into oestradiol via the 
activity of 17p-HSD (Fig 1.3).
In both men and women most sex steroid production therefore proceeds through DHEA 
[49] and in post menopausal women all oestrogens and most androgens are generated in 
peripheral tissue from DHEA. The relative amounts of androgen or oestrogen produced
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depends on the tissue concerned and the relative expression and activity of converting 
enzymes present. These enzymes are distributed extensively within the body indicating 
widespread terminal hormone production [39, 50].
Utilisation of DHEA may be sex-dependent. In DHEA deficient individuals, DHEA 
replacement results in a sexually dimorphic pattern of hormone production: in DHEA 
deficient men there is preferential bioconversion of DHEA to oestrogens and in women to 
androgens [51-53]. DHEA replacement may therefore exert different metabolic effects in 
men and women mediated through oestrogen and androgen respectively.
1.1.7 Secretion
DHEA is synthesised at rates of 16.34 ± 2.60 mg/24 hours in men and 16.19 ± 1.78 
mg/24 hours in women [54] and has a normal adult plasma concentration range of 2.4-9.5 
ng/mL [54-56]. DHEA has a short plasma half-life (approximately 25 minutes) which is 
attributed to rapid conversion into the sulphated ester DHEAS [57]. Concentrations of 
DHEAS are higher (1839 ± 320 ng/mL) than DHEA [56] and DHEAS is thought to 
represent a circulating pool ready to be converted into DHEA and then into further 
downstream metabolites.
Serum concentration of DHEAS is slightly higher in males compared to females. 
Furthermore, serum levels of DHEAS are significantly greater than those of DHEA (pM 
compared to nM), and vary less over a 24 hour period [55]. DHEAS also has a lower 
metabolic clearance rate than DHEA [57], these factors therefore dictate that a large 
plasma pool of DHEAS exists and the majority of DHEA is excreted as the sulphated 
conjugate [34].
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Secretion of adrenal androgens and glucocorticoids is predominantly under the control of 
adrenocorticotrophic hormone (ACTH) which is generated by the pituitary gland through 
the action of hypothalamic-derived corticotrophin releasing hormone (CRH) (Fig 1.6 ).
In young adults concentrations of DHEAS in peripheral blood are far greater than any 
other steroid hormone, with a dramatic fall in levels after the third decade [3, 4], in 
contrast to glucorticoids and mineralocorticoids whose serum concentration varies little 
with age [58, 59]. Adult concentrations of DHEA and DHEAS are reached in males at a 
mean age 13 years and 14 years respectively, while in females adult concentrations are 
reached at a mean age of 12 years and 15 years respectively [60], It is likely that genetic 
influences play a significant role in determining serum DHEAS concentrations with some 
analyses suggesting a heritability of up to 65% [61].
corticotrophin releasing horm one (CRH)
adrenocorticotrophic hormone (ACTH)
cortisol 
adrenal androgens
HYPOTHALAMUS
ADRENAL CORTEX
ANTERIOR PITUITARY
Fig 1. 6  Hypothalamic-pituitary-adrenal axis
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DHEA and DHEAS, like cortisol, are predominantly regulated by pituitary ACTH, 
resulting in pulsatile release, although the pulse magnitude for each is less than cortisol 
and more apparent for DHEA than DHEAS [55]. Similarly, circadian and also seasonal 
rhythms are in operation with higher DHEA values present in the mornings [62] and in 
autumn/winter [63].
For the most part, the observed changes in DHEA concentration are governed by changes 
in ACTH release from the pituitary gland. However, patterns of ACTH release can not 
explain fully the unique pattern of DHEA production through life (Fig 1.7).
DHEA is produced in high concentrations in the foetal state and is the major product of 
the foetal adrenal gland [64]. For reasons that are not entirely clear DHEAS levels are 
approximately 1 0 0  times higher than cortisol in umbilical cord blood with no gender 
difference [65]. DHEA may play an important role in brain development in utero [6 6 ]. It 
is likely that the responses of the adrenal gland in the foetus are influenced by other 
hormones beyond ACTH. For example, activation of the insulin-like growth factor-1 
receptor (by Insulin like growth factor-1 or 2) in the foetal zone of the gland has been 
shown to increase ACTH stimulated cortisol and DHEAS secretion. Furthermore, local 
production of insulin-like growth factor-2 increases ACTH responsiveness as measured 
by steroid production (cortisol and DHEAS) and expression of 17 a-hydroxylase 
(CYP17) and P450- LSCCE (CYP11A) [67].
Levels of DHEA/DHEAS are therefore high at birth but fall rapidly thereafter [6 8 ], 
remaining low until approximately 1 0  years when the zona reticularis of the adrenal gland
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matures and begins to increase production (adrenarche) [69]. The trigger and controlling 
mechanisms for this process are not fully understood. Levels continue to rise through 
puberty and peak in early adult life with a steady fall thereafter [3], despite no alteration 
in the production of ACTH during adrenarche, puberty or normal aging. This suggests 
reduced ACTH responsiveness and is illustrated by Synacthen (synthetic ACTH) testing 
in elderly subjects, whereby peak cortisol responses are similar to young adults but 
responses for DHEA are reduced [70]. Divergent cortisol and DHEA responses are also 
seen in acute illness [71] and conditions of low calorific intake [72] where cortisol, but 
not DHEA levels rise. The precise cause for the aberrant cortisol to DHEA ratios in these 
circumstances is unclear but is likely to be multi factorial involving the influence of extra­
adrenal factors including pro-opiomelanocortin (POMC)-derived peptides [73], relative 
and tissue-specific concentrations of converting enzymes and perhaps the proposed 
adrenal androgen-stimulating hormone, the existence of which has not been confirmed 
[74].
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Fig 1.7 Variations in concentration of DHEAS levels with time
1.1.8 Mechanism of action
Labrie’s review of DHEA action [75] suggested that it was not actually a hormone at all 
but exerted all its actions as a prohormone, though much recent evidence challenges this 
assumption. Studies have shown direct DHEAS action as a neurosteroid: at 
concentrations of 2nM it functions as an allosteric antagonist of the y-aminobuteric acid 
A (GABAa) receptor in rat brain samples. This effect was reduced by barbiturates 
(Phenobarbital) suggesting that DHEAS and barbiturates act at the same receptor sites 
[76, 77]. Low concentrations of DHEA (1 O'9 molar) have also been shown to act on the 
N-methyl-D-aspartate receptor (NMDA) in embryonic neuronal primary cultures where it 
stimulates calcium influx, the rapidity of this effect suggesting action via a cell surface 
receptor. Further studies have shown that DHEA can promote neuronal growth [6 6 ].
14
Much of the DHEAS present in central nervous system (CNS) may be generated locally 
as evidenced by the preserved DHEAS levels in the CNS of rats that have undergone 
adrenalectomy and orchidectomy [78]. These CNS studies suggest that DHEA may 
possess a receptor (nuclear or cell surface) and some evidence for the existence of this 
comes from binding studies in other tissues and cell types.
Binding sites have been located on a human T-lymphocyte cell line that binds DHEA 
with high affinity (dissociation constant=7.4±0.53 nmol/1); in these cells DHEA actually 
increased the number of binding sites [79]. High affinity binding sites have also been 
located on Gaj 2 ,3 -protein coupled receptors on membranes of bovine aortic endothelial 
cells (K<j 48.7pM) that in turn activate endothelial nitric oxide synthase (eNOS) [80, 81]. 
DHEA may also exert direct action through binding to the androgen or oestrogen 
receptors. A study by Chen et al [82] demonstrated that DHEA bound to the androgen 
receptor with a binding affinity of 1 pM and in turn reduced gene transcription in breast 
and prostate tumor cell lines. This study also revealed that DHEA bound to oestrogen 
receptors a and (3 with a low binding affinity of 1.1 pM and 0.5pM respectively, but with 
preferential agonistic activity seen at the oestrogen receptor-p.
However, the major metabolic effects of DHEA are most likely to be indirect, mediated 
by tissue specific bioconversion into downstream metabolites of the sex steroid pathway 
(Fig 1.3).
A further and interesting effect of DHEA is seen in individuals with secondary adrenal 
failure receiving growth hormone replacement, whereby DHEA supplementation leads to
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an increase in Insulin like growth factor-1 (IGF-1) necessitating a reduction in growth 
hormone dose [83]. A similar finding has also been observed following the 
supplementation of DHEA in elderly men and women in association with a reduction in 
IGF-1 binding protein levels [84]. Again it is not known if the mechanism of this effect is 
direct or indirect but the results suggests that there is likely to be continuous interaction 
between DHEA/DHEAS, other hormone systems, and the cell signaling pathways that 
they trigger.
1.1.9 Species differences
The dramatic age-related alterations and high serum concentrations of DHEA and 
DHEAS as well as the large circulating pool of adrenal-derived androgens is only seen in 
humans and higher primates. Other animal models used in the laboratory setting generate 
androgen and oestrogen solely from ovarian or testicular tissue and much lower serum 
concentrations are thus observed [56]. This leads to difficulties in extrapolating results 
from studies that utilise these animals to the human system. Effects that may be seen in 
the rodent following what is physiological exposure for humans cannot necessarily be 
related with confidence to the human situation as these concentrations are grossly supra- 
physiological for that animal. Similarly, experimental work utilising cell lines generated 
from animals will only provide a suggestion as to what the situation may be within the 
human body such that work with human or higher primate cells and cultures remains 
critically important.
1.2 DHEA and adipose tissue
1.2.1 Overview
16
Adipose tissue contains both significant quantities of DHEA [85] and possesses the 
appropriate enzymatic machinery for its metabolism [8 6 , 87]. DHEAS is also present in 
adipose tissue but at lower concentrations relative to DHEA due to increased polarity, 
and thus reduced lipid solubility, which in turn limits transport across the cellular 
membrane, although organic anion-transporting polypeptides B, D and E have been been 
postulated to facilitate internalisation of DHEAS in adipose tissue [87]. As previously 
discussed DHEA is present in high concentrations in plasma relative to other hormones; 
in adipose tissue this concentration is notable, where levels are 1 0  times greater than in 
the circulation [85]. Recent advances have led to changes in the perception of adipose 
tissue function such that it is no longer thought of solely as an energy reservoir. The 
effects of DHEA on adipose tissue have been studied using both in vitro and in vivo 
techniques.
1.2.2 Adipose tissue
Developmentally adipose tissue arises from mesenchymal stem cells along with bone and 
cartilagenous tissue and forms the body’s largest energy reservoir. Traditionally it was 
believed that energy storage, along with insulating and cushioning properties were its 
only functions. Under the influence of various hormones and cytokines surplus energy is 
stored in the form of triacylglycerides (TAGs). This reserve can then be mobilised during 
times of low calorific intake. However, it has now become clear that the adipocyte has 
major metabolic influence affecting many tissues and systems including muscle, the 
hypothalamus, clotting cascades, the pancreas and the immune system.
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Two types of adipose tissue exist: white adipose tissue (WAT) and brown adipose tissue 
(BAT). BAT is not normally thought to be present in significant quantities in humans 
beyond the neonatal period and is more prevalent in smaller mammals. However small 
foci of BAT have been found in human adult WAT and mRNA markers of BAT have 
been identified in adult human WAT utilising sensitive techniques (quantitative real time 
polymerase chain reaction) [8 8 ]. Moreover, in cases of phaeochromocytoma, an 
adrenomedullary tumor which secretes catecholamoines, larger amounts of BAT can 
develop [89] illustrating not only the importance of adrenergic drive in the stimulation of 
BAT production but also the potential capacity of human adult WAT to generate BAT. 
Cold exposure is also an important BAT modulator and this or forced adrenergic stimuli 
in vivo has been shown to increase the amount of BAT-specific genes [90]. The primary 
function of BAT is thermogenesis, hence its preferred locations, for example in the thorax 
surrounding the great vessels or in the interscapular region. BAT possesses a unique 
protein termed uncoupling protein-1 (UCP-1) which mediates this response, converting 
energy storage to energy expenditure; this is in turn dissipated in the form of heat [91]. 
BAT differs morphologically to WAT in that the fat droplets of triacylglycerides are 
smaller and BAT adipocytes contain a far greater number of mitochondria. As will be 
discussed in more detail later, both WAT and BAT are under the control of a complex 
cascade of transcription factors that can in turn be modified by various external stimuli. 
Peroxisome proliferator activated receptor-y (PPARy) is probably the most important of 
these transcription factors in both adipose types. In BAT a specific co-activator for 
PPARy has been identified termed PPARy cofactor-1 (PGC-1); this is involved in BAT 
activation following cold exposure [92].
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WAT is distributed widely though preferentially accumulates in particular locations (e.g. 
subcutaneous, visceral (omental), gluteo-femoral). It is now known that WAT distribution 
is important in determining metabolic risk, notably centrally distributed visceral or 
omental WAT is associated with the development of the metabolic syndrome [93]. This 
term refers to a collection of risk factors which cluster in individuals with an increased 
central adiposity or waist circumference (raised triglyceride levels, reduced HDL 
cholesterol, increased insulin resistance). WAT distributed subcutaneously or around the 
hips is not linked to such abnormalities to the same extent. The metabolic influence that 
WAT exhibits is in part a result of the production of an array of adipocytokines. The 
specific cytokines and their effects are summarised in Fig 1.8 and table 1.1 and will be 
discussed in more detail later in this chapter.
Adiponectin
Tissue
factor
LeptinMIF
Resistin
TNFa
PAI-1
IL-6
TNFa -Tum or n ec ro sis  factor-a 
IL-6 - Interleukin 6
PAI-1 - P lasm inogen activator inhlbltor-1 
MIF -  M acrophage inhibitory factor
Figl . 8  Apidocytokines produced form adipocytes
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Adipocytokine Metabolic effects
Adiponectin
Gluconeogenesis and glucose uptake 
Lipid breakdown and removal (TAG 
clearance and p-oxidation)
Central appetite suppression and 
weight loss 
Endothelial function
Leptin Central (hypothalamic) suppression 
of appetite
Resistin Activating inflammatory cytokines 
Possibly insulin resistance
TNFa Insulin resistance
IL-6 Inflammatory state
PAI-1 Anti fibrinolytic 
Insulin Resistance
Tissue factor Coagulation
MIF Inflammation 
Insulin resistance
Table 1.1 Adipocytokines and summary of metabolic effects 
1.2.3 Adipogenesis and in vitro models
The process by which the precursor adipose cell develops and matures (or differentiates) 
is termed adipogenesis; a process with complex regulatory mechanisms that have often 
been determined with the use of in vitro models. These models have tended to use cells 
that are predetermined to develop into adipoctyes that have lost their multipotent 
potential, termed adipoblasts. Examples of such cells include NIH 3T3-L1 (murine WAT 
cell line) and PAZ6  (Human BAT cell line) which can be stimulated to undergo 
adipogenesis under controlled laboratory conditions. A more comprehensive review of 
these cells and adipogenesis models is provided in chapter 2 .
1.2.4 Control of adipogenesis
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Adipogenesis is controlled by a cascade of transcription factors that in turn can be 
influenced by extracellular factors. Rosen and Macdougald [94] termed the transcription 
factor peroxisome proliferator-activated receptor-y (PPARy) the ‘master regulator’ of 
adipogenesis. PPARy is the most conserved member of the PPAR family and controls 
gene expression through heterodimerisation with the retinoic X receptor (RXR). Evidence 
for the critical importance of PPARy in adipogenesis comes from several sources. For 
example PPARy overexpression in isolation is sufficient to induce adipogenesis in vitro 
[95] whereas PPARy-2 knockout mice exhibit reduced adipose tissue mass [96]. 
Furthermore PPARy expression may be necessary to maintain mature adipocytes in the 
differentiated state [97]. Recent descriptions of dominant-negative mutations in the 
human PPARy gene in subjects with partial lipodystrophy add more evidence to the key 
role of this gene in adipocyte differentiation [98]. An array of other transcription factors 
influence adipogenesis, often through either stimulation or inhibition of PPARy (Fig 1.9) 
[99].
There are 3 PPARy (PPARy-1 and PPARy-3 mRNA code for the same protein) isoforms 
derived from the same gene through the use of alternate promoters [100, 101]. PPARy-1 
is found in many cell types whereas PPARy-2 is adipose tissue specific. PPARy-3 has 
been found in adipose tissue, macrophages and colonic epithelium [100, 101]. The 
precise roles of these differing isoforms of PPARy are yet to be determined.
Another family of transcription factors that play an integral role in adipogenesis are the 
CCAAT-enhancer binding protein (C/EBP) family which interact directly with PPARy 
(C/EBP binding sites are located within the PPARy-2 promoter) in a coordinated manner
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to stimulate adipogenesis. A number of members of this family are involved in 
adipogenesis including C/EBPa/p/y/ 6  and transcription factor homologous to CCAAT- 
enhancer binding protein (CHOP). C/EBPp and 6  are involved early in adipogenesis 
whereas C/EBPa influences the later stages. Glucocorticoids, known to promote 
adipogenesis, cause a transient rise in expression of C/EBPa and 5 during differentiation 
[102]. C/EBPa acts to sustain PPARy expression during differentiation but may have 
differential roles in WAT and BAT as C/EBPa knock-out mice have almost no WAT at 
all; however, BAT remains relatively unchanged [103].
Many other factors have a role in adipogenesis such as the Krupple-like factors (KLF); 
these are zinc finger proteins some of which promote adipogenesis (KLF5/15/6) while 
others inhibit it (KLF2). KLF 15, as well as stimulating differentiation also enhances 
glucose transport through increased expression of glucose transporter 4 (GLUT4) [104, 
105] while KLF2 inhibits PPARy [106]. KROX20 is another pro-adipogenic factor that 
promotes C/EBPp expression in 3T3-L1 cell differentiation [107]. Sterol response 
element binding protein-lc (SREBPlc) triggers PPARy expression possibly by 
elaboration of a PPARy ligand [108].
Anti-adipogenic factors include KLF2 and the GAT A family of proteins which are 
reduced in adipogenesis and can inhibit the PPARy-2 promoter [99].
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Adipoqenesis stimulation Adipoqenesis inhibition
KLF15 KLF2
KLF5 PPARy
GATA2/3
SREBP-lc CEBPs
KROX20 CHOP
KLF 15/5/2 -  Krtipple-like factors 15/5/2
SREBPIc -  Sterol response element-binding protein-1c
CHOP -  Transcription factor homologous to CCAAT-enhancer binding protein
PPARy -  Peroxisome proliferator activated receptor y
CEBPs -  CCAAT-enhancer binding protein family
Fig 1.9 Stimulatory and inhibitory transcription factors in adipogenesis
1.2.5 Adipocyte signal transduction
Adipogenesis is under the constant influence of extracellular factors that can alter 
expression of adipogenesis transcription proteins through binding to specific 
transmembrane receptors that in turn switch on (or off) a variety of cell signalling 
pathways. These cell signalling pathways demonstrate considerable cross-talk such that
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the balance of extracellular constituents at any one time will define adipose cell transcript 
expression rather than any one single factor (Fig 1.10).
Glucocorticoid
IL-6 receptor
Insulin receptor TNF-a receptor
Leptin receptor
GLUT4 
TransolcationJAKs ) JAKs
JAK2
IRS-2IRS-1 IRS-2
SHP-2 Ras TRAFRas/Raf STAT3
SOC-3 MAPKMAPK MAPK MAPK
i /  ^
TRANSCRIPTION FACTORS
4
Nucleus
GR -  glucocorticoid receptor 
JAK- Janus Kinase
MAPK- Mitogen activated protein kinase 
STAT-signal transducers and activators of  
transcription
PI3K- Phosphatidyl inositol 3 kinase 
IRS- Insulin receptor substrate 
GLUT-glucose transporter
SOCS-3- Suppressor o f  cytokine signalling-3 
Akt- protein kinase B 
TRAF-TNF receptor associated factor 
ER -  Endoplasmic reticulum 
JNK- c-jun N-terminal kinase
Fig 1.10 External factors and adipocyte cell signalling adapted form Fruhbeck et al [ 109] 
Adipoctye cell signalling involves a number of signal transduction pathways activated by
cell surface receptor-ligand binding that stimulates phosphorylation/dephosphorylation
and thus pathway activation.
Janus kinases (JAK) are intracellular tyrosine kinases involved in the JAK-STAT (signal 
transducers and activators of transcription) cell signalling transduction pathway. When
24
the cell surface receptor is activated by ligand binding (e.g. leptin binding to its receptor) 
2 JAKs dimerise by autophosphorylation. This then enables phosphorylation and 
activation of STATs. ST AT proteins as their name suggests can enter the nucleus and 
directly affect transcription or can act as further signal transducers [110]. This JAK- 
STAT pathway can be inhibited in a negative feedback fashion by suppressors of 
cytokine signalling (SOCS) which bind to JAKs and inhibit phosphorylation [111].
Ras and Raf are proto-oncogenes that have tyrosine kinase activity and are involved in 
the mitogen activated protein kinase signalling (MAPK) pathway [111]. MAPKs, also 
known as extracellular signal regulated proteins (ERKs), are microtubule associated 
protein kinases that can modulate mRNA translation into proteins as well as affecting 
transcription factor activity. MAPK can alter transcription of cyclic AMP response 
element binding proteins (CREBs) and MYC, a proto-oncogene involved in cellular 
proliferation and differentiation. It appears that the MAPK pathways need to be activated 
to initiate preadipocyte differentiation and then deactivated to allow differentiation 
progression. This is illustrated by the observation that MAPK phosphorylation is required 
for 3T3-L1 cell proliferation. In contrast during later stage differentiation MAPK 
phosphorlyates and so deactivates PPARy [112]. The importance of MAPK signalling in 
adipogenesis is also demonstrated by studies in MAPK knockout mice which display 
reduced amounts of body fat [113].
Akt, also known as protein kinase B is a serine/threonine specific protein kinase involved 
in protein synthesis and inhibits apoptosis. It has a protein domain that binds 
phosphoinositides e.g. Phosphatidyl inositol 3 kinase (PI3K). PI3K can be activated by 
the insulin receptor via IRS-1. Akt is involved in the translocation of the glucose
25
transporter 4 (GLUT4) to the cell membrane following insulin stimulation; Akt knockout 
mice thus develop diabetes [114]. Activation of the insulin receptor phosphorylates the 
Insulin receptor substrate (IRS). Activity of these increases the amount of cell surface 
GLUT4, as well as triggering the signalling cascade which culminate in MAPK activation 
and altered transcription. Tumour necrosis factor associated factors (TRAFs) are major 
signal transducers for the TNF system and MAPK is also a terminal component of this 
protein cascade [115].
A number of other signalling pathways other than those described are involved in 
adipogenesis such as the Wnt pathway [116], transforming-growth factor p and bone 
morphogenic protein pathways, Notch and DLK1/PREF-1 pathways as well as others. 
Hormones that exert effects via nuclear receptors such as cortisol, testosterone or 
oestradiol can also influence transcription directly with the binding of the hormone 
receptor complex to the appropriate DNA response elements. Glucocorticoids for 
example are known to promote preadipocyte differentiation into mature adipoctyes [117]. 
Other intra-adipose tissue factors can also influence cell signalling. In mice with an 
impaired endoplasmic reticulum stress response, insulin resistance develops through 
over-activation of c-jun N-terminal kinase (JNK) leading to phosphorylation of IRS-1 
[118].
1.2.6 Adipocytokines
The adipocyte has important endocrine and paracrine capabilities mediated through the 
production and action of numerous substances known as adipocytokines (Fig 1. 8  and 
table 1 .1 ) which exert effects over neighbouring as well as distant cells and tissues.
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Adiponectin is a 22 amino acid polypeptide whose serum concentrations correlate 
inversely with body fat mass. It exists in 2 form: a low-molecular weight dimer and a 
high molecular weight complex [119] which may be more metabolically active. 
Adiponectin concentrations are lower in subjects with type II diabetes [120] but are 
higher in women compared to men [121]. Concentrations can be increased by exercising, 
perhaps explaining the benefits of exercise in improved insulin sensitivity, probably 
through reduced hepatic glucose production and increased fatty acid p-oxidation in 
skeletal muscle [122]. Adiponectin may thus protect against the development of insulin 
resistance, type II diabetes and coronary artery disease.
Tumour necrosis factor-a (TNF-a) is a 212 amino-acid transmembrane protein which is 
secreted by a number of cell types including adipocytes and macrophages. Serum 
concentrations of TNF-a rise with increasing obesity [123]. It functions predominantly as 
a regulator of the immune response but its metabolic effects include induction of insulin 
resistance through serine phosphorylation of IRS-1 [124].
Leptin is a 167 amino acid protein secreted by WAT and to a lesser extent BAT. It binds 
to receptors in the appetite centers located within the ventral medial nucleus of the 
hypothalamus and may act as a satiety signal [125]. Leptin levels rise in parallel with 
increasing adipose mass and acts as a signal centrally indicating the relative amount of 
adipose tissue stores. Leptin secretion has also been implicated in the development of 
insulin resistance partially through serine phosphroylation of IRS-1 [126] though other 
lines of evidence suggest a beneficial effect of leptin on glucose tolerance [127, 128]. 
PAI-1 is an inhibitor of the fibrinolyic system that is mostly produced by the vascular 
endothelium but is also produced by adipocytes. PAI-1 levels correlate with levels of
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insulin resistance and it has been suggested as a possible link between obesity and insulin 
resistance [129].
Resistin is a 108 amino acid protein whose levels correlate with obesity. It has been 
suggested that it plays a role in the development of insulin resistance [130]; however 
other studies have refuted this claim [131]. What is not in doubt is that it can function as a 
proinflammatory cytokine and can activate other inflammation associated cytokines such 
as IL-6 .
Interleukin- 6  (IL-6 ) concentrations also correlate with body mass index. Although it can 
be produced from many cell types it is thought that up to a third is derived from adipose 
tissue. IL- 6  concentrations have been positively associated with cardiovascular and all 
cause mortality [132] and is likely to be a component of the chronic inflammatory state 
observed in obese individuals [133].
Tissue factor is a potent initiator of the coagulation cascade and is related to the cytokine 
class II receptor family. Expression of tissue factor has been shown to be upregulated in 
adipocytes of genetically obese mice which could, in part, explain the hypercoagulable 
state that is linked to obesity [134].
Macrophage inhibitory factor (MIF) has also been implicated in the pathophysiology of 
insulin resistance [135] and weight loss has been shown to inhibit its production [136]. 
This list of adipocytokines is not exhaustive; new proteins are continually being 
characterised (e.g. Retinol binding protein-4 [137]).
In summary, a wide variety of hormones and cytokines will influence adipose tissue 
growth and development via the action of numerous cell surface or nuclear receptors and 
through the action of a cascade of interlinked intracellular signalling pathways. A number
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of investigators have sought to examine the impact that DHEA has on adipose tissue and 
the adipocyte, and also to determine the underlying mechanisms in any observed affect.
1.2.7 Effect of DHEA on adipose tissue: in vitro and animal studies
Gordon et al showed that DHEA inhibited the differentiation of the murine 3T3 fibroblast 
cell line into mature adipoctyes [138], in keeping with other observations of reduced 
proliferation with DHEA in this cell line [139]. Accepting the limitations of rodent 
models, DHEAS supplementation in rats fed a high fat diet reduced carcass lipid, fat 
depot mass and retroperitoneal and epidydimal adipocyte number [140]. A further study 
by Hansen et al showed that DHEA protected against the increase in visceral fat and the 
decrease in insulin-stimulated glucose uptake in male Wistar rats fed a high fat diet [141]. 
This effect on glucose uptake and insulin sensitivity was corroborated by Ishizawa et al 
who showed that glucose uptake was related to alterations in the activation of 
phospholipase D [142]. They later demonstrated the involvement of protein kinase C and 
phosphatidylinositol 3-kinase in the glucose uptake process [143] and also a down 
regulation of PPAR-y expression through DHEA treatment [144]. DHEA has also been 
shown to up-regulate resistin [145]. An in vitro study by Hemandez-Morante et al that 
utilised human adipose tissue samples cultured in DHEAS for 24 hours demonstrated 
upregulation of adiponectin gene expression in omental adipocytes [146].
These preliminary studies suggest that DHEA supplementation may have a beneficial 
effect on adipocyte number and function though the physiological relevance to humans 
requires further clarification.
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1.2.8 Effect of DHEA on adipose tissue: human studies
In contrast to most in vitro and animal model studies, which have demonstrated an 
inhibitory action of DHEA on adipocyte mass, observational and interventional studies in 
human subjects have failed to demonstrate such convincing results. The various studies 
are reviewed in a paper by Tchemof and Labrie [147]. In both men and women, 
investigators have demonstrated a negative correlation between non-sulphated DHEA and 
measures of obesity (Body mass index, percentage fat) [5, 6, 148-151]. In addition, an 
increase in central adiposity, as measured by waist hip ratio or computer tomography 
(CT) assessment of visceral fat area, has been observed in men with lower DHEA levels 
[5, 6, 148]. However the findings in relation to DHEAS are inconsistent [7, 148-166].
A number of interventional studies have examined the impact that treatment with DHEA 
has on body composition and plasma lipids. The majority of these clinical trials used a 
randomised controlled design, either in parallel groups or cross-over. Some have used 
populations with adrenal failure [12, 167, 168], others have used healthy [169-175], 
menopausal [176, 177] or obese [178, 179] populations and one examined a group of 
middle aged men with hypercholesterolaemia [180]. Doses used (25-1600mg daily) and 
treatment phase duration has also varied (4-52 weeks). As in the observational studies 
results have been inconsistent. A number of studies demonstrated improvements in 
measures of body fat (fat mass, percent body fat and skin fold thickness) [169, 174, 176] 
whereas others showed no effect, including all studies in adrenal failure. The most 
consistent potentially beneficial finding was a reduction in total cholesterol [169, 171,
176, 181]. However a number of the studies also demonstrated a reduction in HDL- 
cholesterol, a potentially negative effect on the lipid profile [171, 176, 177, 181, 182] .
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The discordant results seen in the human studies could be as a result of many factors. In 
the interventional studies DHEA dose and treatment duration has varied widely as have 
study populations and age ranges involved. Furthermore, observational studies may show 
association but do not necessarily imply causation: low DHEA levels in obesity may 
represent an epiphenomenon as chronic disease induces a shift of intra-adrenal 
biosynthesis that favours cortisol over DHEA. The physiological importance of DHEA in 
relation to stage of life may also be a factor and is discussed in a paper by Ebeling and 
Koivisto [183]. They suggest that the effect of DHEA may depend on the hormonal status 
at the time of treatment and discuss the different effects that DHEA replacement could 
have in the pre and postmenopausal states (oestrogen abundant versus oestrogen deplete). 
Thus treatment with DHEA may well be of benefit in a particular group or subgroup of 
individuals at a particular point in life. Further, the possibility of a sexually dimorphic 
response should also be considered and has been discussed earlier in this chapter.
1.3 DHEA and cardiovascular disease
1.3.1 Overview
Cardiovascular morbidity and mortality occur as a result of atherosclerosis, a disease 
process which begins subclinically in childhood before manifesting itself through 
ischaemic events and myocardial infarction in later life. The earliest events in this process 
involve significant dynamic alterations in vascular biology [ 184] with the emergence of
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the endothelium and arterial compliance as key regulators of vascular well-being [185, 
186].
Epidemiological studies in aging populations have demonstrated a gender-specific 
inverse relationship between DHEAS levels and cardiovascular mortality in men [8] [9] 
though few interventional studies have examined the benefits (or risks) of DHEA 
supplementation on vascular outcome. Recent studies in middle-aged men [180] and 
elderly populations [187] have suggested a beneficial action of DHEA supplementation 
on endothelial function in the short term though no studies have yet examined these 
outcomes in pathological DHEA-deficient states. Interventional trials of physiological 
DHEA replacement in subjects with DHEA deficiencies may therefore be important in 
clarifying the vascular benefits of this compound.
1.3.2 The vascular endothelium
The vascular endothelium is a dynamic structure with the ability to modify blood vessel 
diameter in response to a variety of stimuli (posture, stress, exercise) through the release 
of, and in response to a number of vasoactive substances (Fig 1.11).
32
|  V A SO D ILA TIO N  |
cGMP GTP CAMP
NO NO
eNOS NO eNO S
ADA
---------------  ^ B radykin in
A cety lcholine
ET,
InjuryS h ea r s tr e s s
Isch aem ia
ADH
T hrom binA n g io ten s in  II
Endothelin-1
ATR, ET,
p h o sp h o lip a se C IP3
IP3
VASOCONSTRICTION
S m o o th
M uscle
cell
E ndo the lia l
cell
V ascu la r
Lum en
E ndo the lia l
cell
S m o o th
M uscle
cell
NO-nitric oxide
eNOS- endothelial nitric oxide synthase 
MR-Muscarinic receptor 
BR- Bradykinin receptor 
GTP-Guanosine triphosphate 
cGMP- cyclic guanosine monophosphate 
ET-Endothelin receptor 
cAMP- cyclic adenyl monophosphate 
ADA-Arachidonic acid
PGI:-Prostaglandin I2 
IP-Prostaglandin receptor 
ADH- Antidiuretic hormone 
ATR-Angiotesin II receptor 
IP3-Inositol triphosphate 
GTN- glyceryl trinitrate
Fig 1.11 Modulators of vascular tone
In health, vascular tone is maintained via the action of vasodilators and vasoconstrictors. 
Nearly all substances that induce vasodilation do so through nitric oxide (NO). NO is 
produced within the endothelium from the amino acid L-arginine via the activity of 
endothelial nitric oxide synthase (eNOS) [188]. Shear stress is the most important 
stimulating factor for NO production [189]; however, acetylcholine acting on muscarinic 
receptors (Ml and M3) and bradykinin acting on bradykinin receptors (BR2) [190] can 
also activate calcium channels in endothelial cells and generate NO via eNOS. NO is a 
lipophilic gas that can cross cell membranes. In the vascular endothelium NO crosses the
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intima to reach the bundles of smooth muscle within the vessel wall. Here NO causes the 
degradation of GTP, releasing cGMP which in turn modulates cytosolic Ca2+ and causes 
relaxation of smooth muscle fibres and therefore vessel vasodilation [188]. NO can also 
directly inhibit the actions of vasoconstrictors such as angiotensin-II. Angiotensin-II (AT- 
II), produced from angiotensin-1 via the activity of angiotensin converting enzyme 
(ACE), has opposing actions to NO causing vasoconstriction by binding to the 
angiotensin-1 receptor on the vascular smooth muscle wall. The angiotensin-1 receptor is 
a G protein-coupled receptor linked to phospholipase C (PLC). PLC in turn stimulates 
inositol triphosphate (IP3) that acts to open calcium channels at the endoplasmic 
reticulum, thus increasing intracellular calcium and stimulating smooth muscle 
contraction [191]. Another potent vasoconstrictor is endothelin-1. Endothelin-1 is 
generated within the endothelium from precursor molecules (preproendothelin and big 
endothelin). Endothelin-1 acts on the endothelin A receptor on the vascular smooth 
muscle wall in response to ischaemia to increase IP3 and intracellular calcium, in turn 
stimulating contraction [192]. Interestingly, endothelin-1 can also cause vasodilation 
through action on the endothelin B receptor. This triggers smooth muscle relaxation and 
vasodilation through prostaglandin h  (PGI2) production from arachidonic acid and by 
stimulating eNOS. PGI2 , also known as prostacyclin, acts on the prostaglandin receptor 
(IP) to increase cAMP within the vascular smooth muscle cells inducing smooth muscle 
relaxation. The nitrate group of pharmacological agents classically used to treat angina 
(e.g. glyceryl trinitrate) are NO donors and effectively deliver NO directly to the vascular 
smooth muscle cells, bypassing the endothelial NO generating system. The type of
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vasodilation stimulated by NO donors, in contrast to acetylcholine and other agents that 
act directly on endothelial cells, is therefore endothelial independent.
A fine balance exists between the various vasodilating and vasoconstricting substances, 
the combination of these substances along with the intraluminal microenvironment will 
govern vascular tonicity. An inability to respond to these stimuli or dysregulation of 
these mechanisms is known as endothelial dysfunction, a condition which precedes the 
development of atherosclerotic plaques, contributing to lesion development and 
subsequently clinical complications [193].
1.3.3 Arterial stiffness
Increased large artery stiffness is a function of aging and relates to a reduced ability of 
blood vessels to expand and recoil in response to pulsed cardiac output. This dynamic 
ability facilitates transduction of the intermittent cardiac pulse into steady blood flow and 
moves away from the traditional concept of blood vessels acting solely as conduits. The 
proximal aorta will dilate in response to increased volume generated in systole with an 
associated higher pressure (systolic pressure) and will then recoil during diastole, 
maintaining a lower pressure (diastolic pressure) and thus flow. The pulse pressure 
(difference between systolic and diastolic pressures) therefore, is both a reproducible and 
easily measured surrogate marker of artery stiffness. Increasingly stiffened vessels will 
have a reduced ability to accommodate and distend in response to the systolic pulse and 
so higher systolic pressures will be generated along with lower diastolic pressures 
secondary to impaired elastic recoil.
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A number of factors are now known to regulate arterial stiffness (Fig 1.12). Traditionally 
it was thought to be secondary solely to alterations to structural components within the 
vascular wall such as elastin and collagen, both of which are located at the intimal medial 
layer. At higher pressures collagen primarily maintains vessels stiffness (e.g. in systole) 
whereas elastin functions at lower pressures. The ratio of elastin to collagen can therefore 
affect vessel stiffness whereby low elastin-to-collagen ratios are consistent with increased 
stiffness. Smooth muscle hypertrophy will also contribute to increasing vessel stiffness. 
However it is now clear that structural changes are not the only modulator of arterial 
stiffness as it is inexplicably linked to the vascular endothelium and the balance between 
vasodilating and vasoconstricting substances [194] as well as the inflammatory response 
[195].
Hypertension
Increasing age
Disease states (DM, CRF)
Genetic predisposition
Endothelial tonicity 
vasoconstrictors v vasodilators
DM -  diabetes mellitus 
CRF -  chronic renal failure
Fig 1.12 Factors influencing large artery stiffness
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Arterial stiffness has been shown to be an independent predictor of future cardiovascular 
disease [186] and may play a role in the development of hypertension [196] and 
atherosclerosis [197] as well as coronary artery disease. Further, it predicts cardiovascular 
risk in a number of disease states including dialysis dependent end-stage renal failure, 
hypertension and diabetes [198-200].
Pulse wave velocity (PWV) estimation or imaging (mostly ultrasound based) techniques 
can be used to determine arterial stiffness. Pulse wave velocity estimates stiffness by 
employing sensors placed cutaneously over a proximal (e.g. carotid) and distal 
(e.g.radial) palpable pulse to detect passing pulse waveforms. Velocity is then calculated 
as the distance between the 2 sensors (in meters) divided by the time taken for the 
waveform to pass from proximal to distal sensor (in seconds); this will be influenced by 
wall thickness, vessel radius and blood pressure [201]. A highly tortuous vessel may 
generate a falsely low velocity whereas higher pressure vessels will increase velocity 
(hypertension, increased vascular tone).
Augmentation index (Ai) is another non-invasive means of assessing arterial stiffness that 
utilises the phenomenon of wave reflection [202]. A sensor placed over the radial artery 
will detect the passing pulse waveform. When this waveform reaches small, high- 
resistance vessels reflection occurs and a smaller returning wave form is detected at the 
same sensor. The speed of travel of the reflected wave (as well as the out-going wave) is 
influenced by vessel stiffness and will travel at a higher velocity with increasing vessel 
stiffness such that the time difference between the out-going and reflected wave detected 
by the sensor will shorten. When a threshold velocity is reached the reflected wave will 
begin to summate or augment the out-going wave and the degree with which this
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augmentation occurs is termed the augmentation index (Ai). Ai is thus a surrogate marker 
of arterial stiffness (the greater the extent of augmentation the stiffer the vessel). Ai will 
be influenced by vessel length which is often a function of height, gender differences are 
thus evident, Ai being lower in men than in women as well as blood pressure.
Both PWV and Ai can be measured non-invasively and with a high degree of 
reproducibility [203] and so are ideally suited for use in the context of clinical trials. The 
methodology involved in the measurements of PWV and Ai will be discussed in more 
detail in chapter 4.
Direct imaging techniques are another means of determining vessel stiffness and allow in 
vivo visualisation of wall thickness and vessel diameter. These techniques require 
considerable training and can be time consuming. Newer techniques still, such as MRI, 
are able to visualise entire vessels as well as flow and can therefore provide the most 
accurate measures of velocity, but the current expense and limited availability of these 
techniques render them, for now at least, inaccessible to most researchers.
1.3.4 DHEA and vascular dysfunction
A growing number of studies have attempted to address whether the age-related reduction 
in DHEA/DHEAS concentration is linked to diseases of the elderly including 
cardiovascular disease.
Cross-sectional and prospective epidemiological studies have shown an inverse 
correlation between DHEA/DHEAS levels and cardiovascular mortality, initially in older 
men [8, 204] and subsequently in young men [205] and pre and postmenopausal women
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[206, 207]. A similar inverse relationship has also been found for DHEA/DHEAS 
concentration and cardiac graft stenosis as well as atherosclerosis extent [208, 209].
In lower order animals, supplementation of DHEA has been shown to reduce 
atherosclerosis [210] and potential mechanisms have been identified through in vitro 
studies. Liu and Dillon were able to demonstrate that DHEAS stimulates NO release from 
vascular endothelial cells through the activity of a plasma membrane G-protein (G a ^ )  
coupled receptor [81, 211]. Further studies have shown inhibition of human vascular 
smooth muscle cell proliferation by DHEA involving the MAPK signalling pathway 
[212]. The same group also demonstrated an inhibitory action of DHEA on proliferation 
of bovine aortic endothelial and human umbilical vein endothelial cells [187, 212]. 
Interventional studies have shown beneficial effects on both established (cholesterol and 
body fat) [169, 171] and emerging (platelet aggregation and plasminogen activator type 
1) [213, 214] cardiovascular risk factors as well as improvements in endothelial function, 
measured by flow-mediated dilatation, in middle aged men with hypercholesterolaemia 
[180] and in post-menopausal women [187].
The evidence would thus seem to support a beneficial effect of DHEA on cardiovascular 
risk, though the mechanism of this action, its gender dependence and reproducibility in 
pathological DHEA deficiency states have not been fully determined.
1.3.5 Testosterone and oestrogen: effects on the metabolic syndrome and vascular 
status
Clearly any effect that is proposed to be a consequence of DHEA deficiency or 
replacement may be a result not of DHEA itself, but secondary to the generation of active
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terminal metabolites such as testosterone and oestradiol. Indeed Labrie’s review on the 
mechanisms of DHEA action suggests that it is not a hormone at all and acts solely as a 
prohormone up-stream of terminal sex steroids [75]. As discussed earlier in this chapter, 
there are numerous studies that suggest this may not be the case but what is evident is that 
both testosterone and oestradiol themselves can exert actions on the various components 
of the metabolic syndrome (discussed further in chapter 3) as well as vascular health.
In post-menopausal females oestrogen ameliorates menopausal symptoms and protects 
against bone mineral density loss. Oestrogen may also have important vascular and 
biochemical effects in males. For example, men with abnormalities in oestrogen synthesis 
due to mutations in the aromatase gene develop early and advanced cardiovascular 
disease as well as increased levels of insulin, TAGs and LDL cholesterol [215-217] (all 
features of the metabolic syndrome). These inborn metabolic errors are discussed in more 
detail in chapter 4 and illustrate the importance of oestrogen on vascular function in 
males. Further, randomised trials of aromatase inhibition in young men showed impaired 
endothelial function, confirming that endogenous oestrogen production has an important 
role in maintaining vascular health in men [218]. Oestrogen can also stimulate the 
generation of the potent vasodilator nitric oxide through both genomic and non-genomic 
mechanisms again alluding to important vascular effects. Some authors have thus 
suggested that DHEA may exert its potential anti-atherosclerotic benefits through 
generation of oestrogen [219] though others have failed to confirm these findings [220].
Testosterone is also linked with vascular and metabolic health. Numerous observational 
studies show a clear association of subnormal testosterone concentrations in adult males
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with the metabolic syndrome, obesity and type II diabetes [221] Furthermore, 
testosterone replacement can improve anthropometric measures of excess adiposity [222- 
224] and, in men with type II diabetes, improves insulin sensitivity and glycosylated 
haemoglobin levels [222] These benefits may be accompanied by changes to the 
adipocytokine profile with a reduction in leptin, indicating a reduction in fat mass, but 
also adiponectin [223] The mechanisms by which testosterone improves these parameters 
are not fully understood although one potential pathway may involve the androgen 
receptor whereby polymorphic variation in the C AG repeat sequence may influence body 
composition and testosterone levels [224]. Interventional studies have also shown that 
testosterone replacement improves functional capacity in men with heart failure [225] and 
augments ischemic thresholds in men with angina [226]. Further, testosterone has been 
shown to attenuate fatty streak formation in a mouse model of androgen insensitivity 
[227] suggesting mediation through mechanisms independent of the nuclear androgen 
receptor. Studies in men with prostate cancer undergoing induced hypogonadism also 
support an important role for testosterone in maintenance of vascular and metabolic 
health, with increases in measures of body fat and deterioration in insulin sensitivity 
[221] as well as impaired endothelial functioning [228] being observed.
Testosterone also influences lipid parameters, with the most consistent finding being a 
reduction in HDL cholesterol. However, this may not necessarily represent a detrimental 
change as the HDL affected demonstrates enhanced reverse cholesterol transport 
capabilities[229]. Further testosterone affects HDL subclasses differently with HDL3 
reduced but HDL2 remaining unchanged [230]. It is not clear if this effect has long-term 
adverse cardiometabolic consequences. In contrast, testosterone has been shown to
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increase HDL cholesterol concentrations in mice, although the mechanisms accounting 
for these inter-species differences are presently unclear [227]. Further beneficial lipid 
effects in vivo have also been shown with testosterone causing a reduction in total 
cholesterol [222]. It is clear from these discussions that both testosterone and oestrogen 
are intimately liked to lipid and vascular homeostasis such that any potential benefits of 
DHEA therapy on vascular integrity may well be mediated through downstream 
conversion.
1.4 DHEA and adrenal insufficiency
Adrenal insufficiency refers to a deficiency in hormones produced from the adrenal 
cortex and is classified as either primary, where the disease process occurs in the adrenal 
glands themselves, or secondary, where the deficiency is due to disturbance at the level of 
the hypothalamus and/or pituitary. Glucocorticoids (cortisol), mineralocorticoids 
(aldosterone) and the adrenal androgens exhibit varying degrees of deficiency in this 
group of conditions. These hormones are generated in different adrenocortical zones (Fig 
1.13): cortisol and the adrenal androgens are, as previously discussed, synthesised in 
response to the pulsatile and rhythmic release of pituitary-derived ACTH controlled by 
negative feedback (Fig 1.6), while aldosterone production is largely under the control of 
the renin angiotensin system with comparatively little influence by ACTH. Aldosterone is 
intimately involved in the control of fluid balance, blood pressure and Na+ homeostasis.
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Fig 1.13 Functional zones of the adrenal cortex
1.4.1 Primary adrenal insufficiency
Primary adrenal insufficiency refers to conditions causing atrophy or destruction of 
adrenal cortical tissue resulting in reduced hormone production. This is now commonly 
known as Addison’s disease after its first description in 1855 by Thomas Addison as a 
pairing of hyperpigmentation and wasting, a universally fatal condition at the time. In 
Addison’s day the commonest cause for the condition was tuberculosis and this still 
remains problematic in less developed countries. The acid fast bacilli of tuberculosis have 
a particular predilection for adrenal tissue and up to 5% of individuals with active TB 
have adrenal involvement [231 ]. With the emergence of antimicrobial therapy, the 
incidence of Addison’s disease has fallen, in the developed world at least, to current
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disease estimates of 4.7-6.2 per million with a prevalence of 93-140 per million [232, 
233].
1.4.1.1 Causes of primary adrenal insufficiency
Addison’s disease is now most commonly seen as an autoimmue process characterised 
histologically by lymphocytic cell infiltration of the adrenal cortex leading to 
macroscopic atrophy. The majority of cases are thus associated with high titres of 
antibodies directed against the adrenal cortex and/or 21-Hydroxylase enzyme [234]. 
Subjects with primary adrenal failure develop compensatory increased ACTH as a result 
of reduced negative feedback leading to hyperpigmentation through activation of 
melanocytes via the MC1 -receptor.
In common with other autoimmune conditions Addison’s disease occurs more commonly 
in females either in isolation or as part of a wider polyendocrine syndrome (APS 1 and 2). 
Other causes of primary adrenal failure are less common and are outlined in table 1.2.
44
lAutoimmune Isolated f 
APS 1 + 2  !
Infective Tuberculosis
HIV
Fungal (histoplasmosis)
Infiltrative Sarcoidosis
Amyloidosis
Haemochromatosis
Haemorrhagic Anticoagulants
Trauma
Meningococcal septicaemia
iBilateral infarction Antiphospholipid syndrome :
iMetastatic Breast carcinoma 
Malignant melanoma 
Others t
[Congenital Congenital adrenal hyperplasia! 
Congenital adrenal hypoplasia 1 
Adrenoleucodystrophy
■Surgical Bilateral adrenalectomy
Pharmacological Metyrapone
Ketoconazole
Aminoglutethimide
Etomidate
Table 1.2 Causes of primary adrenal insufficiency
1.4.1.2 Investigations in primary adrenal insufficiency
Primary adrenal failure is characterised biochemically by a reduced or absent cortisol 
response to ACTH stimulation in conjunction with a raised serum ACTH level. Random 
cortisol levels, provided they are interpreted in the correct clinical context, can be useful
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in that a value of >600 nmol/L almost always excludes the diagnosis and a morning value 
<100 nmol/L is strongly suggestive. A Synthetic ACTH test (synacthen 250pg) is used to 
confirm or refute the diagnosis (normal response > 550nmol/L) [235, 236].
Further biochemical investigation involves testing for antibodies directed against the 
adrenal cortex or 21-hydroxylase enzyme that are present in over 80% of newly 
diagnosed cases [234]. Serum concentrations of DHEA are invariably low, particularly 
in women [12]; aldosterone concentrations (which are not routinely performed) tend to be 
low or low/normal with increased plasma renin activity [236]. If the precise aetiology is 
not immediately clear further investigations may be required, such as abdominal CT 
scans or other depending on clinical suspicion.
1.4.1.3 Pharmacotherapy in primary adrenal insufficiency
The mainstay of treatment for Addison’s disease is hormone replacement in the form of 
glucocorticoid (most commonly hydrocortisone) and mineralocorticoid (fludrocortisone). 
Typical dosage regimens over 24 hours are 20mg of hydrocortisone divided in 2 or 3 
doses and 0.05-0.15mg of fludrocortisone. Maintenance doses of hydrocortisone are 
typically doubled during intercurrent illness. Adrenal crisis, which is potentially life 
threatening, requires emergency treatment with large intravenous doses of hydrocortisone 
in conjunction with large volumes of 0.9% sodium chloride solution to correct volume 
and sodium depletion.
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1.4.1.4 Morbidity and mortality in primary adrenal insufficiency
Primary adrenal failure has been shown to negatively impact on health related quality of 
life [237] particularly in fatigue, depression and anxiety domains [12]. However until 
recently mortality data in Addison’s disease were lacking partly due to the scarcity of the 
condition and it was assumed that the mortality rates in optimally replaced patients was 
equal to that of the background population [238]. However, a recent Swedish population 
based study found a 2-fold higher risk ratio for death in patients with Addison’s disease 
attributable in the main to cardiovascular causes [239]. Further studies in other 
populations are required to confirm these findings, though an as yet unpublished series 
from Denmark shows similar results.
1.4.1.5 DHEA replacement in primary adrenal failure
A number of authors have now demonstrated improvements in measures of quality of life 
in response to DHEA in primary adrenal failure, such as anxiety, depression and physical 
correlates in women [12], and mood and well-being in both sexes [240]. These studies 
have culminated in the current utilisation of DHEA in this patient group on an ad hoc 
basis, in females in particular, who complain of a reduced quality of life and/or reduced 
libido.
The effect of DHEA supplementation has on metabolic factors has been investigated in 
this population though the results have been, in general, disappointing and the majority of 
studies have been performed on subjects who do not have a pathological deficiency (e.g. 
healthy, obese, postmenopausal, perimenopausal, men with hypercholesterolaemia, 
physiological deficiency). No study has demonstrated improvements in adiposity in this
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group, though one study performed in women with primary adrenal failure demonstrated 
significantly increased insulin sensitivity following a 12 week treatment phase of 50mg 
DHEA daily [10]. A rise in IGF-1 following DHEA therapy in women has been 
demonstrated in a further study [12], which could also influence glucose handling.
A recent study evaluating the effects of long term DHEA treatment in Addison’s disease 
demonstrated a reversal in a trend for bone loss at the femoral neck measured by dual 
energy X-ray absorpitometry (DEXA) scanning [240].
To date there has been no definitive evidence that DHEA replacement in this group has 
any beneficial effects on cardiovascular outcomes and this is largely due to a paucity of 
studies particularly with regards to measures of cardiovascular health. However a recent 
study did attempt to address this issue in females with Addison’s disease but failed to 
demonstrate any improvements in endothelial function or MRI assessment of cardiac 
status following 6 months of DHEA supplementation [241]. Therefore on the basis of 
studies performed to date and despite some intriguing in vitro, animal and human 
interventional studies (though not in pathological deficiency) DHEA remains a treatment 
that benefits quality but not quantity of life in primary adrenal failure.
1.4.2 Secondary adrenal insufficiency
Secondary adrenal insufficiency occurs where there is an absence or a reduction in the 
synthesis and secretion of ACTH, and is more common than primary adrenal 
insufficiency with an estimated prevalence of 150-280 per million [242, 243].
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1.4.2.1 Causes of secondary adrenal insufficiency
In clinical practice, secondary adrenal insufficiency occurs most commonly following 
hypothalamic-pituitary suppression due to exogenous glucocorticoid therapy. Excluding 
iatrogenic disease, most other causes are secondary to, or occur as a result of treatment 
for, a pituitary adenoma. Secondary adrenal failure is found usually in conjunction with 
other hormone deficiencies of the anterior pituitary gland (i.e. hypopituitarism). These 
deficiencies may be partial or complete in which case the deficiency state is referred to as 
panhypopituitarism. The causes of secondary adrenal failure are outlined in table 1.3.
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Tumours Adenoma (functioning/non-functioning)
Craniopharyngioma
Meningiomas, gliomas, hamartomas
Dysgerminomas
Pinealomas
Metastasis (lung, breast, prostate)
Vascular Infarction (apoplexy, Sheehan’s syndrome, post CABG) 
antiphospholipid syndrome,snakebite coagulopathy) 
Giant internal carotid artery aneurysm
Infiltrative/inflammatory Lymphocytic hypophysitis
Sarcoidosis
Histiocytosis
Wegener’s granulomatosis 
Haemochromatosis
Vasculitis (e.g. systemic lupus erythematous)
Infective Tuberculosis, Brucellosis, abscess 
HIV, Syphilis
T rauma/destruction Basal skull fracture with pituitary stalk transection
Pituitary surgery and/or radiotherapy
Cranial irradiation for central nervous system malignancy
Functional Childhood deprivation 
Chronic disease 
Weight loss/low BMI 
Anorexia nervosa 
Athlete syndrome
Congenital Single/multiple hormone deficiencies
Table 1.3 Causes of secondary adrenal insufficiency/hypopituitarism
1.4.2.2 Investigations in secondary adrenal insufficiency
The biochemical diagnosis of secondary adrenal insufficiency, like primary adrenal 
insufficiency, is based on a reduced or absent cortisol response to a stimulus but unlike 
primary adrenal failure this is found in conjunction with undetectable or inappropriately 
low ACTH. There is often other associated hormone deficiencies depending on aetiology 
and the majority can be confirmed by basal blood sampling. Dynamic stimulatory tests
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are however required to assess both integrity of the HPA and GH axis. The gold-standard 
investigation remains the insulin tolerance test which assesses cortisol and GH responses 
to induced hypoglycaemia (glucose <2.2 mmol/L). Further investigations are required to 
determine the cause including pituitary imaging (CT or MRI) and, if suspected 
investigations for hypersecretory pituitary adenomas.
1.4.2.3 Pharmacotherapy in secondary adrenal insufficiency
The cornerstone of the management of secondary adrenal insufficiency is glucocorticoid 
replacement and doses identical to those used in primary adrenal failure are utilised. 
However, unlike primary adrenal failure mineralocorticoid replacement is not required, 
this being primarily under the influence of the renin-angiotensin-system. Frequently other 
anterior (thyroxine, testosterone/oestrogen, GH), and occasionally posterior 
(desmopressin), pituitary hormones are replaced simultaneously.
1.4.2.4 Morbidity and mortality in secondary adrenal insufficiency
Quality of life is impaired in secondary adrenal failure although in this group this is not 
likely to be due solely to adrenal insufficiency. A number of studies have demonstrated 
an adverse impact on long term survival [244-247] and cardiovascular disease is again 
implicated here. A number of explanations have been put forward for this increased risk, 
including untreated GH deficiency, suboptimal gonadal hormone replacement, 
unphysiological glucocorticoid replacement (which may induce fat accumulation, 
hypertension and insulin resistance) and the use of radiotherapy. However no studies 
have examined the potential role of DHEA deficiency on cardiovascular risk to date.
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1.4.2.5 DHEA replacement in secondary adrenal insufficiency
DHEA has been shown to be reduced in secondary adrenal failure [248] and, as in 
primary adrenal failure, replacement of DHEA in women with hypopituitarism has been 
shown to improve both libido and activity as judged by the patient’s spouse after 6 
months of treatment [249]. Clinical trials evaluating metabolic effects of DHEA 
replacement in hypopituitarism are scarce. However, it has been demonstrated that 
DHEA supplementation in hypopituitary patients on GH can stimulate an increase in 
IGF-1 levels necessitating a reduction in GH dosage [83]. No study to date has, however, 
specifically examined the effect that DHEA replacement has on markers of 
cardiovascular risk in this patient group.
The presence of pathologically reduced DHEA/DHEAS concentrations in primary and 
secondary adrenal insufficiency suggests that these are ideal conditions in which to 
examine the influence of DHEA replacement on cardiometabolic risk.
The evidence discussed in this chapter may point to beneficial alterations within the 
cardiovascular risk profile in response to treatment with DHEA. We hypothesised that 
DHEA would have a beneficial effect on endothelial function, arterial stiffness and 
cardiovascular risk markers in primary and secondary adrenal failure and postulated that 
these effects might occur, at least in part, through the modulation of body fat and the 
metabolically active substances that it generates.
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1.5 AIMS
1. To assess the effect that DHEA has on adipose tissue by examining the influence 
of DHEA on preadipocyte cell lines and primary cultures and to investigate the 
mechanism behind any observed effects.
2. To determine whether treatment with DHEA in a group of patients with adrenal 
insufficiency has a beneficial effect on endothelial function and markers of 
cardiovascular risk.
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Chapter 2
Effects of DHEA on proliferation and 
differentiation in preadipocyte cell lines
2.1 From body composition to the preadipocyte
The observation that DHEA supplementation can cause a reduction in body fat in 
both animal and human studies has been discussed in chapter 1. At the level of the 
adipocyte a number of possible mechanisms exist that may explain this. Any agent 
that has a negative effect on fat may do so directly or indirectly by reducing the 
number of fat cells per se, inhibiting the ability of the precursor cells to proliferate 
and/or differentiate or finally by reducing the amount of lipid present within the 
individual fat cells (induction of lipolysis or inhibition of lipogenesis). For the 
purpose of this study I have chosen to examine whether DHEA has a direct and 
negative impact on adipose tissue and have chosen to focus on the precursor fat cell 
the preadipocyte, which allows us to explore the possibility of inhibition on both 
proliferation and differentiation.
The preadipocyte represents an intermediate stage in the development of functioning 
cells of mature adipose tissue. Preadipoctyes are derived from the same 
embryological tissue as muscle and cartilage, termed mesoderm. During the third 
trimester of foetal development, pockets of what will form future adipose tissue 
organise around sites of large vascular structures (neck, shoulder, pelvis) and these 
sites retain their adipose tissue concentrations into adult life. The development of 
adipose tissue and vascular structures appears to be closely linked and, as discussed in 
the review by Ailhaud, Grimaldi and Negerl, adipose tissue secretes a number of 
substances that can modulate angiogenesis such as transforming growth factor-p 
(TGF-p); the release of these factors could explain the developmental link between 
these two systems [250]. The possibility of increasing the number of adipocytes that
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an individual possesses after this developmental period is debatable. In cases of 
obesity, since mature adipocytes do not proliferate, immature precursor cells retained 
within mature adipose tissue may be stimulated to differentiate, and/or proliferate, in 
response to environmental and/or genetic factors. ‘Fatness’ therefore may be 
secondary to a combination of increasing lipid content of the adipocytes that then 
enlarge (adipocytes can vary in size from 20-200pm in diameter) coupled with the 
proliferation/differentiation of these latent precursors.
Adipocyte development can be organised into stages (Fig 2.1). Firstly the multipotent 
mesenchymal stem cell loses the ability to become bone and cartilage and is thus 
predetermined to become an adipocyte (unipotent). This cell can be termed an 
adipoblast but potentially still retains the ability to become either WAT or BAT, 
although the precise developmental interactions between these two types of adipose 
tissue are not fully understood. It is likely that unipotent adipoblasts can remain as 
such into adulthood or can become a preadipocyte. The preadipocyte stage is 
associated with growth arrest at the Gi/S phase, in culture often secondary to cell-cell 
contact (contact inhibition), although this not an absolute requirement [251], and at 
this point the cell is committed to becoming a mature adipoctye. The glucocorticoid 
dexamethasone has been shown to influence this point by inhibiting proliferation and 
then stimulating differentiation [252]. This stage is associated with the disappearance 
of the early differentiation markers such as PREF-1. In murine cell lines a limited 
number of growth cycles occur after this point, known as clonal expansion, although 
this may not be the case in human preadipocyte cultures [253].
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Intermediate and late phases of preadipocyte differentiation are characterised by the 
expression of essential transcription factors such as PPARy and CEBP0. In the in 
vitro environment the addition of specific hormones is often necessary to trigger the 
terminal stages of differentiation (e.g. hydrocortisone/dexamethasone [254], insulin 
[255] and tri-iodothyronine [256]) although differentiation in cell lines (3T3-L1) can 
occur in the absence of these hormones. Sex hormones, for which DHEA is a 
precursor, are not a requirement for adipocyte differentiation. A number of 
experimental models of differentiation have been described each using different 
cocktails of hormones and these will be discussed in greater detail later in this 
chapter. The terminal stage of differentiation is characterised by an increase in 
expression of enzymes such as glycerol phosphate dehydrogenase (GPDH) and 
lipoprotein lipase (LPL) that perform routine adipocyte cell functions. With reference 
to DHEA, chronic (12 days) exposure of the preadipocyte cell line 3T3-L1 to DHEA 
has been shown to inhibit glucose 6  phosphate dehydrogenase activity and block 
differentiation when using a differentiation mixture containing both dexamethasone 
and insulin [257]. Furthermore DHEA has been shown to down regulate PPARy in rat 
preadipocytes [144] and one study has demonstrated down regulation of C/EBPa in 
3T3-L1 preadipocytes [258] whereas another study revealed no effect on this 
transcription factor in rat preadipocytes [144].
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Fig 2.1 Developmental stages of the adipocyte
2.1.1 White and brown adipose tissue
The morphological, biochemical and functional differences between WAT and BAT have 
been discussed in chapter 1. The same transcription factor activation and hormonal 
stimuli are involved in the development of both adipose tissue types (PPARy and 
C/EBPs) but in the case of BAT, cold and adrenergic drive are also of critical importance; 
the transcription factor FOXC2 is known to augment adrenergic signalling in BAT.
WAT and BAT arise developmentally from distinct precursor cells; this is evidenced by 
the observation that precursor cells isolated from BAT deposits can be stimulated to 
produce BAT markers (uncoupling protein-1 (UCP-1) mRNA) but similar cells from 
WAT cannot [259]. What is not known is the exact point in development that WAT and
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BAT precursor cell types diverge or at what point that commitment to either cell type 
becomes irreversible, although it is clear that the BAT-WAT conversion is under the 
influence of a number of cofactors such as PPARy-coactivator-1 (PGC-1) that increases 
UCP-1 expression and stimulates increase in mitochondrial number [260]. Other 
cofactors involved include Retinoblastoma protein [261] and p i07 [262].
2.2 Cell lines
Many of the studies examining the mechanisms of adipogenesis have been performed 
using adipoblast (predetermined to adipose lineage) cell lines and in particular the 
embryonic murine WAT preadipocyte cell line 3T3-L1 [263]. A number of other cell 
lines have been utilised (3T3-F442A, Ob 17 and others), but as all of these are 
adipoblasts, it is the latter stages of differentiation that are better understood. Fewer 
studies have focused on BAT, potentially because questions remain over its relevance to 
human physiology beyond the neonatal period. However, owing to the presence of BAT 
in the foetal state and the high DHEA output from the foetal adrenal it was felt that it was 
important to determine if any relationship existed. In order to establish the effect that 
DHEA has on adipose tissue in vitro this study has utilised the mouse WAT preadipocyte 
cell line 3T3-L1 and the SV-40 (simian virus) transformed human BAT preadipocyte cell 
line PAZ6  [264].
2.2.1 3T3-L1
The 3T3-L1 preadipocyte cell line was obtained form the American Type Culture 
Collection. These cells are derived from isolates of the murine 3T3 fibroblast cell line.
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The 3T3 cell line was established by George Todaro and Howard Green in 1963 from 
Swiss mouse (Mus musculus) embryonic tissue [265]. The 3T3-L1 line differs from the 
standard 3T3 line in that it possesses an exaggerated ability to accumulate lipid [266]. 
3T3-L1, like 3T3 cells, grow as a monolayer on plates in culture until confluence is 
reached, at which point contact inhibition is demonstrated. It is following confluence that 
lipid droplets begin to accumulate. Lipid accumulation can be curtailed by keeping the 
cells in a continual state of growth and following trypsinisation the cells lose their lipid 
content and the resultant cells following passage appear more fibroblast-like once more 
(Fig 2.2). The process of lipid accumulation involves the differentiation of preadipocytes 
into adipocytes [267]. This process of differentiation can be augmented by the addition 
of a differentiation mix, containing a cocktail of hormones, into standard culture medium. 
This cell line has proved to be particularly hardy, maintaining functional capacity through 
a large numbers of passages.
3T3-L1 preadipocytes
Fig. 2.2 3 T3-LI cells after 48 hours of routine culture
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2.2.2 PAZ6
The PAZ6  cell line was kindly provided by Vladimir Zilberfarb (Institut Cochin, 
Universite Paris Descartes). It is a human immortalised brown preadipocyte cell line, 
derived by transfecting human vascular stromal cells from infant brown adipose tissue 
with SV (simian virus) 40 antigen under the control of the vimentin promoter [264]. 
These cells can be cultured for prolonged periods (Fig 2.3) and withstand storage in 
liquid nitrogen. If the culture medium is altered to contain pro-differentiating factors the 
cells differentiate into mature brown adipocytes. This can be seen macroscopically with 
the development of lipid droplets and by polymerase chain reaction (PCR) measurement 
of markers of mature brown adipose tissue that are either specific to BAT such as 
uncoupling protein-1 (UCP-1) or are generic to all mature adipoctyes such as LPL [264].
PAZ6  preadipocytes
Fig 2.3 PAZ6  cells after 72 hours or routine culture
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2.3 In vitro models of adipogenesis
The term adipogenesis encompasses WAT and BAT adipocyte differentiation in all its 
stages. As previously discussed various substances can aid the process of differentiation 
in the laboratory setting and these are reviewed in a paper by Rosen and Spiegelman 
[263]. A number of in vitro models have been used to examine this process, which in turn 
has enabled investigators to assess the impact that various reagents have on 
differentiation.
Early studies suggested that cAMP was a requirement for differentiation and employed 
protocols containing methylisobutylxanthine (IBMX), a phosphodiesterase inhibitor that 
increases cAMP levels, in combination with insulin and the glucocorticoid 
dexamethasone. It is well established that insulin is a crucial component in differentiation 
regimens and increases the number of cells that differentiate per sample as well as 
augmenting lipid accumulation [256]. IGF-1, a component of foetal calf serum, may 
interact with insulin to augment differentiation. Dexamethasone reduces expression of 
PREF-1/DLK1, a requirement for terminal differentiation, as previously discussed, but 
the necessity for this class of hormone for differentiation is debatable as is the use of a 
number of other factors. Thyroid hormone, Growth hormone and Retinoic acid have all 
been employed in differentiation protocols to a varying degree. Previous endeavors in the 
Centre for Endocrine and Diabetes Sciences have optimised an in vitro differentiation 
protocol that utlises a number of the factors discussed here and this will be described in 
detail later in this chapter [268, 269].
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2.4 Cellular proliferation and the cell cycle
The predipocyte by definition exists within the cell cycle and therefore maintains the 
potential to proliferate; only when stimulated to differentiate is this potential lost 
(excluding clonal expansion). Proliferation refers to normal cell division or mitosis and 
for differentiation to initiate, proliferation needs to cease, culminating in exit from the 
cell cycle.
Cell division can be divided into separate stages depending on the specific point of 
eukaryotic cell division, which is in turn determined by the amount of genetic material 
present within the cell and it is these stages that make up the cell cycle (Fig 2.4).
M -  Mitosis 
G, -  GAP 1 
Go -  See text 
S - Synthesis 
G2 -  GAP 2
The cell cycle can be divided into 2 stages, mitosis (M) and interphase, with interphase 
subdivided further into 3 stages, GAP1 (Gj), DNA synthesis (S) and GAP 2 (G2) [270]. 
Cells often exit the cell cycle at Gj and enter either permanently, or temporarily, a Go 
stage in which cells no longer undergo cell division; in the context of the preadipocyte it 
is at this point that differentiation occurs. Checkpoints exist at Gj/S (known as the
Fig 2.4 The cell cycle
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restriction point) and G2/M so that if the external environment is not appropriate or if the 
cell is damaged and repair is required, mitosis can be blocked [271].
Cells within the Gi stage carry out predetermined roles appropriate to the tissue in which 
that cell resides. During this stage the cell also generates various enzymes required for the 
next stage in the cycle. The S phase is characterised by DNA replication and once a cell 
has passed though the S phase it contains double the amount of DNA. The G2 phase is 
concerned with preparation for mitosis in which microtubules are formed. During M 
phase the DNA and cytoplasm divides producing 2 daughter cells containing the same 
genetic material as the parent cell.
The cell cycle is controlled by sequences of cyclins and cyclin dependent kinases that can 
be activated by extracellular stimuli. Activation of these results in a phosphorylation 
cascade culminating in the stimulation of transcription factors that promote progression 
of the cell into the subsequent cell cycle stage [272].
2.4.1 Proliferation
Proliferation represents the balance between cell death and cell division which culminates 
in the rate at which a particular cell type increases (or not) in number. This will occur in 
all eukaryotic cells (within the cell cycle) assuming the environment is suitable. In 
standardised culture conditions a particular cell type will divide at a given rate and the 
addition of a non-toxic substrate can either, increase, decrease or have a neutral effect on 
the rate at which cell division occurs. Cell number determination at the end of an 
exposure period can be performed in a number of different ways. Direct visual counting 
using a haemocytometer allows for estimation of the number of cells present per mL of
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cell suspension and this method, with the addition of an appropriate dye (e.g. trypan blue) 
can be used to determine cell viability and thus toxicity. Direct cell counting is open to 
observer bias and is time consuming and so electronic methods of direct cell or particle 
counting have been developed [273]. Cells under investigation are placed in a solution 
through which an electrical current is passed and this solution then flows through an 
aperture of known diameter. Each time a single particle or cell passes through this 
aperture it causes a drop in voltage by increasing aperture impedance. This drop in 
voltage is then amplified and can be recorded on an oscilloscope. The aperture can be 
configured to identify cells/particles of a particular size.
Other methods for assessing the proliferation rate include the incorporation of a
2
radioactive isotope, such as H-thymidine, into the DNA of the dividing cells. This 
process relies on the principle that more radioactive isotope will accumulate in samples 
that are undergoing more cell division. A proportion of cells can be incubated with
potential proliferation inhibitors/stimulants, while others remain in standard culture
2
medium alone. Following this all cells are incubated with H-thymidine which is DNA 
incorporated. Reagents that inhibit/stimulate proliferation will generate samples that emit 
less/more radiation respectively compared to controls when assessed by scintillography.
2.4.2 Cell cycle analysis
The cell cycle has been discussed above and a number of experimental techniques exist to 
determine what impact an external stimulus will have on the distribution of cells within 
the different phases of the cell cycle.
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As cells pass through the stages of the cell cycle the amount of genetic material varies as 
discussed. If cells treated with the reagent under investigation are fixed with ethanol and 
then exposed to a DNA stain, such as propidium iodide, a detailed cycle stage distribution 
map can be generated outlining the number of cells present in each stage at a given time 
point. If this resulting map is compared to untreated samples it is possible to ascertain if a 
particular reagent affects the progression through the cell cycle and hence proliferation. 
The technique of flow cytometry, when coupled with a DNA specific stain, can be used 
to determine cell cycle distribution of a particular sample. A suspension of cells that have 
incorporated the DNA stain is streamed such that each cell separates. At this point, cells 
are exposed to light (usually in the form of a laser) that excites the stain within the DNA, 
generating a specific scatter pattern of light. This is monitored by an array of detectors 
and varies depending on the amount of DNA present within the cell, and thus the stage 
within the cell cycle. As well as describing the relative amounts of cells within each cell 
cycle stage, flow cytometry can be used to determine if a reagent has triggered apoptosis. 
Apoptotic cells reside in a point just prior to the Gi peak and a substantial amount of cells 
located here suggest exposure to an apoptotic stimulus. Other methods are available to 
determine whether a cell has been triggered to undergo apoptosis. The terminal uridine 
deoxynucleotide transferase (dUTP) nick end labeling (TUNEL assay) technique relies 
on attaching labeled dUTP onto damaged DNA of cells about to undergo apoptosis [274]. 
The attached dUTP can then be stained using avidin-conjugate peroxidase which can in 
turn be visualised, following agarose gel electrophoresis, by ultraviolet transillumination.
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2.4.3 Analysis of cell signalling -  phospho-specific antibody Western blotting
Intracytoplasmic cell signalling relies on numerous protein cascades triggered by external 
stimuli that interact both with each other and the cell nucleus. This has the effect of 
altering transcription and modifying cellular function in response to the external 
environment and thus control over both proliferation and differentiation. The proteins 
involved in cell signalling pathways often exist in two forms, phosphorylated and non- 
phosphorylated. In many, but not all cases the phosphorylated form is active (e.g. MAP 
kinase). This dichotomy of form can by quantified using Western blotting, a technique 
originally described by Burnette in 1981 [275], that can differentiate between the inactive 
and active forms of the specific proteins by identifying the phosphorylated protein state, 
thus allowing investigators to identify specific pathway involvement in response to an 
experimental stimulus. A schematic representation of the steps involved in Western 
blotting is shown in Fig 2.5. The use of phosphorylation state-specific antibodies in the 
investigation of cell signalling events is widespread and is discussed in the review paper 
by Mandell [276] . Following exposure to the reagent under investigation, cells are 
homogenised and the protein components separated by electrophoresis using gels loaded 
with negatively charged sodium dodecyl sulphate (SDS). This covers the proteins which 
then move towards the positive electrode. Smaller particles migrate faster through the gel 
and take up terminal positions corresponding to molecular weight which can be compared 
to a stained marker, placed in an adjacent lane that contains proteins of known molecular 
weight.
The gel is then electroblotted onto a membrane (nitrocellulose or polyvinylidene fluoride 
(PVDF)) to enable detection. After blocking to prevent non-specific antibody attachment,
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the membrane is incubated under gentle agitation with a primary antibody (directed 
against the protein under investigation) and then subsequently with a secondary antibody 
(directed against a species specific component of the primary antibody). The secondary 
antibody typically contains a chemiluminescent conjugate that when activated emits 
luminescence, proportional to the amount of protein present, which is captured on 
photographic film. To confirm the identification of the protein under investigation a 
comparison is made between the pattern of bands on the developed film and the 
membrane blot.
Sam ples loaded
Primary antibody
PVDF membrane
- rT
Gel eletrophoresis —  Electroblotting
Fig 2.5 Western blotting schematic
2.4.4 In vitro assessment of differentiation
The extent to which a particular preadipocyte sample undergoes differentiation can be 
quantified by a number of methods. Most simply it may be appreciated visually through
Detection
Secondary antibody
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light microscopy with the characteristic appearance of rounded mature adipocytes 
containing numerous lipid filled droplets (Fig 2.6). The number of differentiation foci per 
randomly chosen high power field can give an indication of the relative extent of 
differentiation occurring in different samples. This method may be strengthened by 
increasing the number of experimental samples examined but is however open to 
observer bias and the counts should be ideally performed by an independent observer.
Fig 2.6 Foci of differentiation in primary omental preadipocytes 
A further method of differentiation assessment is to determine the extent of lipid droplet 
formation with the use of a lipid specific stain. Oil red O stains the lipid component of 
ethanol fixed mature adipocytes (Fig. 2.7).The relative amount of stain and thus 
differentiation can be ascertained by absorbing the stain in 1 0 0 % propan-2 -ol which can 
then be quantified by colourimetry.
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Fig 2.7 Oil red O stain in 3T3-L1 preadipocytes
A potentially more precise method to determine relative differentiation rates in control 
and reagent exposed samples is to measure transcripts for markers of various stages of 
adipogenesis. This involves RNA extraction followed by reverse transcription and 
real-time quantitative polymerase chain reaction (RT-QPCR) (Fig 2.8).
Extracted RNA is reverse transcribed to produce cDNA which is then amplified by PCR. 
With the use of primers directed to differentiation specific factors (PPARy, GPDH, LPL) 
the extent of differentiation occurring in a reagent exposed sample can be accurately 
determined relative to a control.
The process of RT requires the use of one of two types of reverse transcriptase enzyme, 
avian myeloblastosis virus (AMV), or moloney murine leukeamia virus (MMLV). To 
generate cDNA these enzymes require the presence of a primer. For the purposes of this 
study the primer oligodT has been utilised and this binds to the poly (A) tail at the 3’ 
mRNA terminus. Other primer types can be used such as oligonucleotides of random 
sequences using large numbers of diverse oligonucleotides or specific oligonucleotide 
sequences corresponding to a particular mRNA.
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The cDNA generated by RT provides the template for PCR [277] which occurs according 
to a sequence of temperature sensitive events. Firstly a short high temperature is 
employed to denature the double stranded cDNA. Following this a cooling phase occurs 
during which predesigned oligonucleotide primers anneal to the cDNA sequences of 
interest. An elongation phase then follows in which a DNA polymerase triggers DNA 
synthesis initiating from the cDNA adhered primers, the reaction utlising pre-added 
deoxynucleotide triphosphates (dNTPs).
This tri-stage sequence is repeated numerous times increasing the amount of DNA 
exponentially. Eventually the rate of DNA production plateaus secondary to substrate 
depletion or product/primer competition for cDNA binding sites [278].
Each PCR reaction is, however, open to variability and the efficiency of each reaction can 
be affected by reaction conditions, target region and primer sequences and target region 
length. When quantifying results from PCR reactions it is necessary to attempt to cater 
for efficiency variability. Quantification of PCR (Q-PCR) is performed by comparing the 
results obtained per amount of input RNA to a series of consecutively diluted target 
sequence samples [279]. In order to accommodate potential efficiency discrepancies and 
loading errors each reaction is compared to a housekeeper gene such as human adenosine 
phosphoribosyltransferase (APRT) or acidic ribosomal phosphoprotein (ARP). 
Housekeepers are so termed, as they are involved in routine cellular functions, are found 
in all cells (APRT catalyses the conversion of adenine and 5-phosphoribosyl- 
pyrophosphate to AMP [280]) and are ubiquitously expressed despite alterations in 
experimental conditions. Q-PCR results from the gene under investigation are expressed 
relative to those from the housekeeper.
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Following the RT step it is possible to perform a semi-quantitative PCR. The resulting 
PCR product can be separated by agarose gel electrophoresis and visualised using 
ethidium bromide. This conventional PCR provides a check point that confirms the RT 
reaction has generated the correctly sized product by comparison with an appropriate 
range base-pair ladder.
The amplification of mRNA and the detection of the PCR product can be combined such 
that results can be generated in real-time. PCR product detection is further aided by the 
use of DNA specific dyes. SYBR Green is one such dye that binds to double stranded 
DNA (dsDNA). The binding process increases dye fluorescence in line with product 
generation during PCR (Fig 2.8). The number of PCR cycles that are required for 
fluorescence to increase beyond an arbitrary baseline threshold is used as a quantification 
method and termed the crossing the threshold (Ct) value. Samples containing less input 
cDNA (more dilute) will require more cycles to cross this threshold and will therefore 
have a higher Ct value. As well as quantification the Ct values provides a quality check as 
the Ct value should occur on the exponential/linear portion of cDNA amplification; 
plotting the Ct values against Log concentration should generate a linear graph with a 
correlation coefficient close to 1.0. Another quality check is melting point analysis. At a 
specific melting temperature dsDNA will dissociate into single strands characterised by a 
dramatic reduction in fluorescence. Melting point analysis provides a quality control 
ensuring that the correct product has undergone polymerisation. The correct DNA 
product for a particular pair of primers will have the same melting temperature (Tm-  
temperature where 50% of DNA becomes single stranded) dependent on base 
composition (GC rich DNA has a higher Tm whereas AT rich DNA has the converse). At
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the end of RT-PCR amplification the temperature is increased to the melting temperature 
for this purpose, the presence of other smaller peaks can indicate contaminating DNA or 
primer-dimer.
dsDNA
Primer 
SYBR Green
SYBR Green PCR
mRNA
cDNA
/ \
Emitted light
Standard PCR
Reverse transcription ■ Denaturation Annealing Elongation
Fig 2.8 PCR schematic
2.5 Previous studies
A number of previous in vitro studies have attempted to examine the influence that 
DHEA has on adipose cell biology. These studies have focused on WAT with no BAT 
studies performed to date. DHEA has been shown to inhibit conversion of 3T3 fibroblasts 
into adipocytes and also the proliferation of 3T3-L1 cells [138, 139]. In terms of the 
mechanisms by which adipogenesis may be inhibited a study by Kajita et al demonstrated 
that DHEA can bring about a down regulation of PPARy expression in adipocytes [144] 
and as already discussed this transcription factor is the major controller of adipogenesis.
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Furthermore the differentiation of 3T3-L1 fibroblasts into adipoctyes was found to be 
blocked by DHEA [257]. In relation to cell signalling DHEA has previously been shown 
to reduce the proliferation of vascular smooth muscle cells and this was demonstrated to 
involve alterations in MAP kinase activity [212].
2.6 Aims
Given the previous information on the potential impact of DHEA supplementation on 
body composition in humans together with the reduction of fat mass and protection 
against weight gain observed in rodent models, we hypothesised that DHEA exerts a 
direct and inhibitory action upon adipose tissue. The work presented within this chapter 
aims to investigate this further through analysis of DHEA action on preadipocyte cell line 
(3T3-L1 and PAZ6 ) proliferation and differentiation, including an investigation of the 
mechanisms involved in any observed effects
2.7 Materials and Methods
All culture medium constituents were obtained from BioWhittaker (Belgium) unless 
otherwise stated. A number of experimental reagents have been used during this project, 
DHEA, DHEAS, P-oestradiol, testosterone [all Sigma-Aldrich Company Ltd, Dorset,
UK] and trilostane [donated by Bioaccelerate Inc, London, UK]. All reagents were 
dissolved in dimethyl sulfoxide (DMSO) [Sigma-Aldrich Company Ltd, Dorset, UK] to 
produce stock solutions of 10' molar. As DMSO has been demonstrated itself to have an 
impact on 3T3-L1 adipogenesis [281] further dilutions were made using cell type 
appropriate culture media so a maximum concentration of DMSO of 0.1% was present in
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any one experiment, furthermore 0.1 % DMSO was included in the control in all 
experiments.
2.7.1 Culture Conditions
3T3-L1 and PAZ6  cells were grown in 75cm2 Nunclon™ delta surface flasks [Nunc, 
Roskilde, Denmark]. 3T3-L1 medium consisted of Dulbecco’s modified Eagle medium 
(DMEM) (with 4.5g/L glucose without sodium pyruvate) and Ham’s F12 complete 
medium (ratio 1:1) supplemented with 10% foetal calf serum (FCS) (EU approved), 2mls 
sodium pyruvate, 3mls of 1.5% sodium bicarbonate, lOOU/mL penicillin [Cambrex, 
Berkshire, UK] and 1 OOpg/mL streptomycin [Cambrex, Berkshire,UK].
The PAZ6  culture medium contained DMEM and Ham’s F12 complete medium (ratio 
1:1), heat inactivated fetal calf serum (8 %), 3ml Hepes buffer, 2ml pyruvate, lOOu/mL 
Penicillin and 100pg/mL Streptomycin.
All cell culturing was performed in humidified 5% CO2 atmosphere at 37°C, the culture 
medium being changed every 3rd day.
2.7.2 Routine maintenance of cell lines
On reaching confluence the cells underwent passage. To remove the cellular monolayer 
culture medium was aspirated and cells washed with 2mL 1 % trypsin [Cambrex,
Berksire, UK] then incubated with a further 2mLs of 1 % trypsin until the cells were in 
suspension (5-10 minutes). To the resultant suspension 8 mLs of culture medium warmed 
to 37°C was added for trypsin inactivation. The solution was then transferred to fresh 
flasks or further diluted with culture medium and plated for experiments.
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To replenish the cell line bank, excess cells were trypsinised as above and centrifuged at 
1 OOOrpm for 5 minutes. The remaining cell pellet was then re-suspended in 500 pL 
Freezing mix (FCS containing 10% DMSO) and transferred to 2mL sterile cryo-tubes and 
placed into an insulating freezing box containing propan-2-ol [Fisher Scientific UK Ltd, 
Leicestershire, UK] for slow freezing (rate of l°C/min) in a -80°C freezer [New 
Brunswick Scientific] for 24 hours until transfer to liquid nitrogen (-190°C).
To thaw samples from liquid nitrogen, cells in freezing mixture were warmed in a water 
bath and immediately placed in 9.5mLs of standard medium and centrifuged for 5 
minutes at 1 OOOrpm. Medium was aspirated and the resulting cell pellet was resuspended 
in 1 Omls of fresh medium and transferred to a flask and incubator as above.
2.7.3 Direct cell counting
Culture medium was removed and cells trypsinised as above. The approximate number 
of cells per ml of solution was then estimated using a haemocytometer (Camber counter, 
[Weber Scientific International Ltd, Middlesex, UK]) and then diluted, depending on 
suspension density, to produce intra-well concentrations of 103 or 104 cells. Following 
transfer to 24 well plates (lmL per well of appropriate culture medium) cells were 
incubated at 37°C for 24 hours allowing optimal cell-to-plate attachment. DHEA was 
then added to wells in decreasing concentrations (1 O'6 molar to 1 O'9 molar) in 
quadruplicates. To the first column no reagent was added and to the second column 0.1% 
DMSO was added as a control. All samples were incubated for 24 and 48 hours then the 
medium was removed and each well was trypsinised (0.5mLs trypsin per well). The 
resulting suspension was transferred to a cell counting cuvette containing 1 OmLs of
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isoton (Coulter Isoton II Diluent [Beckman Coulter, Gmbh, Germany]). Each well was 
also washed with 0.5mLs of isoton which was transferred to the same cuvette. Cells were 
counted using a particle counter [Particle counter size analyzer Z2 , Beckman Coulter 
Gmbh, Germany] with particle size set between 3.8nm and 9.0nm. Each sample was 
counted twice and an average value used in the statistical analysis.
2.7.4 Toxicity assay -  Trypan blue
3T3-L1 and PAZ6  cells plated in 24 well plates (Cell concentrations 104or 103 per mL 
per well) were incubated with DHEA 1 O' 5 molar and 10"9 molar and DMSO 0.1 % and 
untreated cells (standard culture medium only) for 48 hours. Cells were then trypsinised 
producing a suspension that was then centrifuged at 1 OOOrpm for 5 minutes. The resulting 
cell pellet was resuspended in 50pL of culture medium to which was added an equal 
volume of Trypan blue (0.1%) [Sigma-Aldrich Company Ltd, Dorset, UK] (from stock 
solution 0.4% diluted with PBS). Cells were immediately examined under a light 
microscope using a haemocytometer. Cells exposed to a toxic substance have damaged 
membranes and take up the blue dye.
2.7.5 Flow cytometry
3T3-L1 and PAZ6  cells (103per mL) were plated into 6  well plates [Nunclon™ delta 
surface, Nunc, Roskilde, Denmark] in standard medium (3mL per well), after 24 hours 
DHEA was added to produce an intra-well concentration of 1 O'6 molar. In separate wells 
DMSO 1% was added as a control. After 48 hours the medium was removed and the well 
contents trypsinised and centrifuged at 1 OOOrpm for 5 minutes producing a cell pellet, to
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which lmL of cold (4°C) 70% ethanol was added drop-wise. The solution was transferred 
to 1.5mL tubes and stored at -20°C.
The ethanol was removed following centrifugation at 1 OOOrpm for 10 minutes and the 
samples washed twice with PBS. Propidium iodide (50pg/mL in PBS) and RNAse A 
(50pg/mL) were added and incubated for 20 minutes at 37°C. The resulting samples were 
then detected using a FACSCalibur flow cytometer [Dakocytomation, Cambridge, UK]. 
For these experiments reagent provision and FACSCalibur flow cytometer operation was 
kindly performed by Dr E. Wang, Department of Immunology, School of Medicine, 
Cardiff University.
2.7.6 Western blotting
Sample collection: Cells grown in 6  well plates until confluence were washed x3 with 
lmL of PBS then incubated in serum free medium (DMEM only) for 2 hours followed by 
fresh serum free medium for a further 2 hours. DHEA dissolved in standard culture 
medium was spiked into wells (10'7 molar) at time points of 5, 10 and 20 minutes. For 
controls 0.1% DMSO was spiked into separate wells at the same time points. Cells were 
then washed 3x with cold (4°C) PBS-V (lmL sodium vanadate [Sigma Aldrich Company 
Ltd, Dorset, UK] per lOOmL PBS) then homogenised on ice with a lmL syringe plunger 
in 200pL of SDS-PAGE Loading buffer (Appendix II) containing lOOmM sodium 
vanadate (lOpL/mL), 1 OOmM phenylmethanesulphonyl fluoride (PMSF) (lOpL/mL) and 
CLAP (chymostatin, leucopeptin, antipain and pepstatin) (lpL/mL) [both Sigma Aldrich 
Company Ltd, Dorset, UK] and stored at -80°C.
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Gel Electrophoresis: 50pL of each homogenate was boiled for 5 minutes and then 
centrifuged for 5 minutes at 13,OOOrpm then loaded into stacking gel wells (Appendix II) 
and separated on a 10% acrylamide gel, (Appendix II) (resolves proteins in size range 21 - 
100 kDa), using a mini-protean II apparatus [Bio-Rad Laboratories] at a constant voltage 
of 200v for 40 minutes.
Electroblotting: This was performed by placing the gel in contact with a Hybond1M 
PVDF membrane [GE Healthcare UK Ltd, Buckinghamshire]. The constituents of the 
electroblotting cassette were arranged as shown in Fig 2.9 and placed into a blotting tank 
(mini-protean II apparatus) [Bio-Rad Laboratories] with blotting buffer (Appendix II) and 
an ice pack. Blotting was performed over 1 hour at 350mA with stirring.
Cassette side (black) 
Foam
Filter paper
Filter paper 
Foam
Cassette side 
Fig 2.9 Preparation of cassette for electrolotting
Detection: The membrane was washed with TBS-T (appendix II) and placed in 50mL 
blocking buffer (appendix II) for 1 hour on an orbital mixer then incubated in primary 
antibody (4pL of phospho p44/42 MAPK mouse mAb, [Cell signaling Technologies]) 
dispersed in 8 mL blocking buffer overnight at 4°C on an orbital mixer. The membrane 
was washed 3X with TBS-T for 5 minutes and incubated with the secondary antibody
Gel 
Membrant
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(2pL ECL antimouse IgG horseradish peroxidase linked whole antibody (from sheep), 
[GE Healthcare UK Ltd]) dispersed inlOmL blocking buffer for 1 hour at room 
temperature on an orbital mixer. The membrane underwent a number of TBS-T washes 
(2><30 seconds, 1x15 minutes, 3 x5  minutes) and was then detected following darkroom 
protocol using ECL detection plus kit [GE Healthcare UK Ltd, Buckinghamshire, UK] 
according to the manufacturer instructions. The resulting photographic films were washed 
in water then dried in air before marking the standards by aligning the film with the 
membrane.
To reprobe the blot for total MAP kinase the membrane was incubated in pre-warmed 
(60°C) stripping buffer (appendix II) in a hybridisation oven at 60°C for 30 minutes with 
gentle mixing. The membrane was again washed with TBS-T then incubated with total 
MAP kinase targeted primary antibodies (2pL ERK1 rabbit polyclonal IgG and 2pL 
ERK2 rabbit polyclonal IgG, [Santa Cruz, Biotechnology]) dispersed in 8 mL of blocking 
buffer for 1 hour at room temperature. After another wash the membrane was incubated 
with the secondary antibody (2pL ECL antirabbit IgG Horseradish peroxidase linked 
whole antibody (from donkey), [GE Healthcare UK Ltd, Buckinghamshire, UK]) 
dissolved in 1 OmLs blocking buffer to 1 hour at RT on an orbital mixer. The membrane 
was then washed and detected as above.
2.7.7 Adipogenesis protocol
3T3-L1 and PAZ6  cells were plated into 6  well plates and incubated in standard medium 
at 37°C until confluent at which point the medium was changed to a differentiation mix 
(Standard DMEM/F12 medium supplemented with 5% FCS, 17pM pantothenic acid*,
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lOOnM hydrocortisone*, 33pM biotin*, 500nM insulin*, lpM  pioglitazone**, 0.2nM tri­
iodothyronine*) [*Sigma Aldrich, ** kindly supplied by Takeda Pharmaceuticals, Osaka, 
Japan] with added DHEA (10'7 molar) /DMSO 0.1% control. Incubation was continued 
for 12 (3T3-L1) and 15 days (PAZ6 ) with differentiation mix changes every 4 days in 
3T3-L1 and every 5 days in PAZ6  coinciding with cell (for RNA extraction) and 
conditioned medium collection. For nucleoprotein complex dissociation lmL of trizol 
was added to each well and left for 15 minutes at room temperature then transferred to 
1.5mL tubes and stored at -80°C. At terminal differentiation photographs were taken and 
foci of differentiation counted.
2.7.8 Oil red O staining
The differentiation protocol was conducted as above in 24 well plates to terminal 
differentiation. 0.5g of oil red O was dissolved in 1 OOmL of propan-2-ol prior to use and 
12mLs of this solution was mixed with 8 mLs of distilled water which was then 
immediately filtered.
Each well was washed with lmL PBS then fixed with 500pL of 60% propan-2-ol. 
Following a further lmL wash with PBS. 300pL of the filtered oil red O solution was 
added to each well for 15 minutes at room temperature then removed. This was followed 
by 3 x washes with 1 mL distilled water and photographs were taken. 200jiL of 100% 
propan-2-ol was then added to each well then transferred to a 96 well plate which was in 
turn placed in an optical density reader [OpsysMR microplate reader, Dynex 
Technologies, Chantilly, USA] set to read at OD4 9 0 .
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2.7.9 Markers of adipogenesis measured by QPCR
RNA extraction: 0.2mLs of chloroform was added to each lmL sample collected for 
RNA extraction and then shaken vigorously and left at room temperature for 2 minutes 
prior to (cold) centrifugation at 4°C [Mikro 22R, Heittich Zentrifiigen, Germany] at 
12,OOOrpm for 15 minutes. This separates the sample into three phases; the uppermost 
aqueous phase contains the RNA, which is then transferred into a new 1.5mL tube,
0.5mL of propan-2-ol was added and mixed gently. Following 10 minutes at room 
temperature samples were cold centrifuged once more at 10,OOOrpm for 10 minutes. The 
resulting pellets were then washed with lmL 75% ethanol which was then removed by 
cold centrifugation at 7500rpm for 5 minutes. The RNA pellet was then redissolved in 
50pL of nuclease free water [Promega] by incubation at 60°C for 10 minutes on a heating 
block, then stored at -80°C. RNA concentration (ng/mL) and ratios were then calculated 
with a spectrophotometer [GeneQuant pro RNA/DNA calculator Biochrom Ltd, 
Cambridge, UK]. Sufficient sample quality was defined as a 260/280 ratio of greater than 
1.7.
Reverse transcription: 1 pg of RNA was used in each RT reaction and preheated to 60°C 
for 10 minutes on a heating block. The remaining RT reaction constituents are shown in 
table 2.1.
RT reaction constituent Amount per reaction
oligodT 4pL (500ng/pL)
RNAse inhibitor (RNasin) lpL (40U/pL)
dNTP 4pL (lOmM)
MMLV reverse transcriptase lpL
5x First-Strand buffer 4pL
nuclease free water To final volume of 20pL
Table 2.1 RT reaction constituents
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Samples in nuclease free 500pL microtubes underwent treatment at 37°C for 60 minutes 
followed by 95°C for 5 minutes in a Techne TC-512 standard PCR machine [Barloword 
Scientific Ltd, Staffordshire, UK] and the generated cDNA was stored at 
-20°C.
Standard Polymerase chain reaction: This was performed using 1 pL input cDNA and 
PGK (phosphoglycerate kinase) housekeeper primers in nuclease free 500pL microtubes 
with reaction constituents described in table 2.2.
Standard PCR reaction 
constituent
Amount per reaction
PGK primers (human for 
PAZ6, mouse for 3T3)
lpL
Taq (DNA polymerase) 0.5pL
dNTP l.OpL (lOmM)
10x PCR buffer 2.5pL
nuclease free water To a final volume of 
25pL
Table 2.2 Standard PCR reaction constituents.
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The PCR machine generated the following temperature sequence to perform the reaction.
95°C (3min)
I
[95°C (3086c)- I 60°C(30sec) 72°C(1min)) JI
72°C(5min)
I
Hold 4°C
Fig 2.10 Temperature sequence in standard PCR reaction
The PCR product was separated on a 2% agarose gel (appendix II) at 150v for 25
minutes. The resulting gel was then visualised using ethidium bromide (0.5pg/mL) 
(Sigma Aldrich) under UV light (Alpha Innotech Corporation, Multilmage™ light
cabinet) and compared to a lOObp ladder (Promega, Madison, WI, USA).
Quantitative polymerase chain reaction: Plasmid maxi preps for standard curves and
optimised primers for mouse and human genes of interest were gifts from Dr Neera
Agarwal and Dr Lei Zhang respectively, Centre of Endocrine and Diabetes Sciences,
School of Medicine, Cardiff University. Primers were obtained from (tables 2.3 and 2.4)
invitrogen.
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Gene
Forward primer Reverse prim er Size
Sequence (5’—>3’) Exon Tm
( ° C )
Sequence (5’—>3’) Exon Tm
(°C) b a s e  p a irs
ARP GAG GAA TCA GAT 
GAG GAT ATG GGA
7 60 AAG CAG GCT GAC 
TTG GTT GC
7 60 172
PPARy TTT TCA AGG GTG CCA 
GTTTC
6 60 AAT CCT TGG CCC TCT 
GAG AT
6 60 220
GPDH ATG CTC GCC ACA GAA 
TCC ACA C
8 60 AAC CGG CAG CCC 
TTG ACT TG
8 60 124
Table 2.3 Mouse primer sequence
Gene Forward primer Reverse primer Size
Sequence (5’—>3’) Exon Tm
(°C)
Sequence (5’—>3’) Exon Tm
(°C) b a s e  p a irs
APRT GCT GCG TGC TCA TCC 
GAA AG
3 60 CTT TAA GCG AGG TCA 
GCT GC
5 60 247
PPARy CAG TGG GGA TGT CTC 
ATA
3 60 CTT TTG GCA TAC TCT 
GTG AT
5 60 390
LPL GAG ATT TCT CTG TAT 
GGA CC
7 60 CTG CAA ATG AGA CAC 
TTT CTC
9 60 275
UCP-1 GGG GCT TCA GCG GCA 
AAT CAG
2 60 TAT AAG TCC CCG TGT 
AGC GAG GTT
3 60 236
PGC-1 GAA GAG CGC CGT GTG 
ATTTA
10-11 60 CGC TGT CCC ATG AGG 
TAT TC 13 60 433
Table 2.4 Human primer sequences
Real time Q-PCR was quantified relative to a housekeeper, for human samples APRT and 
for the murine samples ARP. Each Q-PCR reaction required 1 pL of cDNA/standard, 
12.5pL of SYBRgreen mastermix (Invitrogen) and appropriate quantities of forward and 
reverse target gene primers (Table 2.4) and nuclease free water [Promega] (to final 
volume of 25pL) that were analysed simultaneously with the diluted standard series (107 
to 10 transcript copy number).
Once placed into the PCR 96 well plate the solutions were centrifuged for 5 minutes at 
10,OOOrpm. The plate was then transferred to the Stratagene mx3000P® thermocycler and 
analysed using the thermal profile below.
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Enzyme activation: 10 mins at 95°C
I
[Denaturation: 30 sec 95°C Annealing: 60 sec 60°C Elongation: 30 sec 72°C
I
DNA melt
60 sec 95°C 
30 sec 55°C 
30 sec 95°C
Fig 2.11 Thermocycling protocol for Q-PCR reactions
Q-PCR was performed on duplicate samples averaged for analysis. Results were 
expressed as fold change in target gene copy number relative to control corrected for the 
reference gene (APRT/ARP).
Gene Primer
concentration
(mouse)
Primer
Concentration
(human)
Forward Reverse Forward Reverse
ARP 200nM 200nM - -
APRT - - lOOnM lOOnM
PPARy 200nM 200nM 300nM 500nM
GPDH 500nM 500nM - -
LPL - - 300nM 300nM
UCP-1 - - 500nM 300nM
PGC-1 - - 500nM 500nM
Table 2.5 Optimised primer combinations
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2.8 Statistical analysis
All statistical analysis was performed using SPSS for windows (Microsoft) version 
12.0.1. Graphs for non-parametric data were also generated from SPSS version 12.0.1.
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2.9 Results
Our hypothesis, that DHEA has a negative impact on adipose tissue, was examined using 
a preadipocyte experimental model such that inhibition of either proliferation of 
differentiation could be determined. We chose to begin our studies with an assessment of 
the former.
2.9.1 DHEA inhibits the proliferation of preadipoctye cell lines
In the absence of treatment 3T3-L1 and PAZ6 preadipocytes proliferate at specific rates 
which can be expressed in terms of doubling times. In our experimental model, doubling 
times were found to be approximately 22 hours for 3T3-L1 cells and 28 hours for the 
PAZ6 cells. DHEA appeared to produce a reduction in proliferation rates in both cell 
types. It should be noted however that within the same cell line some differences in 
proliferation rates were observed in different samples, the PAZ6 preadipocytes however, 
had uniformly slower proliferation rates and thus doubling times relative to the 3T3-L1 
preadipocytes.
The generated data sets were not normally distributed and thus defined as non-parametric 
and analysed according to median and interquartile range (IQR) (Table 2.6). Friedman’s 
test was performed on each experiment and Wilcoxon Signed Ranks test was performed 
on individual treatments relative to control. For ease of interpretation all 3T3-L1 (WAT) 
results have been represented graphically in light yellow and the PAZ6 (BAT) in brown.
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Median and IQRs for 3T3-L1 preadipocytes treated with DHEA for 24 hours
Cell 
T reatment
Median and IQR
(number of cells per mL per well)
Non treatment 4642 (3525-8231.75)
Control (DM SO 0.1% ) 5851 (3827-7824)
DHEA 10'5M 5121.5 (3404-7041)
DHEA 10 'M 5352.5 (3531-6976)
DHEA 10'6 M 4811 (3729.75-6497)
DHEA 10'5 M 3462 (3008.5-4128.25)
Table 2.6 1 x 103 3T3-L1 cells were plated in 24 well plates (day 0) and trypsinised and 
counted (coulter counter) on days land 2. The results are the median and interquartile 
ranges for 3T3-L1 cells treated with varying concentrations of DHEA for 24 hours
expressed as number of cells per mL
Box-and-whisker plot demonstrating the effect of DHEA on 
proliferation of 3T3-L1 cells following 24 hours exposure
Cells/well
10000-
8 0 0 0 -
6 0 0 0 -
4 0 0 0 -
2000-
Friedm an te s t p<0.001
Box-and-whisker
highest value 
75th centile
*p=0.015
*p=0.002
*p<0.001
median
'W ilcoxon Signed 
R anks te st
25th centile 
Lowest value
o/*  -  outliers, IQRs from 
median
■ i i i i
DMSO (0.1%) DHEA 10-8 DHEA 10-7 DHEA 10-6 DHEA 10-5
DHEA (logM)
Fig 2.12 Box-and-whisker plot showing the effect on proliferation o f 3T3-L1 cells
following 24 hours exposure to various concentrations o f DHEA. Results shown are a
representative combination o f two experiments performed in quadruplicate
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Median and IQRs for 3T3-L1 cells treated with DHEA for 48 hours
Cell 
T reatment
Median and IQR 
(cell number per mL per 
well)
Non treatment 9695 (6054-10197.5)
Control (DMSO 0.1%) 8024.5 (6258.25-10601.25)
DHEA 10'8 M 6129.5(5234.75-10925)
DHEA 10 ' M 6034.5 (5488.5-7484.5)
DHEA lO^M 5879.5 (5526-7281)
DHEA 10'5M 3490 (3165.25-4332.75)
Table 2.7 1 xlO3 3T3-L1 cells plated in 24 well plates as described above results are 
median and interquartile ranges following 48 hour treatment with varying concentrations
of DHEA
Box-and-whisker plot demonstrating the effect of DHEA on 
proliferation of 3T3-L1 cells following 48 hours exposure
Cells/well
12000-
10000-
8000-
6000-
4000-
2000 -
1  X
T
Friedm an T est p<0.0001
*p=0.002 
*p=0.001 —t-
X
1  *p=0.001
* Wilcoxon 
Signed 
Ranks test
I I I I I
DMSO DHEA 10-8 DHEA10-7 DHEA10-6 DHEA10-5
(0 .1%)
DHEA (logM)
Fig 2.13 Box-and-whisker plot showing the effect on proliferation o f 3T3-L1 cells
following 48 hours exposure to varying concentrations o f DHEA. Results are a
representative combination o f 2 experiments performed in quadruplicate
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The tables and figures presented demonstrate that DHEA significantly inhibits 
proliferation at 24 and 48 hours in 3T3-L1 cells. The PAZ 6 cell line was then 
investigated.
Median and IQRs for PAZ6 cells treated with DHEA for 24 hours
Cell
Treatment
Median and IQR
(Cell number per mL per well)
Non treatment 3807 (3533.25-4010.75)
Control (DMSO 0.1%) 3321 (3133-3684.5)
DHEA 10'* M 2630 (2440-2911)
DHEA 10'7 M 2583 (2568-2910)
DHEA 10'6 M 2388.5 (2229-2536.25)
DHEA 10 s M 1450(1277-1698.5)
Table 2.8 Experiments performed as with 3T3-L1 cell results are median and interquartile 
ranges for PAZ6 cell following 24 hours exposure to varying concentrations of DHEA
Box-and-whisker plot demonstrating the effect of DHEA on 
proliferation of PAZ6 cells following 24 hours exposure
Cells/well
1000 -
Friedman test p<0.0001
* p = 0 .0 2
* p = 0 .001
* p = 0 .0 0 1
* Wilcoxon 
Signed Ranks 
T est
Control DHEA 10-8 DHEA 10-7 DHEA 10-6 DHEA 10-5 
(DMSO 0.1%)
DHEA (logM)
Fig 2.14 Box-and-whisker plot showing the effect on proliferation of PAZ6 preadipocytes 
following 24 hours exposure to varying concentrations of DHEA. Results are a 
representative combination of 2 experiments performed in quadruplicate
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Median and IQRs for PAZ6 cells treated with DHEA for 48 hours
Cell
Treatment
Median and IQR
(Cell number per mL per well)
Non treatment 7049 (6435-8680.25)
Control (DMSO 0 .1%) 7852 (6370-9019)
DHEA 10'8M 5844 (4519-6719.75)
DHEA 1 0 'M 4892 (4633.75-6081.25)
DHEA lO^M 5484 (4626.5)
DHEA 1 O'5 M 1558(1504.25-1700.25)
Table 2.9 Experiments conducted as previous results are median and interquartile range 
for PAZ6 cells following 48 hours exposure to varying concentrations of DHEA
Box-and-whisker plot demonstrating the effect of DHEA on 
proliferation of PAZ6 cells following 48 hours exposure
10000- ■
8 000--
Cells/well eooo- -
4000- -
F r ie d m a n  t e s t  p = 0 .0 0 1
* p = 0 .0 2 5
S
* p = 0 .0 2 8  
^  ■
2000- - W ilcoxon  S ig n e d  
R a n k s  te s t
* p = 0 .0 1 2
 1 1 1 1 1-----
C on tro l DHEA 10-8  DH EA 10 -7  DHEA 1 0 -6  D H EA  10-5  
(D M S O  0 .1 % )
DHEA (logM)
Fig 2.15 Box-and-whisker plot showing the effect on proliferation o f PAZ6 preadipocytes
following 48 hours exposure to varying concentrations o f DHEA. Results are a
representative combination o f 2 experiments performed in quadruplicate
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• 8Our results show that DHEA at concentrations as low as 10' molar (excluding 48 hours 
in 3T3-L1 cells) had an inhibitory effect on proliferation in both cell types. Also, overall 
there was no significant difference in proliferation between the non treatment samples 
and the DMSO controls (Wilcoxon Signed Ranks test p=0.456). Circulating 
concentrations of DHEA are in the nM range but as previously discussed intra-adipose 
concentrations may be an order of magnitude higher still. Due to the differing nature of 
the cells lines utilised in standard culture conditions (PAZ6 cells have a slower 
proliferation rate/doubling time than 3T3-L1 cells) it is not possible to determine if one 
cell type is more proliferation-sensitive to DHEA than another.
DHEAS, the sulphated ester of DHEA, is present within the circulation at higher 
concentrations than DHEA (pM compared to nM) but is believed to have less in terms of 
biological activity due to its reduced ability to cross the cellular membrane. It is thought 
to behave as a circulating pool that can be converted into functional DHEA.
Consequently we chose to assess if DHEAS had any impact on preadipocyte cell line 
proliferation.
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Box-and-whisker plot demonstrating the effects of DHEAS on 
proliferation of 3T3-L1 cells following 48 hours exposure
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Fig 2.16 1 x l0 3per mL plated in 24 well plates (lmL per well) and counted on day 2 
(coulter counter), results are the median and IQRs showing the effect on proliferation of 
3T3-L1 preadipocytes following 48 hours exposure to DHEAS. Results shown are paired
experiments performed in quadruplicate
Box-and-Whisker plot demonstrating the effect of DHEAS on 
proliferation of PAZ6 cells following 48 hours exposure
Cells/well
Control DMSO 0.1%) DHEAS 10-7
DHEAS (logM)
Fig 2.17 0 .5 x l0 3per mL cells plated in 24 well plates and counted on day 2 (Coulter 
counter results are median and IQRs showing the effect on proliferation of PAZ6 
preadipocytes following 48 hours exposure to DHEAS. Results shown are paired 
experiments performed in quadruplicate
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In contrast to DHEA, DHEAS did not significantly inhibit the proliferation of 3T3-L1 or 
PAZ6 preadipocytes except at 1 O'6 molar in 3T3-L1 cells. It is possible that this was 
secondary to conversion to DHEA over the time period examined.
2.9.2 Does toxicity explain the reduced proliferation?
As our results suggested that DHEA had an inhibitory effect on both the 3T3-L1 and 
PAZ6 cells lines it was important to determine whether simple toxicity provided an 
explanation. It was felt that this was unlikely however, as cell numbers continued to 
increase from the 24 hour and 48 hour assessment points. Nevertheless trypan blue assays 
were carried out on both cell lines after 48 hours exposure to DHEA 10"5 molar and 1 O’9 
molar and control (DMSO 0.1 %) as well as on treatment naive samples. Results were 
determined by direct visual assessment.
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3T3-L1 cells stained with trypan blue following 48 hours exposure to DHEA and
Control (DMSO 0.1%)
non-treatment Control (DMSO 0.1 %)
DHEA 1 O'5 molar DHEA 10 8 molar
Fig 2.18 3T3-L1 cells from confluent 75cm2 flask plated in 24 well plate (lmL per well) 
treated with trypan blue following 48 hours exposure to DHEA. Results are a single 
experiment performed in quadruplicate
We estimated toxicity to be less than 1% in all samples assessed. The photographs in Fig 
2.18 do demonstrate some dye uptake into cell fragments that are likely to be a result of 
the trypsinisation/centrifugation as opposed to any toxicity related cell damage. The 
results seen in the PAZ6 cells were similar to those seen in the 3T3-L1 cells although the
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cell number generated per experiment was less as demonstrated in the proliferation 
experiments.
2.9.3 Is the observed anti-proliferation effect specific to preadipoctyes?
The widespread distribution of both the androgen and oestrogen receptor means that 
determination of cell type specific DHEA effect is potentially difficult. Previous studies 
have demonstrated DHEA exhibits effects on bone, vascular smooth muscle and adipose 
tissue. All these cell types have a common embryological origin being derived from 
mesenchymal stem cells as discussed previously. In order to evaluate the possibility of 
DHEA action in other (non-mesenchymal derived) cell types a differentiated thyroid cell 
line (FRTL5) and an undifferentiated skin keratinocyte cell line (HACAT) were 
employed. It is acknowledged that skin as an organ can be potentially influenced by 
DHEA secondary to androgenic action on the glandular tissue present. Both acne and 
greasy skin are well recognized side effects of DHEA therapy particularly in females, 
most likely secondary to the minimal increase in serum testosterone observed, but the 
effect on keratinocytes specifically was examined here.
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FRTL-5 differentiated thyroid cell line
P v V ''-  i y l
"s' 1
Fig 2.19 Untreated FRTL-5 differentiated thyrocytes on day 2 of culture
Box-and-whisker plot demonstrating the effect of DHEA on 
Proliferation of FRTL-5 cells following 48 hours exposure
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Fig 2.20 Following 4 days in treatment free conditions FRTL-5 cells from 75cm2 were 
trypsinised and plated in 24 well plate (lmL per well) and counted on day 2. Results are 
median and IQRs showing the effect of DHEA on proliferation of FRTL5 cells. Results 
presented are from a single experiment performed in quadruplicate
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DHEA did not significantly effect the proliferation of FRTL5 cells (Friedman test 
p=0.225) in culture conditions (for FRTL5 culture medium see appendix II).
HACAT cells
Fig 2.21 HACAT cells after 72 hours in routine culture
Box-and whisker plot demonstrating the effect of DHEA on 
proliferation of HACAT cells following 48 hours exposure
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Fig 2.22 Confluent HACAT cells from 75cm2 flask trypsinised and plated in 24 well 
plated with control (DMSO 0.1%) and varying concentrations of DHEA for 48 hours. 
Results are median and IQRs. Data are from a single experiment performed in
quadruplicate
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In HACAT cells a reduction in cell proliferation at higher DHEA concentrations (10'6 and 
1 O'7 molar) was observed but this was not significant (for HACAT cell culture medium 
see appendix II).
Despite using a differentiated and an undifferentiated cell line we were unable to 
demonstrate statistically significant anti-proliferative DHEA effects. These data, 
combined with those from previous studies, suggest that the inhibitory outcomes of 
DHEA on cell proliferation may be specific for cells of mesenchymal origin.
2.9.4 Does DHEA affect the cell cycle in preadipocyte cell lines?
Previous experiments indicated that inhibition of proliferation was not due to toxicity.
The possible mechanisms that explain this include:
i) Increased apoptosis
ii) Interruption of the cell cycle
Both of these can be tested by flow cytometry and an assessment of the cell cycle was 
undertaken in DHEA treated samples relative to control.
In untreated and control samples (containing DMSO 1 %) following 48 hours in standard 
culture medium the following cell cycle distributions were observed:
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Scatter plot and histogram showing cell cycle distribution in untreated 3T3-L1 cells
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Fig 2.23 Confluent 3T3-L1 cells in 6 well plates were collected and treated with DNA 
stain (propidium iodide) and analysed by flow cytometry. Data shown are from a 
representative experiment performed in duplicate
Scatter plot and histogram demonstrating cell cycle distribution in untreated PAZ6 cells
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Fig 2.24 Confluent PAZ6 cells treated as in previous experiment. Data presented are from 
a representative experiment performed in duplicate
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These data and the table below (table 2.10) outline the cell cycle distributions in untreated 
cells. It is clear that there are differences between the 2 cell types from the outset that 
could be consistent with their differing origins and also suggests potential difficulty in 
direct comparisons between the 2 cell line types.
Cell cycle distribution in untreated and control (DMSO 0.1%) 3T3-L1 and PAZ6 cells
Cell cycle stage 3T3-L
(% of cells)
3T3-LI control 
(DMSO 1%)
PAZ6
(% of cells)
PAZ6 control 
(DMSO 1%)
Gi 65.65 83.85 47.7 60.56
S 6.06 2.75 7.64 6.54
g 2+m 28.21 13.3 41.80 28.57
•3
Table 2.10 1x10 cells per mL plated in 6 well plates (3mL per well). Cells collected on 
day 2 under went flow cytometry (propidium iodide staining). Results are percentages of 
cells in each cell cycle stage following non treatment and treatment with DMSO (1%) 
control. Results presented are for a single experiment performed in duplicate. A repeat 
experiment performed with sets of 6 samples gave similar results.
The results presented in table 2.10 clearly indicate that the diluent DMSO had an impact 
on the cell cycle and these experiments performed early in our study used a 1 % DMSO 
control. For this reason the results following DHEA treatment were all compared to the 
DMSO control. Following the results of these experiments the concentration of DMSO in 
all control samples was reduced to 0.1 % and the proliferation experiments were repeated 
with this as a control.
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Histograms demonstrating the effect of DHEA compared to control on the cell cycle in 
3T3L1 and PAZ6 cells following 48 hours exposure
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Fig 2.25 Cells exposed to DHEA KT6 molar and control (DMSO) in 6 well plates for 48 
hours with treated with DNA strain (propidium iodide) and assessed for cell cycle stage 
by flow cytometry. Results are histograms for PAZ6 and 3T3-L1 cells and controls 
(DMSO 1 %). Data presented are from a single experiment performed in replicates of six 
that provided similar results to a repeat experiment
Results from the above experiments were combined with all flow cytometry results and 
are presented below.
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Median and IQR for cell cycle stage as percentages o f cells gated for 3T3-L1
preadipocytes following 48 hours exposure to DHEA and control
Cell cycle stage and 
treatment
Median and IQRs 
(percentage of gated cells)
Gi DMSO 1% 85.16(68.54-85-45)
S DMSO 1% 5.63 (3.37-5.99)
G2+M DMSO 1% 7.53 (6.82-9.51)
Gi DHEA 10"6 M 87.98 (81-89.5)
S DHEA 10"6 M 4.36 (3.96-4.75)
G2+M DHEA HE6 M 4.36 (3.99-13.76)
Table 2.11 Confluent 3T3-L1 cells in 6 well plates collected and treated with DNA stain 
(propidium iodide) then analysed by flow cytometry. Results are the median and IQRs for 
the percentage of gated cells in each cell cycle stage. Data presented are a combination of 
2 experiments the first performed in duplicate and the second in replicates of 6
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Bar chart demonstrating the effect of 48 hours exposure 
to DHEA on the cell cycle of 3T3-L1 ceils compared to 
control
□  DHEA 10-6 M 
■  DMSO (control)
block in cell cycle at Gi/S phase 
Wilcoxon Signed Ranks test p=0.01
G2+M
cell cycle stage
Fig 2.26 Experiment performed as summarised in table 2.11. Results are median values 
of percentages of gated controls for each cell cycle stage in 3T3-L1 preadipocytes 
following 48 hours exposure to DHEA 10‘6 molar and control (DMSO 1 %)
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Median and IQR for cell cycle stage as percentages o f cells gated for PAZ6 preadipocytes
following 48 hours exposure to DHEA and control
Cell cycle stage and 
treatment
Median and IQRs 
(percentage of gated cells)
Gi DMSO 1% 85.76 (66.56-86.51)
S DMSO 1% 2.86 (2.43-5.65)
g 2+m DMSO 1% 10.74(10.08-24.17)
G i DHEA lO^M 64.46 (58.53-72.88)
s DHEA lO-6 M 12.25 (8.41-13.57)
g 2+m DHEA lO^M 15.8(11.98-27.75)
Table 2.12 Confluent PAZ6 cells in 6 well plates collected and treated with DNA stain 
(propidium iodide) then analysed by flow cytometry. Results are the median and IQRs for 
the percentage of gated cells in each cell cycle stage. Data presented are a combination of 
2 experiments the first performed in duplicate and the second in replicates of 6
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Fig. 2.27 Experiment performed as summarised in table 2.12. Results are median values 
of percentages of gated controls for each cell cycle stage in PAZ6 preadipocytes 
following 48 hours exposure to DHEA 1 O'6 molar and control (DMSO 1%)
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Bar chart demonstrating the effect of DHEA exposure 
for 48 hours on the cell cycle of PAZ6 cells compared to 
control
■ DHEA 10-6 M
■ DMSO (control)
block in cell cycle a t G2+M phase 
W ilcoxon Signed Ranks test p=0.01
G1
cell cycle stage
G2+M
DHEA at a concentration of 10'6 molar caused a block in the cell cycle of both 3T3-L1 
and PAZ6 cells but at different points within the cell cycle (3T3-L1 Gl/S, PAZ6 G2+M). 
Furthermore analysis of the flow cytometry histograms, for both cell types, revealed no 
change at the sub-Gi peak suggesting that DHEA treatment was not an apoptotic 
stimulus.
2.9.5 Are effects directly due to DHEA or secondary to a downstream metabolite?
DHEA is a prohormone that has the potential to be converted to either androgenic or 
oestrogenic terminal hormones (Fig 1.5) and adipose tissue contains the necessary 
enzymes to do this. Therefore any effects that are observed in adipose tissue could be as a 
result of the action of DHEA itself or secondary to the effect of a downstream metabolite. 
In order to address this issue, two separate methods have been employed. Firstly an 
inhibitor of DHEA metabolism that blocks the action of 3-pHSD which catalyses the first 
biosynthetic downstream step of DHEA was used. If inhibition of this enzyme terminated 
any effects generated by DHEA it would suggest that downstream metabolites had 
precipitated any observed response whereas if the addition of this enzyme to the 
experimental model had no impact the suggestion would be that any effects were 
originating from DHEA itself. Secondly the effect that varying concentrations of DHEA 
metabolites (oestradiol, testosterone) have on cell line proliferation has been examined. 
The 3T3-L1 cell line has a more rapid proliferation rate and was therefore chosen for use 
in these experiments.
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Box-and-whisker plot demonstrating the effect of trilostane on 
proliferation of3T3-Ll cells
Cells/well
50000- -
40000-
30000-
20000-
10000 -
F ried m an s te s t  p<0.001
T
X
* 7
I I I I
contro l T rilostane 10-9Trilostane 10-8Trilostane 10-7 
(DMSO 0.1%)
Trilostane (logM)
Fig 2.28 1 x 103 cells per mL were plated in 24 well plates (lmL per well) and counted on 
day 2 (coulter counter) results are expressed as median and IQRs showing the effect of 
trilostane on proliferation of 3T3-L1 preadipocytes
From the box plot (Fig 2.28) it is clear that at a concentration of 10'7 molar trilostane
itself had a negative impact on cell number in our experimental model although it was not
• * 8  determined whether this was secondary to toxicity. At a concentration of 10‘ molar
however, trilostane did not have a negative effect on cell number and at this concentration
did not influence the previously demonstrated DHEA influence on proliferation (Fig
2.29).
107
Box-and-whisker plot demonstrating the effect of DHEA and trilostane on 
proliferation of 3T3-L1 cells following 48 hours exposure
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Fig 2.29 Experiment performed as previous, results are expressed as median and IQRs 
showing the effect of trilostane 10‘8 molar on the antiproliferative effect of DHEA in 
3T3-L1 preadipocytes following 48 hours exposure. Results presented are a single 
experiment performed in quadruplicate
From these data it was initially concluded that 3(3-HSD inhibition (by trilostane 10'8 
molar) did not reduce the effect of DHEA on proliferation thus suggesting a direct action, 
however it was not possible to confirm if this concentration of inhibitor was sufficient to 
block all (or any) downstream metabolite production.
To examine the ability of trilostane to inhibit downstream metabolite production, 
conditioned medium from completed experiments using approximate adipose tissue 
DHEA concentrations (10‘7 molar and 1 O'6 molar) was assayed for testosterone, 
oestradiol, androstendione and DHEAS (assays kindly performed by Dr Carol Evans, 
Medical Biochemistry department, University Hospital of Wales, Cardiff).
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Conditioned medium metabolite concentrations following exposure of 3T3-L1 cells to
DHEA and/or trilostane for 48 hours
Experimental
reagent/s
Androstenedione
(nmol/L)
DHEAS
(pmol/L)
Oestradiol
(nmol/L)
Testosterone
(nmol/L)
Control 
(DMSO 0.1%)
<0.5 <0.2 <0.15 <0.35
DHEA 10"6 >34.9 <0.2 27 15.5
Trilostane 10"7 17.6 <0.2 136 42.4
DHEA 10"b 
Trilostane 10'7
>34.9 <0.2 290 50.1
DHEA 10"6 
Trilostane 10'8
>34.9 <0.2 36 20.8
DHEA 10"6 
Trilostane 10"9
>34.9 <0.2 12 13.7
DHEA 10"7 >34.9 <0.2 <0.15 1.7
Trilostane 10"8 <0.5 <0.2 <0.15 13.7
DHEA 10"7 
Trilostane 10"7
>34.9 <0.2 15 33.4
DHEA 10"7 
Trilostane 10"8
>34.9 <0.2 <0.15 11.8
DHEA 10"7 
Trilostane 10"9
>34.9 <0.2 <0.15 3.2
Table 2.13 1 xlO3 per mL cells plated in 24 well plates for 2 days. Conditioned medium 
(lmL) collected and analysed for metabolites. Results are concentrations of DHEAS, 
androstenedione, oestradiol and testosterone in conditioned medium following exposure 
of 3T3-L1 cells to different concentrations of DHEA and trilostane. Data presented are 
from single experiment repeated with similar results
The results shown in table 2.13 revealed that the addition of DHEA to the experimental 
model increased androstenedione, testosterone and oestradiol concentrations as expected; 
the androstenedione levels are high, consistent with the use of supraphysiological serum 
levels (the assay is designed for the assessment of human serum). Interestingly, despite 
using these DHEA concentrations, no increase in DHEAS was observed and this could
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suggest that, in our in vitro model at least, there is no significant sulphotransferase 
activity (Fig 1.3) catalysing the conversion of DHEA to DHEAS. Whether this is true of 
all adipose tissue is unclear, although a previous study using human subcutaneous 
adipose tissue was unable to demonstrate expression of sulphotransferase despite 
confirming the presence of steroid sulphatase [87]. Another possible explanation is that 
the assay system employed (designed for use with human serum) was unable to detect the 
murine DHEAS; against this theory however was the fact that other hormones were 
readily detected despite species differences.
Somewhat unexpectedly however, our results demonstrate that trilostane itself increased 
the amount of metabolite production and to a greater extent than DHEA alone; further, 
when combined with DHEA the effect was additive. As the concentration of the inhibitor 
was reduced the metabolite concentration also declined, when the opposite was 
anticipated.
These unexpected results with trilostane revealed that it had activity that was the converse 
to that anticipated in our experimental model, therefore the observation previously made 
that the effect on proliferation was as a direct result of DHEA could not be corroborated. 
However to further investigate the continuing question concerning direct versus indirect 
DHEA action I undertook an assessment of terminal metabolites with known metabolic 
activity.
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Box-and-Whisker plot demonstrating the effect of testosterone on 
proliferation of 3T3-L1 cells following 48 hours exposure
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Fig 2.30 Confluent 75cm2 flask containing 3T3-L1 cells was trypsinised and plated into a 
24 well plate. Cell were counted (coulter counter) on day 2 following the addition of 
varying concentrations of testosterone. Results are the median and IQRs showing the 
effect on proliferation of 3T3-L1 preadipocytes following 48 hours exposure to varying 
concentrations of testosterone. Data presented are from a single experiment performed in
quadruplicate
Freidman Test p=0.006
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Box-and-whisker plot demonstrating the effect of P-oestradiol on 
Proliferation of 3T3-L1 cells following 48 hours exposure
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Fig 2.31 Experiment performed as previous. Results are the median and IQRs showing 
the effect on proliferation of 3T3-L1 preadipocytes following 48 hours exposure to 
varying concentrations of p-oestradiol. Data presented are a single experiment performed
in quadruplicate.
Neither testosterone nor P-oestradiol exhibited a significant inhibitory effect on 
proliferation of 3T3-L1 preadipocytes although testosterone did significantly increase the 
amount of proliferation, however further investigation of this observation was not 
undertaken.
Our investigation into direct versus indirect DHEA effect, despite the failings of the 
trilostane experiment, do still favour a direct effect. It is acknowledged however that a 
number of metabolites other than testosterone and oestradiol (Fig 1.3) are generated by
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DHEA metabolism and that these were not investigated as our intention was to focus on 
metabolites with known biological activity.
2.9.6 Does DHEA influence preadipocyte intracellular signaling?
The transduction of extracellular signals into cell function is an integral component in the 
control of both proliferation and differentiation. MAP kinase is a protein located 
terminally in a number of adipocyte signalling cascades (e.g. Insulin, TNFa) and its 
phosphorylation is central to both proliferation and differentiation in adipocytes and was 
therefore selected for investigation.
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Western blots demonstrating short-term effects of DHEA (10' molar) on phosphorylated 
levels of MAP kinase activity in 3T3-L1 preadipocytes
PhosphoMAPK 3T3-L1 cells
47 .5  kda
32.5  kda
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E
o
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Densitom etry 68986 294968 192698 37305 106844
(corrected for background)
TotalMAPK 3T3-L1 cells
47.5 kda
32.5 kda
Densitometry 647356 628565 444315 495258 655487
(corrected for background)
3T3-L1 sample PhosphoMAK densitometry corrected for 
totalMAPK densitometry
Non treatment 0.11
Control 10 minutes 0.47
DHEA 10"7 molar 10 minutes 0.43
Control 20 minutes 0.07
DHEA 1 O'7 molar 20 minutes 0.16
Fig 2.32/Table 2.14 Cells grown to confluence in 6 well plates in standard medium 
followed by 2x2 hours in serum free medium (DMEM) had DHEA 10"7 molar (containing 
0.01% FCS) and DMSO 0.1% control (containing 0.01 %FCS) added for 10 and 20 
minutes. Cells were then homogenised, blotted and detected following standard Western 
blotting protocol for phosphorylated and total MAP kinase. The blots then underwent 
densitomery assessment and correction for total MAP kinase measurement. Experiments
repeated at least 3 times
114
Western blots demonstrating short-term effects of DHEA (10'7 molar) on phosphorylated 
levels of MAP kinase activity in PAZ6 preadipocytes
PhosphoMAPK PAZ6 cells
47.5 kda
32.5 kda
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Densitometry 12739 182489 8574 16293 1738
(corrected for background)
Total MAPK PAZ6 cells
32.5 kda
Densitometry 640750 713093 706925 636081 644725
(corrected for background)
PAZ6 sample PhosphoMAK densitometry corrected for 
totalMAPK densitometry
Non treatment 0.019
Control 10 minutes 0.256
DHEA 10"7 molar 10 minutes 0.012
Control 20 minutes 0.026
DHEA 10‘7 molar 20 minutes 0.003
Fig 2.33/table 2.15 Cells grown to confluence in 6 well plates in standard medium 
followed by 2x2 hours in serum free medium (DMEM) had DHEA 10"7 molar (containing 
0.01% FCS) and DMSO 0.1% control (containing 0.01 %FCS) control added for 10 and 
20 minutes. Cells were then homogenised, blotted and detected following standard 
Western blotting protocol for phosphorylated and total MAP kinase. The generated blots 
then underwent densitometry assessment and correction for total MAP kinase 
measurement. Experiments repeated at least 3 times
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As can be observed in Fig 2.32 and Fig. 2.33 addition of control (containing 0.1% DMSO 
and 0.01% FCS) precipitated significant phosphorylation of MAP kinase and this was a 
consistent finding in both cell populations. The signal intensity for total MAP kinase, 
whilst indicating essentially equal loading in all lanes, provided a method of quantifying 
the level of MAP kinase phosphorylation.
The Western blots indicate that in PAZ6 cells DHEA reduces phosphorylated MAP 
kinase levels over 10 and 20 minutes. Following densitometry assessment and correction 
of phosphorylated MAP kinase for total MAP kinase, the maximum phosphorylated MAP 
kinase levels in the PAZ6 were observed at 10 minutes in the control sample with a 13.5 
fold increase in activity from base line. At both 10 and 20 minutes less activity was 
observed in the DHEA treated samples compared to control (25 and 8.6 fold 
respectively).
In the 3T3-L1 samples there was no obvious difference between DHEA and control 
samples at 10 minutes when corrected for total MAP kinase, and at 20 minutes the 
control sample revealed reduced activity as did the DHEA treated sample but to a lesser 
extent. The data for total MAP kinase in 3T3-L1 cells do however demonstrate some 
variability in lane loading. Following densitometry and correction of phosphorylated 
MAP kinase for total MAP kinase levels it was apparent that maximal phosphorylated 
MAP kinase activity was observed in the control sample at 10 minutes but this was very 
similar to that seen in the 10 minute DHEA treated sample (4.2 and 3.9 fold increase 
from baseline respectively). At 20 minutes marginally more activity was observed in the 
DHEA treated sample compared to control (1.4 and 2 fold respectively). The 3T3-L1 
preadipocyte results may be interpreted as demonstrating essentially no difference in
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levels of phosphorylated MAP kinase in DHEA and control samples. These experiments 
were repeated at least 3 times with similar results.
As MAP kinase activation and deactivation is necessary for cell signal transduction all 
that can be interpreted from the data generated is that DHEA does have an effect on 
intracellular signalling and that this involves MAP kinase, however it is not possible to 
conclude if the cell signalling effect is one of inhibition or stimulation.
In the majority of cases the above technique is used to confirm or refute the activation of 
a cell signalling protein (not the inactivation). In our experiments, the use of standard 
culture medium (containing 10% FCS) as a diluent as well as DMSO, precipitated 
phosphorylated MAP kinase activation though it is not clear which of these agents 
brought about this effect. This was somewhat fortuitous and it enabled us to demonstrate 
an inactivation effect caused by DHEA in the PAZ6 cells.
Protein assay was not performed prior to sample loading as each sample within an 
individual experiment underwent precisely the same procedure and the short exposure 
periods used were unlikely to affect the relative amounts of generated samples the same 
amounts of which were loaded into each well.
The Western blotting experiments were also complicated by a difficultly in obtaining a 
‘zero’ blot for the background level of activation in untreated samples.
2.9.7 Does DHEA affect preadipocyte cell line differentiation?
Placed in the appropriate environment both PAZ6 and 3T3-L1 cells will differentiate into 
mature adipocytes characterised, as previously discussed, by morphological change with 
an increase in size, a more rounded appearance and the accumulation of triacylglyceride
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rich droplets. From experience it is clear that the 3T3-L1 preadipocytes possess a greater 
ability to differentiate when compared to PAZ6 cells with up to 60% of cells in 3T3-L1 
cultures undergoing differentiation. Also the 3T3-L1 cells undergo significant 
differentiation over a shorter time period when again compared to PAZ6. The 
differentiation protocol in the 3T3-L1 cells achieved terminal differentiation in 9-12 days 
whereas in PAZ6 the cells required 15 days or longer to differentiate, and invariably did 
so to a lesser degree. The differential adipogenic capacity impinged on our first chosen 
method of assessing the extent of differentiation in DHEA treated and control samples. 
The number of differentiation foci in PAZ6 cells was easy to ascertain as they tended to 
occur in isolated pockets conducive to counting whereas in the 3T3-LI cultures the 
amount of differentiation could be so great that distinguishing between the various foci at 
terminal differentiation became difficult.
2.9.7.1 Foci of differentiation
Assessing differentiation can be performed visually. What follows are photographic time 
lines for both 3T3-L1 and PAZ6 cells as they proceed through the differentiation 
protocol. At the final points, foci of differentiation were counted.
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3T3-L1 cells differentiation 
day 0
PAZ6 cells differentiation 
day 0
3T3-L1 cells in differentiation 
mix + DHEA 10'7 molar day 9
PAZ6 cells in differentiation mix + 
DHEA 1 O'7 molar day 15
3T3-L1 cells in differentiation 
mix + DMSO 0.1% day 9
PAZ6 cells in differentiation mix 
+ DMSO 0.1% day 15
Fig 2.34 Confluent 3T3-L1/PAZ6 cells in 6 well plates cultured in differentiation mix 
with either control (DMSO 0.1%) or DHEA 10'7 molar for 9/15 days. Results are 
photographs taken on day 0 and day 9/15. Data presented are from a single representative
experiment. Magnification xlOO
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The photographic data demonstrate how readily 3T3-L1 cells undergo differentiation 
relative to PAZ6 cells and also that some differentiation will occur in the absence of 
differentiation mix as evident in the day 0 photograph, which showns cell cultures in 
normal culture medium plus DMSO (0.1%) for 4 days. The photographs taken at day 9 
highlights the difficulty in counting the differentiation foci in this cell type as 
differentiation could be so widespread that identifying individual foci became difficult. 
These data would suggest that more differentiation occurs in the absence of DHEA; 
however, this could simply be a function of the demonstrated reduction in proliferation 
affecting the extent of clonal expansion.
The presented photographs also highlight the reduced differentiation potential of the 
PAZ6 cells relative to the 3T3-L1 cells and the easily identifiable foci present at the end 
of the differentiation protocol. There are a number of potential explanations for these 
differences between the 2 cell lines. It may be related to the species difference (3T3-L1 
mouse and PAZ6 human, it could also be that brown preadipocytes in general have a 
reduced tendency to differentiate relative to the white equivalent and finally it could be as 
a result of the treatments that were used to generate the cell lines in that the PAZ6 cells 
underwent SV40 transformation whereas the 3T3-L1 cells did not.
The following foci of differentiation data refer to the PAZ6 cells only because of the 
difficulty identifying individual foci in the 3T3-L1 cells as discussed. My general opinion 
and one that had been noted on a number of occasions, was that there did appear to be a 
reduction in differentiation observed in the DHEA treated 3T3-L1 preadipocytes.
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Box-and-whisker plot demonstrating the effect of DHEA 10' molar on the number of 
foci of differentiation per field observed in PAZ6 cells following 15 days in
differentiation medium
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Fig 2.35 PAZ6 cells grown to confluence in 6 well plates followed by addition of 
differentiation medium with DHEA 10'7 molar or control (DMSO 0.1%). Medium and 
reagents were changed every 5 days. At 15 days the number of differentiation foci was 
counted. Results are median and IQRs. Presented data are from a single representative 
experiment in which each well underwent 10 randomly chosen field counts using a light
microscope
The presented data clearly illustrate the reduction in differentiation foci observed in the 
DHEA treated samples. This result however may not consider any reduction in clonal 
expansion that may have occurred.
2.9.1.2 Oil red O staining
The oil red O stain taken up by the lipid component in the differentiated adipocytes could 
be dissolved out and assessed per sample via direct colourimetry; this was performed in
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both the 3T3-L1 and PAZ6 preadipocytes. Once more, when interpreting results from 
these experiments, one must consider the impact of the previously demonstrated 
proliferation inhibition for which this methodology was more conducive.
Oil red O stained PAZ6 cells
Fig 2.36 Confluent PAZ6 cells in 24 well plates treated in differentiation mix (with 
DHEA or DMSO control) for 15 days then stained with oil red O 
Magnification x200
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Box-and-whisker plot demonstrating the effect of DHEA on amount of oil red O stain 
measured by direct colourimetry in PAZ6 cells following differentiation
OD 490 ,J I
control (DMSO 0 1%) DHEA 10-8
DHEA (logM)
Fig 2.37 Confluent PAZ6 cells in a 24 well plate exposed to differentiation mix with 
DHEA or control for 15 days then stained (oil red O), the amount of stain was then 
assessed by direct colourimetry. Results are the median and IQRs expressed as OD4 9 0 . 
Data presented are from a single representative experiment
Box-and-whisker plot demonstrating the effect of DHEA on amount of oil red Ostain 
measured by direct colourimetry in 3T3-L1 cells following differentiation
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Fig 2.38 Confluent 3T3-L1 cells in a 24 well plate exposed to differentiation mix with 
DHEA or control for 9 days then stained (oil red O), the amount of stain was then 
assessed by direct colourimetry. Results are the median and IQRs expressed as OD4 9 0 . 
Data presented are from a single representative experiment
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These results indicate that there was no difference between control and DHEA treated 
samples in terms of differentiation despite not considering proliferation rates. These
n
experiments were also conducted with simultaneous cell counts with DHEA 1 O' molar 
such that the results could be expressed corrected for cell count and once again no 
significant difference was observed in DHEA treated cultures relative to control.
The oil red O technique however may not have been sufficiently accurate in that, for 
unknown reasons, many lipid droplets would not take up the oil red O stain and what was 
viewed macroscopically was often not what the OD results suggested. Also the oil red O 
staining process itself resulted in the loss of a significant amount of cellular material 
despite reducing the amount of washes used in the protocol. Secondary to the concerns 
relating to this technique a more sensitive method for assessing the extent of 
differentiation was required. Quantitative PCR was selected; this would facilitate 
measurements of transcripts of adipogenesis markers, such as GPDH and LPL. These 
would be compared between control and DHEA treated cells.
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2.9.7.3 PCR/QPCR
Data on RNA quality, standard and dissociation curves and gene expression rates 
expressed as copy numbers corrected for housekeeper genes follow.
2.9.7.3.1 RNA quality
To confirm effective RNA extraction and RNA quality in 3T3-L1 and PAZ6, 
visualisation was performed using 2% ethidium bromide loaded gels. Tanks were cleaned 
with 0.5% SDS (in distilled H2O) for 1 hour prior to gel analysis.
3T3-L1 RNA PAZ6 RNA
Fig 2.39 5pg of 6*dye with lpg of extracted RNA from PAZ6 and 3T3-L1 cells at day 0 
of the differentiation protocol visualised on a 2% ethidium bromide agarose gel. Data
presented are from a single experiment
The presence of bands at 28s and 18s confirms RNA has not degraded and is thus suitable 
for RT.
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2.9.7.3.2 Standard curve
To allow for the estimation of copy number of a gene of interest in unknown samples 
firstly a standard curve was generated from samples of known copy number quantity. 
Serial dilutions from stock standard solutions (109 copies) analysed using SYBR green 
dye and opitimised primer concentrations generated standard curves for ARP/APRT 
(housekeeper) and GPDH/LPL (terminal adipogenesis markers).
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Fig 2.40 Representative standard curve (for ARP housekeeper gene) generated by
SYBR green QPCR analysis
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2.9.7.3.3 Melting point analysis/dissociation curve
Dissociation Curve
Temperature (*C)
Fig 2.41 Representative dissociation curve (for ARP). The single peak denotes a single 
gene product and the absence of primer dimmers.
Using Ct values generated from QPCR in the experimental (unknown) samples and the 
standard curves an estimation of the copy number in the unknown samples can be made 
in day 0 and in non-treatment and DHEA treated samples at later time points.
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2.9.7J.4 3T3-L1 QPCR results
Analysis was performed on samples collected on day 0 and on final day of differentiation 
protocol (day 12) for housekeeper gene (ARP) and terminal differentiation marker gene 
(GPDH).
Housekeeper and GPDH QPCR in 3T3-L1 cells
Sample ARP GPDH ARP 
adjusted CNCt TCN Ct TCN
3T3 day 0a 15.89 1.756x10* 29.19 2454 0.000014
3T3 day Ob 16.69 9.867x10V 27.21 7558 0.000078
3T3 day 9a 17.64 4.934x1 O'7 24.56 34340 0.000696
3T3 day 9b 17.23 6.672x107 21.67 177800 0.002665
3T3 day 9c 18.27 3.136xl0v 22.61 104000 0.003316
3T3 day 9d 17.52 5.390x107 24.16 42980 0.000797
3T3 day 9e 18.31 3.053 xlO7 24.21 41870 0.000777
3T3 day 9f 16.69 8.133xl07 22.74 96970 0.001728
3T3 day 9 DHEAa 18.02 3.775xl0v 22.46 113700 0.003012
3T3 day 9 DHEAb 18.46 2.743 xlO7 22.73 97410 0.003551
3T3 day 9 DHEAc 18.76 2.203 xlO7 23.15 76780 0.003485
3T3 day 9 DHEAd 18.73 2.259x107 22.78 94670 0.004191
3T3 day 9 DHEAe 16.76 9.3 85 xlO7 24.19 42240 0.000450
3T3 day 9 DHEAf 18.06 3.661 xlO7 23.05 81180 0.002217
Table 2.16 QPCR for GPDH target gene and ARP (housekeeper gene) expression in 
3T3-L1 cells following 9 days exposure to differentiation mix (DMSO 0.1%) and 
differentiation mix + DHEA 10'7 molar. Data shown are Ct value, total copy number 
(TCN) and copy number (CN) adjusted for housekeeper. Results demonstrated are an 
amalgam of 2 experiments performed in triplicate repeated a third time with similar 
results. Each QPCR reaction was performed in duplicate
When corrected for housekeeper gene (ARP) expression the difference in GPDH copy 
number from day 0 to day 9 in both non-treatment and DHEA treated samples was 
increased consistent with the occurrence of differentiation, though the magnitude of 
increase was smaller than anticipated.
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These results demonstrate after 9 days in x 1 differentiation medium, there was a 31-53 
fold increase in GPDH gene expression (corrected for ARP) in 3T3-L1 cells that was not 
significantly different in the presence of DHEA (Wilcoxon Signed Ranks test p=0.075).
2.9.7.3.5 PAZ6 QPCR results
Analysis was performed on samples for day 0 and at differentiation protocol terminus 
(day 15) for housekeeper (APRT) and LPL.
Housekeeper and LPL QPCR in PAZ6 cells
1 Sample APRT LPL APRT
adjusted
CN
Ct TCN Ct TCN
PAZ6 day 0 34.65 56.82 34.04 0.7621 0.0134
PAZ6 day 0 29.52 117.4 29.73 25.44 0.2167
PAZ6 day 15 29.95 91.89 26.85 232.2 2.5269
PAZ6 day 15 31.14 46.2 24.91 1029 22.2727
PAZ6 day 15 30.33 73.6 25.55 625.8 8.5027
PAZ6 day 15 DHEA 29.80 100.2 27.07 151 1.5070
PAZ6 day 15 DHEA 28.94 163.8 28.07 91.13 0.5563
PAZ6 day 15 DHEA 29.99 89.43 28.61 59.97 0.6705
Table 2.17 QPCR for LPL target gene and APRT (housekeeper gene) expression in PAZ6 
cells following 15 days exposure to differentiation mix (DMSO 0.1%) and differentiation 
mix + DHEA 10'7 molar. Data shown are Ct value, total copy number (TCN) and copy 
number (CN) adjusted for housekeeper. Results demonstrated are an amalgam of 2 
experiments performed in triplicate and each QPCR reaction was performed in triplicate
The results demonstrate an increase in LPL expression from baseline in both DHEA and 
non-treatment samples consistent with the occurrence of differentiation, though once 
again not with the extent that was anticipated. No difference was observed between 
DHEA and non-treatment samples. (Wilcoxon Signed Ranks p=0.173) thus concluding
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that DHEA does not influence differentiation in PAZ6 preadipocytes when generic 
adipocyte gene expression is evaluated.
In PAZ6 cell differentiation and also in BAT in general, it is possible that the expression 
of alternate genes may better reflect the degree with which differentiation has occurred 
(or not). The PAZ6 experimental samples were also analysed therefore for BAT specific 
genes following differentiation with and without exposure to DHEA. Interestingly there 
was a significant increase in UCP-1 expression (Wilcoxon Signed Ranks test p=0.028 
corrected for input RNA) in the DHEA treated samples albeit with the caveat that high Ct 
values were observed (35-36).
2.10 Discussion
The experiments described in this chapter demonstrate that DHEA, at intra-adipose tissue 
relevant concentrations has an inhibitory, non-toxic, effect on proliferation in both white 
(3T3-L1) and brown (PAZ6) cell line preadipoctyes and that this effect, as far as this 
body of work can ascertain, is preadipocyte specific. The data suggests, although not 
conclusively, that this effect may be due to a direct action of DHEA. The results 
demonstrate that the anti-proliferative action is likely to be due, at least in part, to cell- 
cycle blockade and that MAP kinase pathway modulation may be involved. The rapidity 
of the response observed on phosphorylated MAP kinase activity is such that a direct 
effect on a cell membrane receptor is likely to have been the mediator. Previously, 
investigators have demonstrated an anti-proliferative action on both the 3T3-L1 cell line 
[139] and other mesenchymal derived cell types [212] and the data presented here would 
be supportive of these findings .
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An anti-proliferation effect could be considered to be pro-adipogenic as the cessation of 
proliferation is a differentiation prerequisite however no appreciable difference in 
differentiation following treatment with DHEA was seen in either the 3T3-L1 or PAZ6 
cells.
Investigators have however demonstrated that DHEA has an inhibitory action on cell line 
preadipoctye differentiation [139, 257]. The discrepancy between the results generated 
here and these previous studies may be due to a number of factors such as the use of 
different DHEA concentrations and methods of assessment. In the paper by Shantz and 
Colleagues [257] DHEA at a concentration of 250 xlO'6 molar caused a reduction in 
differentiation of 3T3-L1 cells as measured by GPDH levels in supernatant fluid 
following centrifugation at 20,000 g for 40 minutes. The DHEA concentration is 
therefore far greater than that used in the experiments presented here and the 
methodology used also differs.
The findings presented relating to the PAZ6 BAT preadipocyte cell line are novel. The 
inhibitory effect on proliferation followed by the possible increase in BAT specific genes 
following DHEA exposure demonstrates a pro-adipogenic effect. Also the Western 
blotting data, as well as demonstrating activation of MAP kinase by 0.1% DMSO/0.01% 
FCS, clearly demonstrates involvement of the MAP kinase signalling system in the 
PAZ6 although though not as obviously in the WAT cell line. The possibility that DHEA 
may be supportive in some way of BAT differentiation is consistent with the temporal 
association between DHEA and BAT in the foetal state.
A further interesting observation is that there was no detectable sulphotransferase activity 
in the 3T3-L1 preadipocytes as demonstrated by the lack of DHEAS production in culture
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conditions, despite the addition of supra-physiological serum DHEA concentrations; this 
in the light of confirmed generation of terminal metabolites (testosterone, oestradiol). 
This observation is in support of a previous study as discussed [87] and may suggest that 
adipose tissue is, in terms of DHEA, pro-metabolic and does not posses the capacity to 
either inactivate it or add to the circulating pool.
These studies demonstate some interesting results though one must acknowledge a 
number of limitations apparent within the various experiments. When interpreting data 
derived from lower order mammals relating to the effects of DHEA, one must consider 
the issue of concentration. The cell line utilised in many of the experiments is murine in 
origin and as such will be exposed to a grossly supraphysiological DHEA environment as 
it is only humans (and higher order mammals) that generate such high and fluctuating 
concentrations [56]. Furthermore direct extrapolation of data derived from different 
species may be misleading and will require confirmation using adipose tissues from the 
same origin. Results generated from transformed cell lines (SV 40 or spontaneous) also 
need to be evaluated with caution particularly if one (as in this case) is assessing effects 
on proliferation and linked modalities (cell cycle, apoptosis). Transformed cell lines by 
definition are altered such that they are encouraged to remain within the cell cycle and to 
undergo repeated cycles of division. This, although conducive to laboratory based 
studies, is far removed from the in vivo setting. Furthermore, cell lines are removed form 
their native environment and as such are protected from any stimulatory or inhibitory 
stimuli that may be present in vivo. It is therefore imperative to confirm any cell line data 
using primary cultures in vitro and preferably in vivo.
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Although demonstrating an antiproliferative effect of DHEA, these studies have only 
utilised a single method, namely cell counting. Other techniques are however available 
that can determine the effect of a reagent on cell proliferation. Thymidine incorporation 
has been discussed earlier in this chapter and relies on radioactive isotope uptake into 
dividing cells such that a substance augmenting proliferation will generate a sample 
containing higher levels of isotope and vice versa. The relative amounts of isotope 
present can then be quantified by scintigraphy. There are obvious advantages in 
confirming results using different techniques and were such an alternate method to 
demonstrate similar findings to my cell counting data the generated data would certainly 
be more robust.
The data generated from the flow cytometry experiments suggests that there is no 
increase in apoptosis following exposure to DHEA. Since the process of apoptosis can 
occur rapidly, applying a single method can not exclude the possibility of stimulated cell 
death with confidence. Consequently no single universally accepted method of 
determining apoptotic stimuli exists and thus it is important to confirm ones finding using 
different approaches. The TUNEL method has been described earlier in this chapter and 
relies on labeling damaged sections of DNA of cells about to undergo programmed cell 
death. Other methods are also available namely Annexin 5 staining which probes for the 
presence of the apoptotic cell surface marker phosphatidyl serine. Apoptotic regulatory 
protein (Bcl/Bax ratio) analysis is a further possible method available. Therefore, 
although my data does not suggest that DHEA stimulates apoptosis, in order to state this 
with confidence experiments using these alternate methods would be required.
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I have attempted to address the possibility of oestrogen and testosterone effects in this 
experimental model. However an admitted limitation to this body of work is the absence 
of experiments utilising androgen and oestrogen receptor blockade and certainly these 
should be included in any future studies. This would have obvious benefits when 
attempting to establish the origin of the observed effects (DHEA or a downstream 
metabolite). Other authors have also employed albumin bound DHEA in order to 
investigate genomic versus non-genomic actions, the albumin bound form being unable 
to penetrate the cell membrane such that any observed actions must therefore be directed 
through cell surface receptors [81,211].
Exactly what role the demonstrated possible anti-proliferative effect of DHEA on 
preadipocytes may play in human physiology is not clear; moreover it may not be 
possible to extrapolate with confidence from these cell line data directly to the human 
model. Nevertheless these effects may point to a modulating action of DHEA on adipose 
tissue in humans although further investigation is paramount.
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Chapter 3
Effects of DHEA on proliferation and 
differentiation of human primary preadipocytes
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3.1 Overview
In the previous chapter the effects of DHEA on preadipocyte cell lines has been 
examined. 3T3-L1 is a well established in vitro model for evaluating adipogenesis and 
PAZ6 is one of the few openly available BAT cell lines. However studies utilising cell 
lines are associated with a number of short comings. Firstly and most obviously many 
cell lines, such as 3T3-L1, are non-human and as such will tend to generate questions 
concerning the extrapolation of derived data to the human model. The observation that 
clonal expansion occurs during cell line differentiation, but most probably not in primary 
cell differentiation illustrates one potential difference. There is a commercially available 
immortalised human preadipocyte with augmented differentiating capacity termed Chub- 
87. The differentiating ability in this cell type is preserved following SV40 T-antigen 
transformation by co-expression of human telomerase reverse transcriptase (hTERT) and 
papillomavirus E7 oncoprotein (HPV-E&7) genes [282]. As attractive a cell type as this 
may be its acquisition was beyond the financial capacity of our unit.
Cell lines are designed purposely with exaggerated proliferation potential, the curtailment 
of which is a requirement to initiate differentiation, and this innate tendency to remain 
within the cell cycle may impair differentiation capacity. Furthermore cell line studies do 
not allow depot specific differences to be assessed which is of particular importance with 
the emergence of centrally distributed fat as a cardiometabolic risk factor. Also, cell lines 
by definition are developed out of their normal environment and are not exposed to other 
factors that could prime or protect against proliferation/differentiation. There are also 
specific considerations concerning DHEA itself in that there is a stronger body of 
evidence to support the notion that it can precipitate beneficial effects, relating either to
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adipose tissue or the vasculature, from in vitro and animal models when compared to the 
data available from human studies. There is a possible explanation for this that has been 
discussed in chapter 1 centering around the fact that it is only in higher primates that high 
levels of DHEA/DHEAS are generated. Furthermore only higher primates demonstrate 
the dramatic reduction in circulating concentrations after early middle age; thus the 
concentrations of DHEA/DHEAS that have been used, particularly in animal studies or 
those using non-human cell lines, are potentially non-physiological for that particular 
model. In order to address some of these issues it was therefore necessary to repeat some 
of the previous experiments with human primary preadipocyte cultures.
Our hypothesised link between the adipocyte and any observed vascular and/or metabolic 
effects is modification of the adipocytokine profile. Signs of a pro-metabolic health effect 
could be determined for example by observed increases in adiponectin production or a 
reduction in levels of TNFa, leptin or IL-6. These adipocytokines have been discussed in 
greater detail in chapter 1. Once a preadipocyte approaches maturity it will gain the 
ability to synthesise and secrete these apidocytokines in response to alterations in the 
external environment so their identification could also provide a measure of effective 
differentiation, and to that end whether a particular reagent impinges upon it. The 
adipocytokine adiponectin was chosen for examination in this study for a number of 
reasons. It has well known metabolic actions as illustrated by the inverse correlation with 
obesity. Furthermore, in the context of the cell line data demonstrating proliferation 
inhibition, any observed increase in production would have to overcome any potential 
reduction in cell number and therefore be of greater significance. As briefly discussed in 
chapter 1 adiponectin is found in low and high molecular weight forms, the high
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molecular weight form potentially being more metabolically important. However, most 
commercially available adiponectin assays measure total adiponectin, as was chosen for 
use in this study.
Conditioned medium collected at the end of the differentiation protocol (21 days 
exposure to x 1 differentiation mix) formed the raw material for the adipocytokine assays 
utilising the enzyme-linked immunosorbent assay (ELISA) technique.
ELISA methodology (Fig 3.1) uses a sequence of linked antibodies and is termed a 
sandwich technique. A plate surface coated with a capture antibody directed against the 
analyte of interest (e.g. adiponectin) is blocked to prevent non-specific binding and 
exposed to samples containing the analyte that then binds to the capture antibody.
Primary antibodies specific for the target substance are then added followed by secondary 
antibodies that are specific to the primary antibody and are conjugated to an enzyme able 
to generate a colour change following substrate addition. The reaction is terminated and 
the colour intensity is determined using a plate reader that measures optical density.
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ELISA schematic
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Fig 3.1 ELISA method schematic
3.1.1 Human primary cultures
The use of primary cultures is attractive for a number of reasons, not least for the 
proximity to human physiology however a number of problems are involved with their 
usage. Any such study will require approval from both the local ethics committee, and 
hospital and/or trust Research and Development departments. This involves a not 
inconsiderable amount of bureaucracy and can therefore take a prolonged period of time. 
Consequently, our consent forms and information sheets (appendix III) not only 
encompass this study but a number of other current and possible future projects. Due to 
the internalised location of adipose tissue a surgical procedure will invariably be required 
for retrieval and so consent from individuals concerned as well as assistance from those 
performing the surgical procedures is paramount. Obtaining consent for research
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purposes from individuals before what is often a major surgical procedure and 
coordinating surgeons and theatre staff is not always straight forward.
Extracted primary preadipocyte cultures in general exhibit slower proliferation rates such 
that individual experiments tend to be many times longer than when using cell lines and 
furthermore, secondary to the extraction methods, contamination rates are likely to be 
higher. Nevertheless human primary cultures remain the gold standard for in vitro 
investigations and confirmation of data in such cultures will invariably increase the 
significance of generated results.
3.1.2 Visceral fat depots
Region specific fat depots have differing metabolic effects and abdominally distributed 
adipose tissue has been demonstrated to generate a greater metabolic derangement than 
that located subcutaneously. The metabolic abnormalities associated with an increased 
visceral fat depot include insulin resistance [283] and dyslipidaemia [284], which, in 
conjunction with hypertension and a predilection to cardiovascular disease [285], have 
been termed the metabolic syndrome (Fig 3.2 and table 3.1). Possible explanations as to 
why this particular distribution of fat has a greater associated health risk include an 
exaggerated lipolytic activity of omental fat cells and the portal circulation drainage 
pattern that potentially exposes hepatocytes to higher levels of free fatty acids resulting in 
dyslipidaemia and hepatic insulin resistance [283]. As to whether the metabolic 
syndrome is simply a reflection of dietary habits in today’s society or whether the laying 
down of central fat deposits during times of excess had past survival benefits remains
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unclear. What is clear however is that the metabolic syndrome, be it a separate disease 
entity or a collection of risk factors, predisposes to cardiovascular risk [286-288].
Tcardiovascular risk
t  BPDyslipidaemia 
Insulin resistance
t waist circumference
Fig 3.2 Features of the metabolic syndrome
Diagnostic criterion Measurement
t Waist circumference S  > 94cm
+ any 2 of the following $ > 80cm
t triacylgyceride 
(or treatment for)
> 1.7mmol/L
i  HDL cholesterol c? < 1.03mmol/L
(or treatment for) $ < 1.29mmol/L
|  BP (or treatment for) >138/>85 mmHg
t fasting glucose (or diabetes) >5.6 mmol/L
Table 3.1 International Diabetes Federation diagnostic criteria (Caucasian) for the 
metabolic syndrome 2005 (www.idf.org)
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3.1.3 Previous human adipose tissue studies
There have been no studies to date that have specifically compared the body composition 
of individuals with a pathological DHEA deficiency to matched controls. Individuals 
with either primary of secondary adrenal insufficiency may be overweight due to 
mechanisms that are most likely independent of DHEA deficiency, such as excessive 
glucocorticoid replacement or hypothalamic dysfunction secondary to disease and/or 
treatment for hypopituitarism. Insufficiently replaced thyroid hormone will precipitate 
weight gain as will growth hormone deficiency, although DHEA may exhibit co­
stimulatory activity with IGF-1.
Numerous in vivo, observational and interventional studies as well as work performed in 
vitro have attempted to evaluate the influence that DHEA has on adiposity and adipocytes 
and these have been reviewed in chapter 1. Overall, however, the results have not been 
conclusive, although in some studies in men with physiological DHEA deficiency there is 
some evidence of reduction in measures of body fat [169]. Many of the in vivo studies 
have been performed on individuals with a physiological rather than pathological DHEA 
deficiency presumably due to the low incidence of pathological deficiency and possibly 
due to the greater potential reward that demonstrating anti-aging DHEA related effects 
would generate.
There is a paucity of in vitro studies examining the effect of DHEA on primary 
preadipocyte cultures. However one study by McIntosh and colleagues [258], having 
previously demonstrated inhibition of both proliferation and differentiation after DHEA 
treatment in both 3T3-L1 preadipocytes [139] and rat and pig derived preadipocytes 
[289], concluded that DHEA reduces proliferation of preadipocytes isolated from
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subcutaneous adipose tissue but stimulated the differentiation of these cells. DHEA has 
also been shown to reduce the proliferation of human vascular smooth muscle cells 
which, like preadipocytes, are of mesenchymal origin [212]. A further study in human 
adipose tissues demonstrated upregulation of adiponectin in omental adipocytes 
following exposure to DHEAS [146].
3.1.4 Aims
Following the results from the cell line experiments the aims were firstly to compare 
these results to the effect that DHEA has on proliferation and differentiation on human 
primary preadipocytes and also to compare effects observed in subcutaneous and visceral 
fat depots.
3.2 Materials and Methods
Once primary samples had been obtained essentially the same experimental techniques 
were applied to this section of the study that were used in the cell line experiments 
described in chapter 2. However, modifications were required taking account the 
differing nature of the primary culture cells that became apparent during the course of the 
study.
3.2.1 Study design
Cardiff and Vale NHS trust Research and Development office (reference 06/CMC/3598) 
and Local Ethics committee (South East Wales Research Ethics Committee (reference 
06/WSE/03/37)) approval was obtained to approach individuals undergoing routine open
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abdominal surgery at the University Hospital of Wales, Cardiff. The gastrointestinal 
surgeons based at this site (Mr M. Puntis, Mr B. Rees and Mr N. Kumar) kindly agreed to 
provide possible participants for the study and also performed the adipose tissue harvest. 
Initially it was intended that all participants would be undergoing surgical procedures for 
non-malignant conditions, however it became apparent that the number of non­
malignancy related open abdominal surgical cases were limited to such a degree that 
malignancy related cases were eventually included. Potential study subjects were 
approached by a member of the research team following admission to the surgical wards 
and were then provided with a patient information sheet (appendix III) that outlined the 
study. Subjects were then given the opportunity to discuss their inclusion with the 
research team member. On agreement, subjects were asked to co-sign an informed 
consent form with the research team member (appendix III). Information on subject age, 
sex, past medical history and prescription medications was collected followed by 
measurement of height, weight, waist and hip circumference and percentage body fat 
[Tanita Body fat monitor/scale TBF-538, Tanita Corporation, Tokyo, Japan]. During 
surgery paired subcutaneous and omental samples of approximately 1cm3 in size were 
obtained and then collected by the investigating team. Samples were stored at 4°C until 
processed which in most cases occurred within hours of collection. Occasionally samples 
were kept overnight and processed the next day in which case l-2mLs of standard 3T3- 
L1 culture medium was added to the samples to prevent sample dehydration.
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3.2.2 Reagents and materials
Identical materials and reagents to those used in the cell line experiments described in 
detail in chapter 2 were utilised for human primary preadipocyte maintenance, storage 
and experimentation.
3.2.3 Preadipocyte extraction
2 different preadipocyte extraction methods were trialled during the study with varying 
degrees of success.
Explants: samples were scalpel dissected into small pieces (0.25-0.5 millimeters 
diameter) then placed directly (4-5 explants per well) into 6 well plates with sufficient 
standard 3T3-L1 culture medium to surround the base of each explant (l-2mls). Fresh 
medium was added every 3rd day. Preadipocytes potentially migrate out of the explant 
and attach to the surrounding plate.
Collagenase digest: collected adipose tissue samples were placed in 20ml universal 
containers (approximately 1cm3 of tissue per container) to which 7ml of Hank’s balanced 
salt solution, 2ml of 7.5% BSA (7.5g Bovine serum albumin in 100ml distilled H2O) and 
lml of collagenase type II (300mg collagenase type II in lOmls of 3T3-L1 culture 
medium) were added. This was then incubated for 1 hour in a water bath at 37°C, shaking 
every 5 minutes. The resultant solution was centrifuged at 4°C for 5 minutes at 1500rpm. 
Supernatant was removed leaving a cell pellet that was resuspended in 3T3-L1 culture 
medium and placed in a 75cm flask containing 10ml of 3T3-L1 culture medium at 37°C. 
Following 24 hours the cells were washed twice with 5ml of Hanks balanced salt solution 
removing any remaining red blood cells.
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3.2.4 Human primary preadipocyte culture
All cells were cultured in 75cm flasks at 37°C in standard 3T3-L1 medium changed 
every 4^-5* day. Trypsinisation, freezing and thawing procedures were identical to those 
used in cell line culture experiments described in chapter 2.
3.2.5 Assessment of proliferation
Approximately 103 preadipocytes (per well) were plated into 24 well plates in standard 
3T3-L1 culture medium for 24 hours to allow optimal cell-to-plate adhesion. Following 
this, varying concentrations of DHEA (10‘5 - 10'8 molar) and control (DMSO 0.1%) were 
introduced in a similar manner to that described in chapter 2. Cells were counted in 
duplicate with a Coulter cell/particle counter at 72 and 168 hours with a medium/reagent 
change at 72 hours. Each experiment was performed in quadruplicate.
3.2.6. Primary culture cell signalling
Confluent preadipocytes in 6 well plates following PBS wash underwent 2x2 hour 
incubations in serum free medium (DMEM only). Exposure to DHEA 10‘7 molar and 
control (DMSO 0.1%) was then performed over 10 and 20 minute periods. Resulting 
samples then underwent homogenisation as described in detail in chapter 2 followed by 
standard protocol Western blotting to determine phosphorylated and total MAP kinase 
activity.
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3.2.7 Primary culture differentiation protocol
Preadipoctyes in 6 well plates were grown to confluence in standard 3T3-L1 medium. 
Culture medium was then changed to a x 1 differentiation mixture (standard medium + 
x2 differentiation medium ratio 1:1) containing DHEA 10' molar or control (DMSO 
0.1%) and cultured for 21 days with medium/reagent change every 7 days. RNA was 
extracted using trizol reagent (as described in chapter 2); conditioned medium was 
collected on days 0, 7, 14 and 21. Rates of differentiation relative to control were 
assessed via foci counting and by transcription rates of differentiation markers in control 
and DHEA (10'7 molar) treated cells relative to the APRT housekeeper as described in 
chapter 2. Due to the slower rate of metabolic events observed in both subcutaneous and 
omental preadipocytes the differentiation protocol time frame was duly increased. 
Furthermore to obtain sufficient RNA for QPCR, RNA from 3 wells for each conditon 
was amalgamated such that each experiment generated only a single data set.
Human primer sequences and optimised concentrations have been described in chapter 2.
3.2.8 Adiponectin ELISA
The Human adiponectin Duoset® ELISA development system was employed [R&D 
systems, Oxford, UK]. Costar ELI 96 well plates [R&D systems] were coated with 
lOOpL of capture antibody (55pL/mL in PBS) the day prior to experimentation. All 
reagents were brought to room temperature before use. Following the wash protocol, 
wells were blocked with reagent diluent (1% bovine serum albumin [Sigma-Aldrich] in 
PBS) for 2 hours then lOOpL of prepared standard/neat conditioned medium was added 
to each well and incubated for 2 hours at room temperature. 1 OOpL detection antibody
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(55pL/mL reagent diluent), IOOjuL Strepavidin-HSP (50pL/mL reagent diluent), and 100 
pL substrate solution (1:1 colour reagent A and B [R&D systems]) were then sequentially 
added interspersed by wash protocols as per the manufacturer’s instructions. Experiments 
were terminated by addition of 50pL of stop solution (10% sulphuric acid) and optical 
density immediately determined using a microplate reader [OpsysMR microplate reader, 
Dynex Technologies, Chantilly, USA] set to 450nm.
3.2.9 Statistical analysis
Data sets generated were deemed not parametric and examined as such using SPSS 
version 12.0.1 for Windows (Microsoft).
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3.2.10 Demographic data of study subjects
The demographic and brief medical history data from study subjects who provided 
samples of sufficient quality for preadipocyte extraction and culture are described below.
Number Age Sex Diagnosis Height
(cm)
Weight
(Kg)
Waist/hip
Circumference
(cm)
% fat BMI
Weight 
(kg)/Height (m2)
1 64 F Carcinoma
Pancreas
163 74 Waist 92 
Hip 111
31 27.9
2 74 F Diverticular
Abcess
155 48 Waist 91 
Hip 91
27 20.0
3 74 F Rectal
Carcinoma
163 59.5 Waist 83 
Hip 98
30 22.4
4 55 M Crohn’s
Disease
178 69.9 Waist 91 
Hip 89
10 22.1
5 76 M Rectal
Carcinoma
175 62.2 Waist 100 
Hip 106
8.5 20.3
6 75 M Pancreatic
neuroendocrine
Tumor
178 82 Waist 94 
Hip 107
26 25.9
7 30 F Insulinoma 155 60 not
measured
not
measured
25.0
8 66 F Liver lesion 
(possible 
metastasis)
152 57 Waist 79 
Hip 102
35 24.7
Table 3.2 Demographic data from subjects providing adipose tissue samples for
preadipocyte extraction
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3.3 Results
Data has been presented in the same manner as in chapter 2 as median and interquartile 
ranges of DHEA treated samples versus DMSO 0.1 % controls. Human primary 
preadipocyte experimentation began with an assessment of the effect on proliferation.
3.3.1 Primary preadipocyte extraction
Explants: following previous success extracting preadipocytes from synovial and orbital 
fat [269] it was anticipated that this would be a successful mode of extraction however 
despite several attempts no identifiable preadipoctyes migrated out of the explant culture 
such that this technique was abandoned.
Collagenase digest: Preadipocytes were derived form this procedure but often in very 
small numbers such that up to a month in standard culture conditions was necessary to 
generate sufficient cell number for experimentation.
3.3.2 Primary preadipocyte cell culture
No macroscopic differences were observed between omental and subcutaneous samples 
during routine culture although in the majority of omental samples a second cell type 
(mesothelial cells) was seen; these were smaller relative to the adipocytes, more elliptical 
in shape and also more granulated. This contaminating cell type was present to a varying 
extent in most of the omental samples and exhibited a greater proliferation rate than 
preadipocytes which were larger, more rounded and less granulated (Fig 3.3). Wells 
containing a high concentration of these contaminating cells failed to demonstrate the
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typical macroscopic features normally associated with differentiation following standard
protocol suggesting that the contaminating cells were not preadipocytes.
subcutaneous Omental
preadipocytes preadipocytes
Fig 3.3 Subcutaneous and omental preadioctye in standard culture conditions. Note the 
presence of atypical cells in the omental sample located in the circled area
Magnification xlOO
The primary preadipocytes were invariably larger than the cell line preadipocytes and so 
working cell number was reduced. It was also apparent the preadipocytes became less 
biologically active with increasing passage number entering replication senescence 
invariably after passage 3. It therefore became my intention to perform all experiments at 
as low a passage number as possible, particularly when attempting to stimulate 
differentiation.
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3.3.3 Does DHEA effect proliferation in human primary preadipocytes?
Proliferation was determined in omental and subcutaneous preadipocytes. Presentation of 
the results begins with the latter. For ease of interpretation subcutaneous preadipocytes 
have been represented graphically in yellow and omental preadipocytes in orange.
Box-and-whisker plot demonstrating the effects of DHEA on proliferation of human 
subcutaneous preadipocytes following 72 hours exposure
Cells/well
Friedman test p<0.0001
4000- -
*p<0.0001
3000- -
2000-  ■
1000- -
* Wilcoxon Signed 
Ranks test
control DHEA 10-8 DHEA 10-7 DHEA 10-6 DHEA 10-5 
(DMSOO.1%)
DHEA (logM)
Fig 3.4 103 subcutaneous preadipocytes per well were plated into 24 well plates and 
exposed to varying concentrations of DHEA for 72 hours. Results are medians and IQRs 
for DHEA treated cells and control. Pooled data are presented from 4 experiments
performed in quadruplicate
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Box-and-whisker plot demonstrating the effect of DHEA on proliferation o f
subcutaneous primary preadipocytes following 168 hours exposure
Cells/well
7000- -
6000- -
5000--
4000- -
3000- -
2000-  -
1000- -
0 - -
Freidman test p<0.0001
*p=0.005
*p=0.018
*p=<0.0001
*Wilcoxon Signed 
Ranks test
control DHEA 10-8 DHEA 10-7 DHEA 10-6 DHEA 10-5 
(DMSO 0.1%)
DHEA (logM)
Fig 3.5 103 subcutaneous preadipocytes per well were plated into 24 well plates and 
exposed to varying concentrations of DHEA for 168 hours. Results are medians and IQRs 
for DHEA and control exposed cultures. Pooled data are presented from 4 experiments
performed in quadruplicate
These data demonstrate that in subcutaneous preadipocytes DHEA inhibits proliferation 
at both 72 and 168 hours although no effect was seen at the longer incubation with
o
DHEA 1 O' molar, and at 72 hours only the highest concentration caused a significant 
effect. Nevertheless our results demonstrate that following prolonged exposure 
particularly, DHEA inhibited proliferation at physiological, intra-adipose tissue 
concentrations.
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Box-and-whisker plot demonstrating the effect o f DHEA on proliferation o f
omental preadipocytes following 72 hours exposure
Cells/well
8000- -
6 0 0 0 --
4000- -
2000- -
*Wilcoxon Signed Ranks test
*p<0.0001
control DHEA 10-8 DHEA 10-7 DHEA 10-6 DHEA 10-5 
(DMSO 0.1%)
DHEA (logM)
Fig 3.6 10 omental preadipocytes per well were plated in 24 well plates and exposed to 
control and varying concentrations of DHEA for 72 hours. Results are medians and IQRs 
representing the number of cells in DHEA and control treated samples. Pooled data are 
presented from 4 experiments performed in quadruplicate
Although an inhibitory effect on proliferation was demonstrated this occurred at a 
supraphysiological concentration. These data suggest that over a short time period at least 
DHEA has no effect on omental preadipocyte proliferation at both serum and intra­
adipose relevant concentrations.
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Box-and-whisker plot demonstrating the effect o f DHEA on proliferation o f omental
preadipocytes following 168 hours exposure
Cells/well
4500- -
4000- -
3500- -
3000- -
2500- -
2000-  -
1500--
Friedmans test p<0.0001
p=0.047
p=0.008
p=0.008
p<0.0001
Wilcoxon Signed
Ranks Test
control DHEA 10-8 DHEA 10-7 DHEA 10-6 DHEA 10-5 
(DM SO O .1% )
DHEA (logM)
Fig 3.7 103 omental preadipocytes were plated in 24 well plates and exposed to control 
and varying concentrations of DHEA for 168 hours. Results are medians and IQRs 
representing the number of cells in DHEA and control treated samples. Pooled data are 
presented from 2 experiments performed in quadruplicate
The data from experiments in omental preadipocytes suggest that 72 hour exposure to 
DHEA does not affect proliferation at physiological concentrations, however following 
more prolonged exposure inhibition is demonstrated at relevant concentrations. Also the 
dose related effect is more pronounced in the omental relative to the subcutaneous 
preadipocytes.
Overall the effects in the primary cells are less dramatic than those observed in the cell 
line experiments described in chapter 2 and this possibly relates to the fact that primary
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cultures are likely to have been exposed to high DHEA concentrations previously, when 
their donors were in middle age, and thus are less sensitive to the experimental 
concentrations utilised. The absence of effect following 72 hours exposure to DHEA may 
relate to the slower proliferation rate which may be too short to determine any anti­
proliferation affects.
Due to the low working number of primary preadipocytes generated and the larger and 
more variable size observed, cell cycle analysis by flow cytometry was thought unlikely 
to generate interpretable results. Therefore in order to further evaluate the mechanisms 
behind the observed affect on proliferation, cell signalling was chosen for subsequent 
analysis.
3.3.4 Does DHEA affect MAP kinase cell signalling in human primary 
preadipocytes?
As in the cell line experiments described in chapter 2 the effect of DHEA exposure on 
P42/44 MAP kinase phosphorylation was used to determine any effect on cell signalling.
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Western blots demonstrating the effect o f DHEA on phosphorylated MAP kinase activity
over 10 and 20 minutes in subcutaneous preadipocytes
PhosphoMAP Kinase 
subcutaneous preadipocytes
o o
Densitometry 1.011 7951 7390 27 0 9 0 1 .02
(corrected for background)
TotalMAP Kinase 
subcutaneous preadipocytes
Densitometry 23 2 6 7 5 3 0 7 8 0 4 3 32804 3 4 1 0 0 9 306441
(corrected for background)
Subcutaneous preadipocyte 
Samples
PhosphoMAPK densitomtry corrected for 
totalMAPK densitometry
Non treatment 4.3 x 10'6
Control 10 minutes 0.026
DHEA 10‘7 molar 10 minutes 0.022
Control 20 minutes 0.079
DHEA 10 '7 molar 20 minutes 3.3 x 10'6
Fig 3.8/Table 3.3 Cells grown to confluence in 6 well plates in standard medium followed 
by 2x2 hours in serum free medium (DMEM) had DHEA 10'7 molar (containing 0.01% 
FCS) and DMSO 0.1% control (containing 0.01 %FCS) control added for 10 and 20 
minutes. Cells were then homogenised, blotted and detected following standard Western 
blotting protocol for phosphorylated and total MAP kinase. The blots then underwent 
densitomery assessment and correction for total MAP kinase measurement. Data shown 
are a representative blot of duplicate experiments
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Western blots demonstrating the effect o f DHEA on phosphorylated MAP kinase activity
over 10 and 20 minutes in omental preadipocytes
47.5 kda
32.5 kda
PhosphoMAP Kinase 
omental preadipocytes
DtnsHomatry 43698 92289 99760 140970 131232
(corrected for background)
47.5 kda
TotalMAP kinase 
omental preadipocytes
32.5 kda
I Densitometry 441921 443344 461491 397467 342236
|  (corrected for background) I
Omental preadipocyte 
Sample
PhosphoMAPK densitomtry corrected for 
totalMAPK densitometry
Non treatment 0.09
Control 10 minutes 0.21
DHEA 10'7 molar 10 minutes 0.22
Control 20 minutes 0.35
DHEA 1 O'7 molar 20 minutes 0.38
Fig 3.9/Table 3.4 Cells grown to confluence in 6 well plates in standard medium followed 
by 2x2 hours in serum free medium (DMEM) had DHEA 10'7 molar (containing 0.01% 
FCS) and DMSO 0.1% control (containing 0.01 %FCS) control added for 10 and 20 
minutes. Cells were then homogenised, blotted and detected following standard Western 
blotting protocol for phosphorylated and total MAP kinase. The blots then underwent 
densitomery assessment and correction for total MAP kinase measurement 
Data shown are a representative blot of duplicate experiments
These data demonstrate that both control and DHEA treatment increase phosphorylated 
MAP kinase levels. DHEA exposure had no effect relative to control on phosphorylated
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MAP kinase levels in omental preadipocytes. In subcutaneous preadipoctes however at 
both time points less activity is observed in the DHEA treated samples relative to control. 
This is a situation similar to that seen in the PAZ6 preadipoctye cell line. It is also noted 
that phosphorylated MAP kinase deactivation is delayed in the subcutaneous 
preadipocytes relative to the cell line.
As previously discussed phosphorylation followed by dephosphorylation of MAPK 
kinase is necessary for preadipocyte differentiation therefore it is only possible to 
conclude from these results that MAP kinase signal transduction is influenced by DHEA, 
though these data suggest that DHEA may influence cell signalling in omental 
preadipocytes to a lesser extent than in subcutaneous preadipocytes. It is not possible to 
determine however whether this effect on cell signal transduction would influence 
proliferation/differentiation in a positive or negative manner.
3.3.5 Does DHEA affect differentiation in human primary preadipocytes?
A number of independent end-points were used to evaluate the effect of DHEA on 
adipogenesis in primary preadipocyte differentiation. As described in chapter 2 foci of 
differentiation were counted at terminus of differentiation protocol (21 days) in DHEA 
exposed and control samples. Greater amounts of differentiation were observed 
macroscopically at early passage (1 or 2) and differentiation capacity varied between 
samples. QPCR evaluation of a terminal differentiation marker (LPL) was also utilised. 
Finally an assessment of the degree of the generation of the adipocytokine adiponectin 
was also utilised as a potential sign of the occurrence (or not) of adipogenesis. 
Presentation of the results commences with the foci of differentiation data.
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Subcutaneous Omental
preadipoctyes preadipocytes
Fig 3.10 Confluent omental and subcutaneous preadipocytes in differentiation mix 
(+ 0.1% DMSO) for 21 days. Photographs presented are representative of a number of 
experiments and clearly demonstrate differentiation foci 
Magnification x 100
Box-and whisker plot demonstrating the effect of DHEA on foci of differentiation in 
subcutaneous preadipocytes following 21 days exposure
150- ■
120- -
number of 90- -  
differentiation 
foci
6 0 +
0 2 4
0 2 8
823
0 1 8
30--
0 -  -
 1---------
Diff mix +DMSO 0.1%
 1---------
Diff mix + DHEA 10-7
culture conditions/concentrations (M)
Fig 3.11 Confluent subcutaneous preadipocytes in 6 well plates cultured in differentiation 
mix + DHEA 1 O'7 molar or control (DMSO 0.1 %) for 21 days. Results are the number of 
foci of differentiation per microscopic field (10 random fields examined per well). Pooled 
data are presented from 3 experiments performed in triplicate
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In subcutaneous cultures no reduction in foci number was demonstrated, conversely more 
foci were observed in DHEA exposed samples and the difference just achieved statistical 
significance (Wilcoxon Signed Ranks test p=0.034).
Box-and-whisker plot demonstrating the effect of DHEA on foci of differentiation in 
omental preadipocytes following 21 days exposure
number of 
differentiation 
foci
20 - -
15--
10- -
5 --
0 -  -
088
Wilcoxon Signed Ranks test p<0.0001
T T
Diff mix + DMSO 0.1% Diff mix + DHEA 10-7
culture conditions/concentrations (M)
Fig 3.12 Confluent omental preadipocytes in 6 well plates cultured in differentiation mix 
+ DHEA 10'7 molar or control (DMSO 0.1%) for 21 days. Results are the number of foci 
of differentiation per microscopic field (10 random fields examined per well). Pooled 
data are presented from 3 experiments performed in triplicate
In the omental preadipocyte cultures a significant reduction in the number of foci of 
differentiation was demonstrated. These data overall could suggest that DHEA may be 
inhibitory in omental but not in subcutaneous preadipocyte differentiation. The potential 
failings of this method of assessment have been discussed in chapter 2 and a more robust
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technique is required to confirm these results; as in the cell line experiments QPCR 
assessment of terminal differentiation marker (LPL) expression rate was chosen.
3.3.5.I. QPCR -  subcutaneous preadipocytes
QPCR assessment of the terminal differentiation marker (LPL) was performed.
Subcutaneous preadipocyte LPL QPCR
Subcut
samples
Day 0 1)ay 21 control 
[DMSO 0.1%)
Day 21 
DHEA 10'7 molar
Ct Copy
number
Ct Copy
Number
Fold
increase
Ct Copy
number
Fold
increase
8 32.17 18.17 26.75 557.8 30.7 24.00 3163 174.1
la 36.11 96.8 34.53 246.9 2.57 34.16 306.7 3.19
lb 36.33 84.99 37.33 47.26 0.56 34.93 195.2 2.3
7a 38.17 28.7 34.82 207.4 7.22 34.49 252.4 8.79
7b 37.04 10.59 34.52 247.6 23.38 34.89 199.0 18.26
Table 3.5 Ct value, copy number and fold increase in LPL copy number from day 0 to 
day 21 of differentiation protocol in control (DMSO 0.1 %) and DHEA 1 O'7 molar treated 
subcutaneous preadipocyte cultures. Data presented are from 3 separate patients and each
sample was analysed in duplicate
These data suggest an overall increase in LPL copy number following the differentiation
protocol (mean fold increase in control samples 12.89 and in DHEA treated samples
41.31) consistent with the occurrence of adipogenesis. However the various samples
demonstrate considerable variability in adipogenesis potential hence the amount of
differentiation occurring in DHEA and control samples was not significantly different
(Wilcoxon Signed Ranks test p=0.138). On interpretation of these data one must also
consider the high Ct values generated. Furthermore the results are not corrected for
housekeeper gene expression due to the formation of primer dimers following
housekeeper QPCR.
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3.3.5.2 QPCR -  omental preadipocytes
The tendency for the omental preadipocyte samples to be affected by a contaminating cell 
type reduced the number of samples available for QPCR analysis however samples from 
patients 2, 2a (2nd passage sample 2), 1, 5 and 8 were analysed although samples from 1 
and 5 did contain the non-preadipocyte population. QPCR assessment of the terminal 
differentiation marker (LPL) was performed.
Omental preadipocyte LPL QPCR
Omental
samples
Day 0 1fay 21 control 
DMSO 0.1%)
Day 21 
DHEA 10‘7 molar
Ct Copy
number
Ct Copy
number
Fold
increase
Ct Copy
number
Fold
increase
2 29.57 185.0 24.22 4918 26.58 25.29 2546 13.76
2a 30.29 207.4 27.72 994.1 4.8 29.54 327.0 1.6
8 32.01 139.0 21.78 70130 504 22.42 47500 341
5* 29.13 399.4 30.19 208.6 0.52 31.00 127.3 0.31
1* 33.60 122.9 33.45 134.2 1.09 33.92 102.6 0.83
Table 3.6 Ct value, copy number and fold increase in LPL copy number from day 0 to 
day 21 of differentiation protocol in control (DMSO 0.1%) and DHEA 1 O'7 molar treated 
omental preadipocyte cultures. Data presented are from 4 separate patients analysed 
simultaneously in duplicate (* denotes mesothelial cell presence)
These results confirm that in general, differentiation was occurring although not in 
samples 5 and 1 (mesothelial cells). It is also apparent that a large degree of variation in 
extent of differentiation potential existed between samples and also, as anticipated the 
extent of differentiation in the second passage sample (2a) was reduced relative to the 
initial, passage 1 sample (2). In all experiments with evident differentiation there was a 
tendency for reduced adipogenesis following treatment with DHEA in keeping with the 
data on foci of differentiation and this observation reached statistical significance
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(Wilcoxon Signed Ranks test p=0.043). These data are corrected for input cDNA (1 pL 
cDNA per QPCR reaction generated from lpg input RNA RT) as the housekeeper gene 
(APRT) data generated by QPCR tended to develop primer dimers.
3.3.6 Does DHEA affect adiponectin production in human primary preadipocytes?
From the generated ELISA data it was clear that not all samples synthesised sufficient 
adiponectin for assay detection. This observation is likely to be a function of the variable 
amounts of differentiation occurring within each sample despite the use of identical 
experimental conditions. Also, no sample beyond the first passage generated sufficient 
adiponectin for assay detection, suggesting the occurrence of senescence. Alternatively 
the ELISA kit chosen may not have been sensitive enough to detect lower levels of 
differentiation. However, 4 omental and 5 subcutaneous samples underwent sufficient 
increases in adiponectin levels following a standard 21 day differentiation protocol with 
and without DHEA exposure for analysis.
3.3.6.1 Adiponectin standard curve
From the standard solution provided in the human adiponectin ELISA kit [Duoset® 
ELISA, R&D Systems, Oxford, UK] a standard curve was generated in order to estimate 
sample adiponectin concentration.
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ELISA adiponectin standard curve
8
0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2 750  3000 3250  3500 3750  4000  425 0  4500  4750
concentration (pg/mL)
Fig 3.13 Human adiponectin standard curve
3.3.6.2 Does adiponectin production increase following the differentiation protocol 
in subcutaneous and omental preadipocytes?
The adiponectin assay data demonstrate a statistically significant overall increase in 
concentration (fig 3.14) from day 0 to differentiation protocol terminus (day 21) in 
omental and subcutaneous preadipocyte samples and in DHEA treated and untreated 
samples. Considerable variability was however observed in different samples, which is 
likely to be a reflection of the heterogeneity of adipose tissue as well as the originating 
subjects.
0.693
0.668
0.643
0.618
0.593
0.568
0 .543
0.518
0 .493
0.468
0 .443
0.418
0.393
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0.343
0.318
0.293
0.268
0 .243
0 .2 1 8
0 .193
0 .168
0 .143
0 .118
0 .093
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Box-and-whisker plot demonstrating the change in conditioned medium adiponectin 
concentration from omental and subcutaneous preadipocyte cultures following 21 days 
exposure to differentiation mix (± DHEA/control)
Adiponectin
concentration
(pg/mL)
1,500- -
1,200- -
900- -
600- -
300- -
0 - -
Wilcoxon Signed Ranks test p = 0 .0 1 1
* 3
Day 0
 1--------------------
D a y  21 preadipocytes (O M /S C )
Experiment time points
Fig 3.14 Conditioned medium was collected from omental and subcutaneous 
preadipocyte cultures following 21 days exposure to differentiation mix and assayed for 
adiponectin concentration using a standard ELISA method. Data presented are from day 0 
and day 21 for both cell types using control and DHEA treated samples
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3.3.6.3 Does DHEA affect adiponectin production in human omental preadipocytes?
Adiponectin generation in omental preadipocytes
Omental samples Day 0 Day 21 control 
Diff mix + DMSO 
0.1%
Day 21 Diff mix + 
DHEA 10‘7 molar
OD450 pg/mL OD450 pg/mL OD450 pg/L
2 0.048 65 0.188 900 0.046 62
1 0.042 54 0.044 58 0.053 100
3 0.046 62 0.616 3950 0.689 4450
4 0.045 60 0.067 125 0.048 65
Fold increase from 
base line
- - - 21 - 19.5
Table 3.7 ELISA generated optical density and concentration of adiponectin in 
conditioned medium of omental preadipocyte culture following exposure to 
differentiation mix for 21 days with and without DHEA 10'7 molar. Results are optical 
density measurement ( O D 4 5 0 )  and concentration (pg/L) from standard curve analysis. 
Data are from 4 experiments. Each sample was assayed in duplicate
3.3.6.4 Does DHEA affect adiponectin production in human subcutaneous 
preadipocytes?
Adiponectin generation in subcutaneous preadipocytes
Subcutaneous sample Day 0 Day 21 control 
Diff mix + DMSO 
0.1%
Day 21 Diff mix + 
DHEA 10'7 molar
OD45
0
Pg/m
L
OD450 pg/mL OD450 pg/L
5 0.042 56 0.103 375 0.049 72
1 0.045 60 0.058 115 0.188 900
4 0.088 200 0.683 4440 0.624 3825
2 0.043 56 0.123 460 0.113 450
3 0.044 58 0.043 56 0.059 120
Fold increase from base 
line
- - 12.7 - 12.5
Table 3.8 ELISA generated optical density and concentration of adiponectin in 
conditioned medium of subcutaneous preadipocyte following exposure to differentiation 
mix for 21 days with and without DHEA 1 O'7 molar. Results are optical density 
measurement ( O D 4 5 0 )  and concentration (pg/L) from standard curve analysis. Data are 
from 4 experiments. Each sample was assayed in duplicate.
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The omental preadipocytes tended to generate a greater increase in adiponectin 
concentration than the subcutaneous preadipocytes following differentiation though this 
was not statistically significant (Wilcoxon Signed Ranks test p=0.889). Furthermore there 
was no difference observed between the control and DHEA treated samples in either the 
omental or subcutaneous cell types (Wilcoxon Signed Ranks test p=1.0 and p=0.5 
respectively).
3.4 Discussion
In support of the findings presented in chapter 2, DHEA inhibited the proliferation of 
both subcutaneous and omental primary preadipocytes and at similar concentrations to 
those shown to be effective in the cell line experiments. The absence of effect at 72 hours 
in the primary cells is most likely a reflection of the overall slower proliferation rate in 
these cell types. The relative absence of effect on proliferation in the primary 
preadipocytes at 72 hours compared to 168 hours suggests possible implications to the 
cell line data presented in chapter 2. If the cell line experiments had been continued over 
further time points (terminated at 48 hours currently) a greater effect may have been 
observed. Antiproliferative activity may also have been seen to be greater at 
physiological concentrations had I continued the experiments to further time points and 
certainly this should be a part of any future experiments.
MAP kinase primary preadipocyte cell signalling is also shown to be influenced by 
DHEA though differential effects are seen in the subcutaneous and omental cell types 
whereby DHEA reduces the level of phosphorylated MAP kinase in the subcutaneous 
cells but not in the omental cells over a short time period (20 minutes). As in the cell lines
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it is not possible to conclude if these effects are adipogenesis supporting or inhibiting as 
first phosphorylation then dephosphorylation are required for adipogenesis progression as 
discussed in chapter 1.
Two methods of assessing the extent of preadipocyte differentiation have been employed; 
foci counts and QPCR. These confirm the occurrence of differentiation in response to the 
adipogensis protocol employed and also interestingly show that DHEA inhibits 
differentiation in omental but not subcutaneous preadipocytes. This is of potential 
importance given the adverse metabolic effects associated with omental fat 
accumulations relative to subcutaneous adipose tissue deposits. These experiments were 
however performed on a limited number of samples that exhibited a wide degree of 
differentiation potential. Furthermore RNA concentrations, and copy number generated 
were often low with associated high Ct values at QPCR, despite attempts to increase 
sample yield. The omental samples were also complicated by a contaminating cell line 
which, when present in larger enough quantities prevented the occurrence of 
differentiation which is likely secondary to the contaminating cell effectively ‘taking- 
over’ the plate. In order to combat the heterogeneity observed within the primary cell 
cultures it would be necessary to either perform these experiments in many more samples 
or, if possible to identify a sample with optimal differentiation potential and perform a 
number of experiments with this.
Although the data from these QPCR experiments demonstrates that DHEA may inhibit 
adipogenesis in omental but not subcutaneous primary preadipocytes the results have 
been generated without the use of a reference (housekeeper) gene. Thus the data have 
been exposed to potentially excessive experimental variability and this in turn increases
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the risk of type I statistical errors. The results must therefore be interpreted with this in 
mind, although the fact that results obtained by counting foci of differentiation produced 
a similar and statistically significant effect lend weight to the conclusions drawn. 
Adipogenesis in both omental and subcutaneous preadipocytes resulted in the generation 
of the adipocytokine adiponectin and thus represents a further marker of the occurrence 
of differentiation though no difference was observed between DHEA treated and control 
samples. Once more a large degree of variability in the production of adiponectin was 
observed and it is likely that only with an increased number of experimental samples 
would potential differences between omental, subcutaneous, DHEA and control samples 
be observed. QPCR assessment of adipogenesis markers remains however a more 
sensitive method of determining the extent of differentiation.
The anti-adipogenic effect of DHEA on human omental preadipoctyes is a novel finding 
with potential significance in the clinical setting, particularly in individuals with 
pathological DHEA deficiency in whom there is known to be augmented cardiometabolic 
risk. To further investigate and also to add weight to these findings a clinical trial 
supplementing DHEA in this population group is required.
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Chapter 4
A randomised, double blind, placebo-controlled, cross­
over study of the effects of dehydroepiandrosterone 
replacement on vascular function and body composition 
in patients with primary and secondary adrenal 
insufficiency -  Study design
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4.1 Overview
From the in vitro studies described in chapters 2 and 3 it is evident that in the laboratory 
setting at least, DHEA exerts a negative influence over some biological actions of 
precursor fat cells. In the clinical setting however, the role of DHEA supplementation in 
either physiological or pathological DHEA deficiency remains unclear. In order to 
determine the impact of DHEA replacement on adipocyte biology in vivo, a clinical trial 
was designed to investigate direct measures of body fat as well as markers of vascular 
health. The populations chosen for the study comprised individuals with pathological 
DHEA deficiency arising as a result of primary or secondary adrenal insufficiency. 
Various adipose and vascular parameters were examined before and after a period of 
DHEA therapy thus enabling correlation of any beneficial vascular effects to alterations 
in adiposity.
The clinical trial consisted of a randomised, double blind, placebo-controlled cross-over 
design, thereby adhering to gold standard clinical trial methodology as well as 
augmenting study power, which was of particular importance when considering the 
relative rarity of the chosen study population and limited sample size.
Supplementation of DHEA in either pathological or physiological deficiency has been a 
topic of previous investigations and studies have attempted to address the potential 
benefits of DHEA replacement in a variety of settings, in particular in adrenal 
insufficiency and mood disorders. In the normal elderly population, treatment with 
DHEA improves psychological well-being, lean body mass and bone turnover, and 
increases circulating IGF-1 levels [182, 290]. More recently, studies have reported the 
effects of DHEA replacement in patients with Addison’s disease (primary adrenal
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insufficiency) who were on standard glucocorticoid and mineralocorticoid replacement 
[12, 13]. These patients are generally young, have severe DHEA/DHEAS deficiency at an 
age when serum DHEA/DHEAS concentrations would normally be high, and have few of 
the confounding variables associated with ageing. In randomised, double blind, placebo- 
controlled studies, DHEA therapy has been shown to increase DHEAS concentrations in 
both sexes from subnormal to within the young adult physiological range [12, 13]. In 
women, total testosterone similarly increases, though as testicular Leydig cell function is 
normal in men with Addison’s disease, testosterone levels are already normal at baseline 
and do not rise further with treatment. Improvements were also evident in self-esteem and 
mood, with reduced fatigue and variable improvement in sexual function [12, 13], leading 
to suggestions that DHEA therapy should be considered as part of the standard 
replacement therapy in all patients with Addison’s disease.
However, comparatively little attention has been paid to the vascular effects of DHEA 
therapy in this population, despite cross-sectional and prospective epidemiological data in 
elderly populations demonstrating an inverse correlation between DHEAS concentration 
and vascular mortality. Furthermore, the evidence suggests that this relationship may be 
gender-specific. In a prospective cohort study of 622 elderly subjects, lower DHEAS 
levels were significantly associated with increased total mortality in men but not women 
[9]. A separate larger study has confirmed this relationship and the sexually dimorphic 
nature of this effect but also has shown a clear association with cardiovascular in addition 
to all-cause mortality [8]. These studies point to a gender difference in correlation 
between DHEAS levels and disease which could be explained, at least in part, by the sex- 
specific differences in the bioconversion of DHEA, whereby DHEA administration
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increases androgens in women [51] and oestrogens in men [52]. It is possible, however, 
that this association is merely an epiphenomenon as chronic disease induces a shift of 
intra-adrenal steroid biosynthesis that favours cortisol over DHEA production [71], 
raising the possibility that low DHEAS levels merely represent a surrogate marker of an 
unrelated illness. It thus remains unclear whether the relationship between DHEAS 
concentration and vascular risk is a causative one or simply an association.
To address some of these questions Kawano and colleagues prospectively examined the 
effects of DHEA administration on endothelial function in a cohort of middle-aged men 
with hypercholesterolaemia [180]. Endothelial dysfunction contributes to the 
pathogenesis of atherosclerosis and cardiovascular disease, preceding the development of 
overt complications. DHEA supplementation in this cohort improved flow-mediated 
dilation of the brachial artery, an endothelium-dependent process. The authors were also 
able to demonstrate a reduction in PAI-1 and steady-state glucose concentrations without 
alteration in fasting insulin, demonstrating improved insulin sensitivity. Similar 
prospective analyses on vascular risk have not been conducted in women and it remains 
unclear whether or not these beneficial effects of DHEA administration are confined to 
men, or whether indeed these improvements are restricted to a normal ageing population 
or are also apparent in disease states such as adrenal insufficiency. Furthermore, the 
mechanisms of these effects are not yet fully apparent though animal studies have 
demonstrated an antiatherosclerotic effect of DHEAS [210, 219], possibly by prevention 
of platelet aggregation [214] and uptake of cholesterol [180], and decreasing vascular 
smooth muscle cell proliferation [212]. However, little is known about the direct effects 
of DHEA on the vasculature. DHEA has no known cellular nuclear receptors though
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recently nongenomic plasma membrane receptors for DHEA have been identified in 
endothelial cell cultures which couple to eNOS [211]. Thus, DHEA has potential to 
stimulate NO generation. In addition, DHEA may be converted in vivo to oestradiol 
which itself increases NO synthase activity and NO production by either genomic or 
nongenomic mechanisms within the vascular endothelium [291]. It is entirely possible 
therefore that oestradiol converted from DHEA may have been responsible for the 
improvement in endothelial function observed in the study by Kawano et al [180].
The critical importance of oestrogens to endothelial health in males is highlighted by data 
from studies in an individual with an oestrogen receptor mutation and in men with 
aromatase deficiency. The patient with a mutation in the oestrogen receptor gene, and 
thus oestrogen insensitivity, was shown to have premature coronary artery disease [215]. 
His serum oestradiol and oestrone, FSH and LH concentrations were elevated, though 
serum testosterone concentrations were normal [216]. Computed tomography scanning 
showed premature calcification of a coronary artery and brachial artery studies 
demonstrated absence of flow-mediated dilation in response to ischaemic cuff occlusion 
despite preserved nitroglycerin and oestradiol-induced vasodilation [215]. Of the few 
male individuals described with aromatase deficiency to date [217, 292], one displayed 
elevated LDL, triglycerides and insulin levels, indicative of insulin resistance. Hormone 
analysis demonstrated undetectable oestrogens and very high circulating androgens in 
one of these individuals, together with elevated FSH and LH, indicative of an important 
role of oestrogens in the negative feedback regulation of gonadotrophins in males as in 
females. No cardiovascular studies have been performed to date in either of these 
individuals though there is evidence of impaired endothelium-dependent vasodilation in
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the aorta of aromatase knockout mice, suggesting a role for endogenous oestrogens in the 
regulation of endothelial function in this model [293]. A recent randomised, double-blind, 
placebo-controlled study in healthy young men treated with the aromatase inhibitor 
anastrozole showed an impairment in endothelial function independent of changes in 
well-established cardiovascular risk factors such as high-sensitivity C-reactive protein 
(HSCRP), homocysteine or lipoprotein(a) [218], supporting the hypothesis that 
physiological levels of oestrogen play an important role in the male cardiovascular 
system.
The data from these studies suggest that DHEA could improve endothelial function and 
in turn contribute to an improved vascular risk profile in patients with low circulating 
DHEAS levels, though it is conceivable that these effects may be gender-specific and 
mediated indirectly via conversion of this steroid to oestrogens. I sought to test this 
postulate in two cohorts of patients with primary and secondary adrenal insufficiency.
4.1.1 Study approval and funding
Prior to study commencement approval to conduct this clinical trial was obtained from 
Cardiff University (Sponsor; reference number SPON CU 086), Cardiff and Vale NHS 
trust Research and Development department (reference number 05/CMC/3294E), the 
South East Wales Research Ethics Committee (reference number 05/WSE04/42) and the 
Medicines and Healthcare Products Regulatory Authority (EudraCT number 2005- 
000115-10) who also, during the course of the study undertook an inspection of the trial 
as part of their routine statutory inspection of clinical trial activity at Cardiff and Vale 
NHS Trust (December 2007). The study was registered prospectively on the
176
International Standard Randomised Controlled Trial Number register and ascribed the 
registration number ISRCTN 46268487. Grant funding was obtained principally from the 
Wales Office for Research and Development, supplemented by support from the Cardiff 
and Vale NHS trust small grant scheme and a one-year Clinical Fellowship awarded to 
me from the Royal College of Physicians (Lewis Thomas Gibbon Jenkins of Briton Ferry 
Fellowship). The pre-initiation approval process began in January 2005 and final 
approval was obtained in August 2006 following which patient recruitment commenced. 
The delay in approval was mainly related to the need to accrue data, as part of the final 
approval process by the MHRA, to support the proposed shelf-life of the study drug.
4.1.2 Overall study design
This was a 32 week randomised, double-blind, placebo-controlled, cross-over study of 
the effects of DHEA on arterial stiffness and endothelial function in patients with primary 
(PAI; n=20) and secondary (PAI; n=20) adrenal insufficiency. Patients were randomly 
assigned to consecutive 3-month treatment periods of either DHEA 50mg followed by 
placebo capsules of identical appearance or placebo followed by DHEA. A wash-out 
interval of 2 months separated the two treatment phases. Randomisation was performed 
prospectively by an independent source, with half receiving DHEA first and the other 
half receiving placebo; this was carried out by St Mary’s Pharmaceuticals Unit. Arterial 
stiffness and endothelial function were assessed non-invasively by means of pulse wave 
analysis and pulse wave velocity measurements at baseline and after each treatment 
phase.
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4.1.3 Discussion of design
Primary adrenal insufficiency is an uncommon disorder and the total number of subjects 
available for study is limited. A double-blind, placebo-controlled, cross-over design is 
therefore justified in order to enhance the likelihood of detecting true change in outcome 
measures after DHEA treatment. A dose of 50mg was used as this has been shown from 
previous studies to increase DHEAS levels to young adult values. A washout interval of 2 
months was used to separate the two treatment phases to minimise the chance of ‘carry 
over’ into the next treatment phase; DHEA has a short circulatory half-life and 1 month 
washout intervals have usually been employed on this basis in previous studies.
4.1.4 Study participants, inclusion and exclusion criteria
Patients were recruited from the Endocrine clinic at the University Hospital of Wales.
The diagnosis of primary or secondary adrenal insufficiency was based on the following 
criteria. Addison’s disease was confirmed by documented hypocortisolaemia (subnormal 
ACTH stimulation test) associated with raised serum ACTH and, where available, 
positive adrenal autoantibodies. A minimum of 1 year duration of Addison’s disease was 
an inclusion criterion. Patients with a history of current or previous DHEA replacement 
were excluded from participation in the study. All participants had a stable glucocorticoid 
and/or mineralocorticoid replacement dose for at least six months prior to study 
commencement.
Secondary adrenal insufficiency was defined by documented hypocortisolaemia on an 
insulin stress test or short ACTH stimulation test associated with inappropriately low 
ACTH where available. To minimise confounding, subjects in this group comprised
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patients with a history of non-functioning pituitary adenoma or craniopharyngioma only 
(as opposed to hormone-secreting adenomas) who were treated surgically with or without 
concomitant radiotherapy, and were panhypopituitary on full hormone replacement 
therapy including growth hormone.
Exclusion criteria for both study groups were age less than 18 years or greater than 70 
years, pregnancy, breastfeeding and any intercurrent significant medical or psychiatric 
condition. All patients took their usual glucocorticoid and mineralocorticoid hormone 
replacement, with dosage and timing being kept unaltered before and during the study, 
though brief increases in glucocorticoid therapy were permitted in cases of intercurrent 
illness. Similarly, patients with secondary adrenal insufficiency took their usual hormone 
replacement therapy with no alteration in dose or drug timing prior to or during the study.
4.1.5 Recruitment
Potential participants were initially identified from the Endocrinology database at the 
University Hospital of Wales. Eligible subjects were invited to participate through a letter 
(patient information sheet see appendix IV) from the clinician responsible for their care 
(Dr J. S. Davies, Professor M. F. Scanlon or Dr D. A. Rees). Potential participants were 
also identified as they passed through the Endocrine clinic systems at UHW.
Following provisional agreement an appointment was made for the initial visit. At this 
visit participants were first given the opportunity to ask any questions regarding the study 
and were shown the study techniques involved. If subjects were still in agreement 
informed consent was obtained using a participant-investigator signed consent form 
(appendix IV). All study visits took place in the temperature controlled ward area of the
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Clinical Research Facility at the University Hospital of Wales, Cardiff. Subjects attended 
fasted on weekday mornings, each visit lasting 2-3 hours.
4.1.6 Interruption or discontinuation of treatment
The term discontinuation refers to a patient’s non-completion of the study. Information 
about discontinuation was collected in this study. Patients who discontinued from the 
study prematurely completed the final safety evaluations at the time of their 
discontinuation. An explanation of why the patient was withdrawn from the study was 
recorded, even if the patient refused to return for a final visit. Patients who discontinued 
prematurely due to significant adverse events were followed until resolution of the 
adverse event. Patients who discontinued due to clinically significant abnormalities in 
clinical laboratory results continued to be evaluated until the abnormality resolved or 
until it was judged to be permanent.
If for any patient either study treatment or observations were discontinued the reason was 
recorded. Reasons that a patient could discontinue participation were considered to 
constitute one of the following:
1. adverse event(s)
2. abnormal laboratory value(s)
3. abnormal test procedure result(s)
4. unsatisfactory therapeutic effect
5. subject’s condition no longer requires any study treatment
6. protocol violation
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7. subject withdrew consent
8. lost to follow-up
9. administrative problems
10. death
4.1.7 Treatments/Interventions
The two treatment arms were DHEA and placebo. The DHEA and placebo were sourced 
and packaged by St Mary’s Pharmaceutical Unit, Cardiff. During the study phase, 
patients received consecutive daily 50mg doses of DHEA for 12 weeks (84 days) 
followed by placebo or placebo followed by 50mg DHEA, separated by an 8 week wash­
out period.
First treatment phase Wash-out
^ W
Second treatment phase
Group A (n=10)
DHEA (50mg) DHEA (50mg)
Group B(n= 10) Placebo Placebo
12 weeks weeks 12 weeks
Visit 2 (Day 84) 
Post-treatment
Visit 3 (Day 140) 
Pre-treatment
Visit 4 (Day 224) 
Post-treatment
Visit 1 (Day 1) 
Pre-treatment 
Randomisation
Fig 4.1 Clinical trial overview
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50mg DHEA per day increases DHEAS levels to those of young adults and 
administration of this dose of DHEA over 1 year in an elderly population was shown to 
be safe with no harmful consequences [294]. Mild facial acne has been reported in some 
women [13] which is usually self-limiting, and subjects were monitored for these effects 
with withdrawal of therapy where appropriate. A minor reversible rise in serum 
aminotransferase concentration has also been reported, though other studies have not 
reported similar findings [13]. Serial hepatic enzyme measurements were performed at 
each study visit and study drug discontinued where necessary.
4.1.8 Investigational therapy
Patients were assessed at four points: baseline tests at visit 1 and at the end of the wash­
out phase (visit 3) and after each treatment (DHEA or placebo) phase (visits 2 and 4; see 
fig 4.1). Following an overnight fast, subjects were admitted to the Clinical Research 
Facility at 08:00 hours. Patients were not assessed if they had evidence of recent or 
ongoing infection as this would skew measurement of C-reactive protein. Pre-menopausal 
women underwent a pregnancy test and were excluded from participation if this was 
positive.
Baseline anthropometric data, consisting of blood pressure, height, weight body mass 
index (BMI), waist/hip circumference and body composition measured by bioelectrical 
impedance were collected. Body height (without shoes) was measured to the nearest 0.5 
cm using a stadiometer and body weight (in light clothing without shoes) to the nearest
0.5 kg on a balance beam scale. Waist circumference was measured at minimal 
respiration and reported to the nearest 0.5 cm by positioning a flexible anthropometric
182
tape parallel to the floor and immediately above the iliac crest. Hip circumference was 
measured at the maximum circumference over the buttocks and recorded to the nearest
0.5 cm. Body mass index (BMI) was calculated as weight (kg) divided by height (m) 
squared. Waist:hip ratio (WHR) was calculated as waist circumference divided by hip 
circumference. Standard bioimpedance was performed using a commercial bioimpedance 
meter (Tanita Body Fat analyser TBF-305, Tanita Corporation, Japan).
Blood samples were collected for analysis of DHEAS, testosterone, insulin-like growth 
factor-1 (IGF-1; SAI group only), SHBG, LH, FSH and androstenedione (the immediate 
downstream metabolite of DHEA). In addition, fasting blood samples were collected for 
measurement of total, HDL and LDL cholesterol, triglycerides, high sensitivity C- 
reactive protein (HSCRP), PAI-1, insulin, glucose, adiponectin and liver function tests. 
HSCRP measurements have emerged as powerful predictors of cardiovascular risk in a 
broad spectrum of patient populations [295] and the haemostatic factor PAI-1 is a 
circulating marker of endothelial function [180, 296]. Furthermore, DHEA therapy has 
been shown to reduce PAI-1 levels in middle-aged men with hypercholesterolaemia 
[180]. Adiponectin has emerged as a metabolically active adipoctykine the levels of 
which are inversely correlated with amounts of body fat [122]. Serum concentrations of 
adiponectin are lower in type II diabetes [120] and data suggest it may protect against the 
development of insulin resistance in normal individuals. Estimates of the degree of 
insulin resistance in the study population were performed by the homeostatic model 
assessment (HOMA) method. The HOMA method has been validated as a good index of 
insulin resistance in subjects with a broad range of insulin sensitivity [297] and
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demonstrates good correlation with insulin-mediated glucose uptake calculated by the 
euglycaemic hyperinsulinaemic glucose clamp [297].
Serum samples collected at each visit were subsequently stored at -20°C until later 
analysis.
Measures of arterial stiffness and endothelial function in our cohort were performed by 
means of pulse wave analysis (PWA) and pulse wave velocity (PWV) using a non- 
invasive technique (SphygmoCor system, AtCor medical). Traditional methods for 
assessing endothelial function centre on measuring the response to an endothelium- 
dependent, NO-mediated stimulus such as acetylcholine or reactive hyperaemia, and a 
direct, endothelium-independent nitrovasodilator such as sodium nitroprusside or glyceryl 
trinitrate (GTN). These methods, however, are time-consuming and can prove difficult to 
reproduce accurately and are thus not ideally suitable for inclusion in large-scale trials. 
PWA combined with provocative administration of GTN and salbutamol has been shown 
to provide a simple, repeatable, non-invasive means of assessing endothelial function in 
vivo [298]. Aortic PWV, a classical index of aortic stiffness, can be easily measured in 
humans using non-invasive methods of high reproducibility [203, 299]. These techniques 
make use of the SphygmoCor system and the principle of applanation tonometry first 
described by O’Rouke and collegues in Australia [202]. This method involves placing a 
sensor (termed a tonometer) over the point of maximal palpable pulsation, typically at the 
radial pulse (also carotid or femoral). Minimum downward pressure is then applied to the 
sensor which compresses the vessel beneath against underlying structures (e.g. radius) 
thus increasing the lateral vessel diameter. This has the effect of equalising
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circumferential pressure conducive to high-fidelity waveform capture by the tonometer 
(Fig 4.2).
Tonometer
Radial artery
Bone
Fig 4.2 Applanation tonometry schematic
The waveforms detected by this method comprise paired systolic peaks, the first peak 
representing the out-going systolic pulse wave, the second representing the reflected 
wave from peripheral resistance vessels (Fig 4.3).
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mmHg
Secondary systolic peak
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Fig 4.3 Radial pulse wave analysis recorded by applanation tonometry
Once the pressures are recorded at the radial artery a validated [300, 301] and generalised 
transfer factor is applied in order to generate the corresponding central wave form (Fig 
4.4). The transfer function calculation is performed by the SphygmoCor software and is 
typically applied to the radial pulse waveform as the radial artery is less compliant 
relative to the aorta and tends to alter less with ageing and following the introduction of 
pharmacological agents. The transfer function used by the SphygmoCor system is based 
on a population with a mean age of 51 years [302] and can be defined as an arithmetical 
description of the difference in pulsatile phenomena experienced at the peripheral (radial) 
and proximal (ascending aorta) sites in terms of modulus and phase. The term generalised 
refers to the ability of the same transfer function to be used in different individuals under
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different circumstances [300, 302]. Individualised [300], disease-specific [303] and 
gender-specific [304] transfer function calculations may be marginally more accurate in 
certain populations but this is not likely to interfere with a study of this design. 
Following application of the transfer function a central pressure waveform can then be 
determined and from that the augmentation index (Ai) (difference between the first and 
second systolic peaks (AP) expressed as a percentage of the pulse pressure (PP)), a 
measure of arterial stiffness can be derived. Central waveform pressures represent more 
accurately the left ventricular work load [305] than peripheral waveform pressures and 
thus potentially provide a better marker of cardiovascular risk.
Blood
pressure
m m H g
AP
incisura PP
time (milliseconds)
Pi- First systolic peak P2 - Second systolic peak PP- Pulse pressure
AP- difference between Pi and P2 Tp- Foot of Wave
Tr - time between Tf and inflection point Augmentation index (Ai) = AP/PP (%)
Fig 4.4 Central aortic waveform calculated from peripheral wave form using transfer
factor showing P2 augmentation of Pi
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Overt cardiovascular complications are preceded by structural changes within the arterial 
wall that becomes less elastic or distensible. This in turn leads to a reduction in vessel 
capacity to accommodate volume changes occurring throughout the cardiac cycle. In 
systole the aorta will distend less well and so generate higher systolic pressures and 
during diastole, secondary to impaired elastic recoil, maintenance of pulse pressure will 
be impaired. The less compliant, diseased vessels generate peripheral and central arterial 
waveforms that are different in shape from waveforms generated form healthy vessels 
and this can be easily detected using the SphygmoCor system. ‘Stiffer’ vessels produce 
waveforms exhibiting exaggerated reflected wave augmentation as well as increased 
pulse wave velocities.
Arterial wave forms are a composite of a pulse pressure wave produced in systole by left 
ventricular contraction and a reflected wave produced as the forward wave hits smaller 
vessels with increased resistance and is reflected back on itself. Waveforms will differ 
depending on which artery is examined, as the distance from the left ventricle increases 
and the composition of the arterial wall becomes less elastic more distally. In stiffer 
arteries waveforms will travel faster and the reflected wave will be seen earlier in the 
formation of the forward wave. If the reflected wave appears early enough, before aortic 
valve closure, it will add to or augment the pressure produced by the initial wave, 
producing an increase in central systolic pressure [306]. The extent of this augmentation 
can be measured peripherally and expressed as a percentage. However central 
augmentation and pressures are of greater importance as these reflect more directly left 
ventricular workload. To determine central arterial values a validated transfer function
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[299] can be applied to the peripheral arterial assessment and from this central aortic 
pressures can then be generated as discussed above.
Central ascending aorta pressures and waveforms are influenced by both height [307], 
and heart rate [308]. The higher Ai values observed in females are therefore likely to be a 
function of vessel length which is in turn a function of overall height. Alterations in the 
timing of the reflected wave and thus the extent to which it augments the forward wave 
explain the differences seen in association with pulse rate.
In the context of end stage renal disease, hypertension and glucose intolerance PWV has 
been shown to predict mortality [198-200, 309]. Increased arterial stiffness is associated 
with some of the classical cardiac risk factors such as age and male sex [310] and has also 
been shown to precede overt atheroma formation [311]. Arterial stiffness is also 
intimately involved with endothelial function as discussed in chapter 1. Ai has also been 
demonstrated to be an independent risk marker for coronary artery disease [186]; 
moreover the high central arterial pressures (that can be generated via the transfer 
function from peripheral pulse waveforms as discussed above) have been associated with 
increased arterial stiffness [312]. Theoretically central blood pressure better predicts 
cardiovascular status as it more accurately describes left ventricular pressure exposure 
and this is evidenced by the observation that central blood pressure, as opposed to 
peripheral blood pressure, has been shown to be an independent predictor of total and 
cardiovascular mortality [313].
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4.1.9 Treatment assignment/randomisation methods/blinding
Subjects were randomised into two groups in a double-blind fashion: for each cohort 
(PAI and SAI), group A (n=10) received DHEA 50mg followed by placebo treatment and 
group B (n=10) received placebo followed by DHEA 50mg treatment for 12 weeks 
separated by an 8 week washout. The treatment assigned to each patient was determined 
according to a computer generated randomisation list, produced by St Mary’s 
Pharmaceutical Unit using Microsoft XL random number generator. The patient 
packs/study drug were labelled with a unique patient identification number. When a 
patient was found to be eligible for the study and had completed all baseline procedures, 
he/she was allocated a unique patient identification number in sequential, chronological 
order. The patient was then treated with the medication labelled with the same number. 
Should a patient withdraw from the study, his or her identification number was not 
reallocated.
4.1.10 Emergency procedure for unblinding
The randomisation code for each patient was delivered to the Pharmacy department at the 
University Hospital of Wales in individually sealed envelopes for emergency use only. In 
the absence of any emergency, patient allocation details were kept coded and remained 
confidential until the trial was complete.
Only in the case of a serious adverse event was there a plan for the investigator to open 
the relevant sealed envelope containing the patient’s treatment allocation and only if this 
would be of help in the treatment of the patient.
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4.1.11 End of study unblinding
Following the last patient visit and completed biochemical analysis an electronic database 
was prepared containing all generated results. Once complete, a research governance 
officer from Cardiff University undertook a study closedown visit which included 
obtaining a CD copy of the dataset as evidence of the final, completed and verified data. 
St Mary’s Pharmaceutical Unit was then informed by the Sponsor of study completion 
and permission to release the treatment allocation codes was given. The data were then 
analysed in conjunction with Professor Robert Newcombe, Department of Primary Care 
and Public Health, Centre for Health Sciences Research, Cardiff University.
4.1.12 Concomitant therapy
All medications taken during the four weeks prior to visit 1 and throughout the study 
were recorded. As indicated above, patients were expected to take their usual 
glucocorticoid or mineralocorticoid replacement therapy with dosage and timing being 
kept unaltered before and during the study, though brief increases in glucocorticoid 
therapy were permitted in cases of intercurrent illness. These were recorded. Similarly, 
patients with secondary adrenal insufficiency took their usual hormone replacement 
therapy with no alteration in dose or drug timing prior to or during the study.
Investigators discouraged patients from taking any medication during the study that was 
not being taken at baseline, an exception being medication required to treat an adverse 
event.
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4.1.13 Procedures and Instructions
Instructions on the reporting procedures for serious adverse events 
Information about all non-serious and serious adverse events (SAEs), irrespective of 
causality, whether volunteered by the subject, discovered by investigator questioning, or 
detected through physical examination, laboratory test or other means, were collected and 
recorded. An adverse event was defined as any undesirable sign, symptom or medical 
condition occurring after starting the study treatment. Study treatment included the study 
drug under evaluation (DHEA) or placebo given during any phase of the trial. Adverse 
events were followed as appropriate.
Medical conditions/diseases present before starting the study were considered adverse 
events if they worsened after starting the study drug. Abnormal laboratory values or test 
results constituted adverse events only if they induced clinical signs or symptoms or 
required therapy, or were considered clinically significant for any reason, in which case 
they were recorded.
Where possible, each adverse event was also described by:
1. Its duration
2. The severity grade (mild, moderate, severe)
3. Its relationship to study drug (suspected, not suspected)
4. The action(s) taken
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Serious adverse events
Information about all SAEs was collected and recorded. A SAE was defined as an 
undesirable sign, symptom or medical condition which:
1. was fatal or life-threatening
2. required or prolonged hospitalisation
3. was significantly or permanently disabling or incapacitating
4. constituted a congenital anomaly or a birth defect
5. was medically significant, jeopardised the subject or required medical or surgical 
intervention to prevent one of the outcomes listed above.
Any SAE, irrespective of causality, occurring in a patient after providing informed 
consent and until sixteen weeks after ending study participation was recorded. Suspected 
unexpected serious adverse reactions (SUSARS) were reported immediately to the trial 
sponsor (Cardiff University), the Research Ethics Committee and the Medicines and 
Healthcare products Regulatory Agency (MHRA) as per European Union requirements 
and ICH-GCP (International Conference of Harmonisation of Good Clinical Practice).
4.1.14 Endpoints
Based on previous studies in middle-aged men with hypercholesterolaemia, an 
improvement in endothelial function following DHEA administration was anticipated. 
Change in augmentation index alone and measured post-salbutamol versus post-GTN, 
central aortic blood pressure and pulse wave velocity from baseline were therefore 
designated the primary outcome measures. Secondary end-points included changes in
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DHEAS, androstenedione, testosterone (in females), PAI-1, HSCRP, insulin resistance 
(HOMA-IR), IGF-1, lipid profile, adiponectin and measures of body composition.
4.1.15 Sample size and power calculations
Sample size advice was sought from Professor R. Newcombe, Department of Medical 
Statistics and Epidemiology, School of Medicine, Cardiff University. The design for 
these two studies was based largely on a precedent study by Kawano et al [180]. 
Important differences between the proposed study and the precedent study relate to the 
patient population studied, the method used to measure endothelial function, and the fact 
that Kawano et al used a parallel groups design, for reasons that are not made clear.
Based on Kawano et aVs figures, a difference of 8.4 -  4.4 = 4.0 FMD units (i.e. % of 
baseline) was postulated at 12 weeks i.e. when equilibrium is reached. Kawano et al gave 
a standard error of 0.7 units for the mean at 12 weeks in the DHEA group based on 12 
subjects. The corresponding SD is 0.7 x Vl2 = 2.4 units. Disregarding within-patient 
correlation, the standard error of the mean change from 0 to 12 weeks based on 20 
subjects all receiving the same treatment was expected to be 2.4 x V(2/20) = 0.77 units. 
The standard error of the mean change from 0 to 12 weeks based on 20 subjects all 
receiving active minus the mean change from 0 to 12 weeks based on 20 subjects all 
receiving placebo was expected to be 0.77 x V2 = 1.08 units. The resulting critical ratio, 
4.0 / 1.08 = 3.7, corresponded to a 96% power to detect a 4.0 unit difference at the 
conventional 5% alpha level. Since the main rationale for using a crossover study is that a 
substantial within-subject correlation was anticipated, we therefore anticipated that the 
power should be well in excess of this figure. Any potential disadvantages of reduced
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precision using augmentation index compared with FMD (Kawano et aV s study) to assess 
endothelial function should be outweighed by the within-subject correlation.
4.1.16 Statistical methods
The recommended method of analysis for a cross-over study design was described by 
Hills & Armitage [314]. The assessment of treatment efficacy compares the within- 
subjects period I minus period II differences between the treatment sequence groups AP 
(active-placebo) and PA (placebo-active) by unpaired t-test. In the event of serious 
departure from Gaussian distributional form (Kawano et al gave no evidence that this 
occurs), scale transformation or an equivalent non-parametric approach [315] was used. 
Point and interval estimates of the treatment difference (half the AP -  PA difference) 
were given as well as p-values.
4.2 Project Management
The day-to-day conduct of the study, recruitment, consent, blood sampling and 
measurements of pulse wave velocity and augmentation index in the study participants 
were performed by myself. I was also responsible for data entry and storage. The Clinical 
Trials Section of the Pharmacy Directorate (managed by Kathryn Bethuene, Clinical 
Trials pharmacist) was responsible for DHEA/placebo dispensing and storage and 
destruction. The randomisation process was performed by St Mary’s Pharmaceutical unit, 
Cardiff, using a Microsoft XL random number generator. The same organisation sourced, 
produced and packaged the investigational medicinal product (IMP) (DHEA 50mg) as 
well as the placebo capsules.
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Dr Aled Rees (Principal Investigator) acted directly as project supervisor. Formal 
meetings took place on a weekly basis to discuss all aspects of the study and to plan the 
work for the forthcoming week. Formal training was undertaken on all aspects of pulse 
wave analysis including attendance at an arterial stiffness course (Addenbrooke’s 
Hospital, Vascular Research Unit, Cambridge, March 2005). A run in study was 
performed to ensure optimal operator quality with minimal variability prior to study 
commencement. Informal discussions regarding any difficulties that arose with the 
project took place as required. In the event of an emergency I was contactable on a 24 
hour basis and my contact details were provided on all IMP/placebo containers.
4.2.1 Administrative Procedures
Changes to the protocol: Changes or additions to the protocol required a written protocol 
amendment. Amendments significantly affecting the safety of subjects, the scope of the 
investigation or the scientific quality of the study were submitted for additional approval 
by the Local Research Ethics Committee, Cardiff and Vale NHS Trust Research and 
Development department and the Medicines and Healthcare products Regulatory Agency.
Auditing procedures: As part of Good Clinical Practice, Dr Rees ensured that the study 
protocol and documentation were closely monitored. All study documentation was 
available for inspection at any time by appropriate regulatory authorities including 
internal audits by the Cardiff and Vale NHS Trust and Cardiff University Research and 
Development audit officers.
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Handling of study medication: All study medication was dispensed by the Pharmacy 
department at UHW. Drug supplies were stored in an appropriate, secure area and 
accurate records of the dispensing of study drug were kept in a drug accountability 
ledger. An accurate record of the date and amount of study drug dispensed to each subject 
was available for inspection at any time.
4.2.2 Consent
As outlined (see section on recruitment), potential participants were initially identified 
from the Endocrinology database at the University Hospital of Wales and eligible 
subjects were invited to participate through a letter from the clinician responsible for their 
care (Dr J. S. Davies, Professor M. F. Scanlon, Dr D. A. Rees). Potential participants 
were also identified as they passed through the Endocrine clinic systems at UHW 
(Professor M. F. Scanlon, Dr J. S. Davies, Dr D. A. Rees) and a patient information sheet 
was provided (appendix IV).
This explained the nature of the study, its purpose, the procedures involved, the expected 
duration, the potential risks and benefits involved and any discomfort it might entail.
Each subject was informed that participation in the study was voluntary and he/she could 
withdraw from the study at any time and that withdrawal of consent would not affect 
his/her subsequent medical treatment or relationship with the treating physician. Patients 
were given adequate time to review the patient information sheet and ask questions about 
any aspects of the study. Consent was obtained in the ward area of the Clinical Research 
Facility, University Hospital of Wales.
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This informed consent was given by means of a standard written statement, written in 
nontechnical language. The subject read and considered the statement before signing and 
dating it, and was given a copy of the signed document. If the subject could not read or 
sign the documents, oral presentation was made or signature given by the subject’s 
legally appointed representative, if witnessed by a person not involved in the study, 
mentioning that the patient could not read or sign the documents. No patient could enter 
the study before his/her informed consent had been obtained.
4.3 Investigator variability
In order to determine intra-operator variability 20 fasted subjects underwent tonometry 
for Ai on 2 occasions 30 minutes apart. These subjects consisted of healthy individuals 
from the Centre for Endocrine and Diabetes Sciences at the University Hospital of Wales. 
Measurements took place either in the Clinical Research Facility at the University 
Hospital of Wales and were performed in duplicate (table 4.1).
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Subject Gender Age
(yrs)
Height
(cm)
Weight
(kg)
BP
(mmHg)
Ai 1 (%) Ai 2 (%)
1 M 37 166 70 127/84 22.5 22.5
2 M 35 175 71 120/81 15 15.5
3 M 42 180 102 132/74 21.5 22
4 M 38 175 71 128/64 15.5 12.5
5 F 40 156 59 127/81 24.5 28
6 F 56 163 57 138/88 28 28
7 F 37 160 53 121/94 30 26.5
8 F 29 160 69 119/88 17.5 16
9 M 33 173 80 120/80 5 3.5
10 F 31 160 78 132/78 30 28
11 M 35 173 78 134/83 15 14.5
12 F 36 158 75 118/75 29.5 27.5
13 F 38 158 80 144/104 40.5 38
14 F 40 161 58 98/70 16.5 16
15 F 34 146 74 116/75 26 25.5
16 F 37 164 123 131/68 16.5 18
17 F 28 165 83 141/93 -4.5 -6
18 F 20 167 78 132/73 15 18.5
19 F 22 180 69 122/67 -8 -5
20 F 26 167 72 110/71 11.5 10.5
Overall ntra-operator variabili ty is <1%
Table 4.1 Ai in control subjects 30 minutes apart demonstrating overall investigator
variability of less than 1%
4.4 Procedure for measurement of arterial stiffness and endothelial function
Ai, PWV and endothelial function were all determined using the SphygmoCor equipment 
(SphygmoCor model MM3, AtCor Medical Ltd, Sydney, Australia) and software 
(SphygmoCor version 8.0 for Microsoft Windows). Required input data entered into the 
software prior to pulse wave measurements were gender, height, weight (Tanita Body Fat 
analyser TBF-305, Tanita corporation, Japan), and brachial blood pressure (British 
Hypertensive Society approved Omron 705IT, Omron Matsusaka Co Ltd, Japan).
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Ai was calculated by the SphygmoCor software from tonometry performed over the 
radial pulse. Recordings were repeated until 2 readings were obtained within 5% of each 
other with operator quality index over 75%. The 2 measurements collected were averaged 
prior to data entry.
The SphygmoCor system was used to determine pulse wave velocity [203] by recording 
the time point at which the reflected wave occurred in the waveform of a proximal artery 
(carotid) compared to a distal artery (radial or femoral) in milliseconds. The vessel length 
(in millimeters) was determined (radial -  distance from sternal notch to radial pulse in an 
out-stretched arm; femoral - distance from suprasternal notch to umbilicus and umbilicus 
to femoral pulse) and then subtracted from the distance from the suprasternal notch to the 
carotid pulsation by the SphygmoCor software. The subject was then attached to the basic 
electrocardiogram (ECG) component of SphygmoCor MM3 and Ai readings taken firstly 
from the distal vessel (radial or femoral) and then the proximal vessel (carotid). The use 
of the ECG allows the system to ascertain precisely the point of cardiac contraction 
(taken to be the R wave peak) and this point is taken as waveform time zero. The 
software thus generated a pulse wave velocity for both the carotid-radial (brachial pulse 
wave velocity - bPWV) and carotid-femoral (aortic pulse wave velocity - aPWV) sites. 
Measurements were repeated until 2 recordings were obtained within 0.5 meters per 
second of each other that were then averaged prior to data entry.
The precise endothelial function assessment protocol was obtained form I.B. Wilkinson’s 
group in Cambridge (Vascular Research Clinic, Addenbrooke’s Hospital, Cambridge,
UK) [298] and is described in appendix IV. The pharmacological agents utilised in this 
protocol were 400pg salbutamol (four of a lOOpg metered inhaler dose) (an endothelial
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dependent nitric oxide-mediated vasodilator) [Salamol CFC-free inhaler, IVAX 
Pharmaceuticals, London, UK] and 500pg glyceryl trinitrate (GTN) (an endothelial- 
independent vasodilator) [Alpharma, Barnstable, UK]. An estimation of endothelial 
function was established through the of generation Ai values from peripheral waveforms 
following treatment with these agents, the vasodilating effects of which decrease Ai 
correspondingly. The vasodilating action of GTN generated data corresponding to 
optimum dilating ability (by NO endothelial saturation) whereas the vasodilating action 
of salbutamol produced data corresponding to the ability of the endothelium to dilate 
given current endothelial microenvironment.
The effect of firstly GTN and then salbutamol on Ai was determined due to the slower 
clearance of salbutamol. Endothelial function was defined as the maximum change in Ai 
following salbutamol treatment occurring within 20 minutes of drug administration. Each 
Ai recording was repeated until 2 were obtained within 5% of each other with an operator 
quality index of over 75%. Measurements were averaged prior to data entry.
4.5 Assay characteristics of biochemical analyses
At each visit blood was collected for a number of measurements. All biochemical 
analysis was performed at the Department of Medial Biochemistry at the University 
Hospital of Wales, apart from adiponectin which was measured in-house using the 
ELISA method outlined in chapter 3.
DHEAS was assayed by electrochemiluminescent immunoassay on an automated system 
(Roche Codas El 70 Immunoassay analyser). Insulin was measured by a solid phase two- 
site immunoassay (Mercodia Iso-insulin ELISA, Mercodia AB, Uppsala, Sweden).
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SHBG was determined via an electrochemiluminescence immunoassay on an automated 
immunoassay system (Roche Elecsys 170 immunoassay analyser). LH and FSH were 
analysed via a two-site sandwich immunoassay on an automated analyser (ADVIA 
Centaur LH and FSH assay and Siemens Healthcare Diagnostics immunoassay analyser); 
the same analyser was used to measure testosterone through competitive immunoassay 
(ADVIA Centaur Testosterone assay). IGF-1 was measured using a chemiluminescent 
immunometric assay (IMMULITE® 1000 chemiluminescent immunoassay system, 
Diagnostic Products Corporation, Llanberis, Wales, UK).
Androstenedione was manually assayed in duplicate using the coat-a-count system 
(Diagnostic Products Corporation, Llanberis, Wales, UK). Glucose, liver function tests 
and serum lipids (total cholesterol, triglyerides, HDL and LDL cholesterol) were all 
measured using the AEROSET general chemistry photometric system (Abbott 
Diagnsotics, Berkshire, UK). HSCRP was assayed via nephelometry (BN™ II system, 
Dade Behring). PAI-1 was measured using a tissue plasminogen activator coated ELISA 
plate that assays only active PAI-1 (ZYMUTEST, Hyphen Biomed, Nodia, Amsterdam). 
The performance characteristics of each of these assays are summarised in table 4.2.
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Test Coefficient of 
variation
Lower limit 
Of detection
Reference range
Insulin 4.1-4.9% 1 mU/L N/A
IGF-1 5.8-8.4% 20 ng/mL Age and sex specific
Androstenedione 3.2-15.6% 0.14 nm/L 4.4-10.6 nmol/L
Glucose 1.5-2.2% 0.1 mmol/L > 5.6  mmol/L (IDF diagnostic criteria for 
the metabolic syndrome see chapter 3)
Triglyerides 0.8-1.1% 0.07 mmol/L 0.6-2.0 mmol/L
HDL 5.5-1.4% 0.13 mmol/L 0.7-1.7 mmol/L
Cholesterol 0.8-1.6% 0.16 mmol/L Evaluate in conjunction with other cardiac 
risk factors (BP, FMH, DM, smoking)
DHEAS 2.3-3.3% 0.1 pmol/L Age and sex specific
SHBG 1.1-4.0% 0.35 nmol/L Male 11.4-52.3 nmol/L
Female premenopausal 19.8-122 nmol/L
Female post menopausal 14.1-68.9 nmol/L
HSCRP 2.5-4% 0 mg/L 0-3.0 mg/L
LH 2.7-3.8% 0.07 U/L 1.5-9.3 U/L
FSH 2.2-3.9% 0.3 U/L 1.4-18.1 U/L
Testosterone 2.1-1.6% 0.35 nmol/L 8.0-30.3 nmol/L (male) 3nmol/L (females)
PAI-1 not available 0.5 ng/mL < 5.0  ng/mL
Table 4.2 Biochemical test characteristics 
(BP-blood pressure, FMH-family history, DM-diabetes Mellitus)
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Chapter 5
A randomised, double blind, placebo-controlled, cross­
over study of the effects of dehydroepiandrosterone 
replacement on vascular function and body composition 
in patients with primary and secondary adrenal 
insufficiency — results
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5.1 Overview
From the currently available evidence the use of DHEA therapy, in the clinical setting at 
least, can only be justified in females with primary adrenal insufficiency/Addison’s 
disease, although its use is generally restricted to individuals with reduced quality of life 
and/or complaints of a reduced libido [12,13].
There is however a sufficient body of work that suggests that DHEA/DHEAS deficiency 
and therefore its replacement may have further beneficial effects relating to potential 
actions on adipose tissue [139-141, 152, 316] and the vasculature [180, 208, 210, 317]. 
Many of these studies have however been performed in the in vitro setting or in animal 
models and the human studies performed have often been in cases of physiological rather 
than pathological deficiency. These various studies have been reviewed earlier in this 
thesis and are supported by some of the in vitro data presented in chapters 2 and 3. 
Extrapolation of data from in vitro and animal models to human physiology is associated 
with a number of potential problems. As previously discussed the high and fluctuating 
concentration of DHEA/S are only observed in humans and higher primates; hence 
supplementation of DHEA into animal feeds or culture conditions often generates non- 
physiological environments [56]. Furthermore any data generated from studies performed 
in vitro by definition removes material of interest from its native environment and in 
doing so prevents the occurrence of any in vivo co-activating or co-suppressing 
interactions. For these reasons it becomes necessary to confirm (or refute) any in vitro 
observations in vivo.
Addison’s disease provides a particularly good vehicle with which to examine the impact 
of DHEA replacement as DHEA deficiency may potentially be the condition’s sole
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uncorrected hormonal abnormality, assuming optimal glucocorticoid and 
mineralocorticoid replacement and the correct treatment of any other associated 
autoimmune disease. Addison’s disease is a relatively rare condition; however utlisation 
of a cross-over study design and recruiting subjects from a large tertiary referral 
endocrine centre, enabled sufficient recruitment and maximal power. Addison’s disease 
was therefore chosen as the first group in which to evaluate the effect of DHEA 
replacement on vascular function and adiposity.
Secondary adrenal insufficiency is a component of hypopituitarism which is known to be 
associated with impaired survival as well as cardiovascular risk [244-246]. Unlike 
primary adrenal insufficiency, however, the aetiology of hypopituitarism is more 
heterogeneous resulting from an array of pathological processes. Nevertheless DHEA 
deficiency is a feature of secondary adrenal insufficiency although replacement with 
DHEA is not commonplace as previously discussed. The accumulation of adipose tissue 
and excessive vascular risk in the context of hypopituitarism may be secondary to a 
number of factors such as sub-physiological (thyroxine, growth hormone) or supra- 
physiological (cortisol) hormone replacement, hypothalamic appetite centre damage 
secondary to either disease processes or therapy/treatment (radiotherapy, surgery) in 
addition to DHEA deficiency.
206
5.1.1 The flow o f patients through each study phase
Figure 5.1 summarises the flow of patients through each phase of the study.
Enrolment
Screened for eligibility n=150  
Inclusion criteria 
Aged 18 to 70 years 
Definitions of PAI and SAI met
Allocation
Randomised (n=40)
I
DHEA 50 mg/day Discontinued
(n=20) (n=1) due to
10 PAI hirsutism
10 SAI and acne
DHEA 50 mg/day 
(n=18)
10 PAI 
9 SAI
Analyses ( End of Study Analysed (n=37)
Excluded (n=89)
Met inclusion criteria (n =61) 
Refused/couldn’t be contacted 
(n=21)
1
Placebo 
(n=20) 
10 PAI 
10 SAI
Placebo
(n=19)
9 PAI
10 SAI
Discontinued 
(n=1) due to 
non- 
compliance 
with therapy
Discontinued 
(n=1) due to 
failure to attend 
for final visit
Fig 5.1 Flow of patients through each phase of the study
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5.2 Safety, tolerability and compliance
Both the DHEA and placebo preparations were tolerated well and only one individual 
withdrew from the study as a result of DHEA related side effects. This female participant 
experienced greasy skin and hair as well as some acne following approximately 4 weeks 
of the first treatment phase that resolved within 2 weeks of treatment cessation. All 
adverse events were documented in the study case report (Table 5.1 and 5.2) form 
following which a Trust (Cardiff and Vale NHS Trust) incident report form was 
completed which in turn was passed to the Trust Research and Development department. 
Yearly safety reports were completed (containing reports of all adverse events) and sent 
to the study local ethics committee, sponsors (Cardiff University) and the Medicine and 
Healthcare Products Regulatory Authority.
A single serious adverse event (Table 5.2) was experienced during the course of the study 
when a male participant in the primary adrenal insufficiency group was seen in the 
Medical Assessment Unit at the University Hospital of Wales with a lower respiratory 
tract infection. This was considered to be unrelated to the study medication and was 
defined as serious as it necessitated hospital admission. Nevertheless, following the 
University adverse event reporting policy the sponsors were informed within 24 hours 
from when I became aware of the event.
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A summary o f the adverse events are outlined below:
AE
number
Patient
ID
Description
of
event
Start
Date
Finish
Date
outcome Intensity Expectedness Causality Seriousness
1 101 Acne
Greasy skin
24/9/06 5/10/06 resolved Mild Expected probably
related
not serious
2 102 Rash 10/12/06 1/04/07 resolved Mild Unexpected not
related
not serious
3 103 Acne
Greasy skin
21/11/06 1/2/07 resolved Mild Expected probably
related
not serious
4 119 Faulty 
pregnancy 
test kit
30/5/07 19/6/07 repeat
test
negative
Mild Unexpected not
related
not serious
5 115 muscle ache 26/7/07 6/8/07 resolved Mild Unexpected not
related
not serious
7 219 abdominal
cramps
15/10/07 27/11/07 resolved Mild Unexpected not
related
not serious
Table 5.1 Summary of adverse events (n=6)
AE
number
Patient
ID
Description
of
event
Start
Date
Finish
Date
outcome Intensity Expectedness Causality Seriousness
6 120 Upper
respiratory
tract
infection -  
seen in 
hospital and 
discharged
31/10/7 31/10/7 resolved Moderate Unexpected not
related
resulted in 
hospitalisation
Table 5.2 Summary of serious adverse events (n=l)
Liver function tests were performed on study participants at each study visit and no 
increases were observed in these during the course of the study.
A further 2 individuals were withdrawn from the study due to protocol violations. One 
individual failed to attend for the final study visit due to work commitments and a second 
individual reported poor/variable compliance not only with the study medication but with 
other hormone replacements. Overall, however, compliance was good as DHEAS levels 
were found to be elevated in all but 2 subjects following the active treatment phase. One 
of these individuals was unable to have blood taken at the time of the visit and attended
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10 days later, and the second individual had stopped taking the medication of her own 
accord 4 weeks prior to the study visit.
5.3.1 Primary adrenal insufficiency baseline demographic and anthropometric data
20 subjects with the diagnosis of Addison’s disease were recruited into the study over a 9 
month period. The table below describes the demographic and anthropometric baseline 
data of this group.
Subject
Number
Age
(years)
Sex Disease
duration
(years)
Height
(cm)
Weight
(Kg)
BMI
(Kg/m2)
%
Fat
Waist
(cm)
Hip
(cm)
101 52 F 20 157 81.0 33.0 44.5 99 116
102 47 M 15 179 83.9 26.2 23.0 96 109
103 59 F 25 159 72.0 28.5 39.5 94 104
104 67 F 18 160 71.0 27.7 38 90 104
105 57 F 7 151 65.0 28.5 35 85 103
106 68 F 22 153 78.0 33.3 45 100 116
107 30 M 4 177 83.0 26.5 25.5 99 98
108 50 F 2 161 74.0 28.6 40.5 97 106
109 39 M 23 168 104.0 36.9 45.5 126 118
110 40 F 12 167 95.0 34.1 48 89 125
111 44 M 12 175 77.0 25.1 18 85 95
112 62 F 37 153 51.0 21.8 28 79 90
113 50 F 22 165 68.1 25.0 36.5 81 102
114 52 F 16 156 80.8 33.2 44.5 100 113
115 39 F 2 173 60.3 20.2 24.5 83 93
116 38 F 7 155 87.0 36.2 47 105 113
117 61 M 22 178 79.3 25.0 22.5 96 97
118 19 M 1.5 170 52.1 18.0 6.5 73 83
119 24 F 14 168 102.7 36.4 48 99 125
120 67 M 51 183 107.6 32.1 29 114 123
MEAN 48.25 F 13 
M 7
16.625 F 159.8 
M 175.7
F 75.8 
M 83.8
28.8 F 39.9 
M 243
F 92.4 
M 98.4
F 108.5 
M 103.3
Table 5.3 Demographic and anthropometric data from subjects recruited into the study
with PAI
The baseline characteristics indicate that the study cohort is representative of the general 
population with Addison’s disease; the increased numbers of females is consistent with
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the expected higher disease frequency in women. Five individuals were current smokers. 
Overall both males and females in the study population demonstrated a tendency for 
increased adiposity with the mean BMI within the overweight range. As expected, 
females were shorter, had a higher fat percentage, greater hip circumference and lower 
waist circumference than males.
5.3.2 Primary adrenal insufficiency baseline arterial stiffness and endothelial 
function data
Subject
Number
Sitting
BP
(mmHg)
Supine
BP
(mmHg)
Ai
(%)
Central
BP
(mmHg)
bPWV
(m/s)
aPWV
(m/s)
Endothelial 
Function 
(% reduction in Ai 
post salbutamol)
101 125/80 117/70 47.5 122/81 7.6 6.9 -9
102 160/101 152/93 30 148/103 8.45 7.0 -3
103 143/86 137/81 32 134/87 8.6 7.6 -9
104 160/97 140/90 41 157/97 7.65 7.8 -13.5
105 144/112 156/103 31.5 140/113 8.25 5.9 -20.5
106 131/95 130/91 39.5 126/98 9.1 7.05 -24
107 134/98 126/83 9 121/97 7.3 6.7 -11
108 134/95 134/88 31.5 128/96 8.15 6.55 -9
109 146/107 140/98 24.5 138/109 6.85 7.8 -18
110 118/87 124/84 21.5 111/88 7.6 6.4 -9.5
111 141/90 125/83 28 133/91 6.9 7.35 -18.5
112 125/70 137/98 33 116/72 9.55 8.6 -17.5
113 145/97 136/92 36.5 138/97 8.05 7.25 -33.5
114 107/67 101/64 31.5 100/68 8.6 4.95 -9.5
115 140/95 134/98 36.5 135/96 10.6 7.1 -12.5
116 112/83 114/86 25.5 106/84 6.6 6.35 -13
117 125/75 130/76 18.5 110/74 8.1 8.3 -9
118 135/96 135/79 1 120/98 7.65 4.6 -7
119 136/87 131/86 16.5 119/87 7.9 5.5 -11
120 163/102 147/89 29.5 153/103 11.4 11.2 -4
MEAN 1363/91 1323/86.6 28.2 127.8/92 8.2 7.0 -13.1
Table 5.4 Baseline arterial stiffness and endothelial function data in the PAI group
Half of the individuals had peripheral blood presures above or equal to that defined as 
hypertension in the IDF definition of the metabolic syndrome (>138/85). The mean Ai of
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28.2% was approximately 10% higher than that found in an as yet unpublished reference 
population (Cockcroft J, Cardiff, UK) of 405 individuals (239 males, 166 females) with 
the same mean age.
5.3.3 Primary adrenal insufficiency baseline biochemical data
Table 5.5 summarises the baseline biochemical, metabolic and other characteristics of 
the PAI cohort.
Subject
Number
DHEAS
(fimol/l)
Testosterone
(nmol/1)
HSCRP
(mg/1)
Fasting
glucose
(mmol/1)
Fasting lipids
TC
(mmol/1)
HDL
(mmol/1)
LDL
(mmol/1)
TAG
(mmol/1)
101 0.2 0.7 6.14 4.6 8.7 nd nd 1.7
102 1.3 10.4 2.12 4.7 7.9 nd nd 1.7
103 0.2 0.7 1.15 5.4 5.9 nd nd 2.2
104 0.5 0.7 1.11 5.1 6.0 nd nd 1.9
105 0.5 0.7 0.47 4.7 7.1 nd nd 0.9
106 0.2 0.7 2.41 5.5 7.7 nd nd 1.5
107 2.9 13.8 1.2 5.5 4.9 1.5 5.5 1.2
108 0.0 0.7 0.7 6.5 4.2 1.3 3.1 2.1
109 0.5 11.5 13.1 5.3 4.8 1 2.2 0.9
110 0.8 0.9 1.49 5.6 5.1 0.9 3.5 0.7
111 1.0 10.6 0.69 5.5 3.9 1.2 3.2 1.4
112 0.5 0.7 1.23 5.3 4.4 1.9 2.1 1.1
113 0.5 0.7 5.62 6.3 7.0 2 2.0 0.7
114 0.5 0.7 2.38 5.5 5.6 1.3 4.7 1.0
115 2.2 1.9 2.39 5.4 5.1 1.8 3.8 1.2
116 0.2 0.7 3.47 4.9 8.3 1.4 5.6 2.8
117 0.8 11.4 0.8 5.5 6.6 1.3 4.0 2.8
118 3.4 25.7 0.16 4.5 4.6 1.5 2.6 1.2
119 2.0 2.1 2.47 4.5 4.3 1.3 2.4 1.4
120 0.6 8.4 0.7 4.6 4.1 1.2 2.5 0.9
MEAN 0.96 6 13.1 
$ 0.81
3.04 5.25 5.34 1.4 337 136
Table 5.5 Baseline biochemical data in study subjects with PAI (nd - not done)
40% of subjects within this study group met the diagnostic criteria for the metabolic 
syndrome; approximately double the estimated population prevalence (www.idf.org).
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5.3.4 Primary adrenal insufficiency baseline data correlations
Although the number of cases is comparatively low (n=20) significant correlations 
(Pearson’s) were confirmed between Ai and age (p=0.001) and Ai and height (p=0.05) 
(Figs 5.2).
Age and Ai in PAI Height and Ai in PAI
> ;4 0
&
Pearson's correlation p=0.001
Al<%)
Pearson's correlation p=0.05
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Fig 5.2 Patients with PAI Ai correlations with age and hight
Furthermore, as expected measures of body fat (BMI, percentage fat) correlated 
positively (but not strongly) with insulin resistance (HOMA-IR) (Correlation with BMI 
shown in Fig 5.3). A positive correlation between waist circumference and HSCRP was 
also observed (Fig 5.3).
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Fig 5.3 Correlations in PAI, Insulin resistance (calculated from fasting insulin and 
glucose) and BMI, waist circumference (wc) and HSCRP
Further statistical extrapolation of the inter-dependence of these variables was not 
undertaken in view of the small numbers
5.3.5 Secondary adrenal insufficiency baseline demographic and anthropometric 
data
20 subjects with the diagnosis of hypopituitarism secondary to either non-functioning 
pituitary tumors or craniopharyngiomas treated surgically with or without concomitant 
radiotherapy on full hormone replacement therapy including growth hormone were 
recruited into the study over a 9 month period. The table below shows the demographic 
and anthropometric baseline data of this group.
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Subject
Number
Age
(years)
Sex Disease
duration
(years)
Height
(cm)
Weight
(Kg)
BMI
(Kg/m2)
%
Fat
Waist
(cm)
Hip
(cm)
201 40 F 3 158 99 39.66 50 95 139
202 35 M 11 186 104 30.06 28 102 110
203 24 F 4 165 122.8 45.11 53.3 131 148
204 63 M 16 194 124 32.95 34.5 113 114
205 66 M 33 177 103 32.88 33 111 109
206 62 M 19 188 104.8 29.65 31 119 120
207 50 M 7 178 99 31.25 28 106 107
208 42 M 7 174 95 31.38 32 100 108
209 58 M 9 171 91.7 31.36 31.5 103 107
210 21 F 8 158 70.5 28.24 39.5 91 100
211 26 F 11 161 74.5 28.74 38 88 98
212 62 M 4 183 111.4 33.26 31.5 112 108
213 64 M 7 193 122.8 32.97 33.5 125 127
214 60 M 21 165 84.2 30.93 27 109 106
215 38 M 4 188.5 98.6 27.75 26.8 94 108
216 70 M 15 186 97.2 28.01 25 106 102
217 18 F 12 162 53.6 20.42 35 89 90
218 63 F 12 156 92.8 38.13 50.5 117 124
219 37 F 29 158 98.6 39.44 45.5 126 138
220 48 F 13 170 74 25.6 39.5 93 107
MEAN 47.35 F 8 
M 12
12.25 F 161 
M 182
F 85.7 
M 103
31.9 F 43.9 
M 30.2
F 103.8 
M 108.3
F 118 
M 110.5
Table 5.6 Baseline demographic and anthropometric characteristics of subjects recruited
with SAI
More males were recruited into the SAI group. As expected the males were taller, heavier 
and had greater waist circumference; hip circumference, fat percentage and BMI were 
again greater in females. There was a high prevalence of obesity (mean BMI of 31.9). 
Three individuals within this group were current smokers.
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5.3.6 Secondary adrenal insufficiency baseline arterial stiffness and endothelial 
function data
Subject
Number
Sitting
BP
(mmHg)
Supine
BP
(mmHg)
Ai
(%)
Central
BP
(mmHg)
bPWV
(m/s)
aPWV
(m/s)
Endothelial 
Function 
(% reduction in Ai 
post salbutamol)
201 134/91 129/99 27.5 124/91 7.85 5.8 -17
202 157/91 140/82 12 137/93 6.65 7 -9
203 156/96 165/106 30.5 143/100 9.4 5.85 -9
204 115/79 103/61 24.5 107/80 6.1 5.95 -4
205 141/90 142/81 35 134/90 7.8 8.2 -8
206 138/106 134/80 24 131/107 7.8 7.95 -14.5
207 134/83 145/78 -5.5 133/85 6.75 6 1.5
208 146/94 130/82 17.5 131/96 7.8 6.4 -5
209 156/89 161/98 26 142/91 8.1 9.8 -9.5
210 118/70 122/72 -10.5 98/71 6.05 4.25 -20
211 126/84 112/68 5.5 111/85 6.7 4.8 -12
212 183/107 186/107 26.5 168/108 7.75 8.3 -0.5
213 164/101 155/96 29.5 156/101 7.65 6.1 -10
214 150/100 145/97 29 141/102 6.85 8 -7
215 125/83 117/73 8 111/82 7.5 7.65 0
216 160/93 147/88 30 150/94 8 9.1 -18
217 114/74 107/65 21.5 104/75 6.2 4.95 -49.5
218 96/78 136/63 21 91/78 6.15 Nd -5.5
219 139/79 132/79 25 125/81 6.75 Nd -14.5
220 117/81 115/70 28 111/79 8.15 7.75 -10.5
MEAN 138.5/88.5 136.2/823 20.25 127.4/89.4 7 3 6.88 -11.1
Table 5.7 Baseline arterial stiffness and endothelial function data in the SAI group
(nd - not done)
40% of the recruited subjects demonstrated overall peripheral BPs above or equal to that 
defined as hypertension in the IDF definition of the metabolic syndrome (>138/85). The 
mean Ai of 20.25 was higher than that found in an unpublished reference population but 
Ai, aPWV and bPWV were all marginally lower (slower) than those observed in the PAI 
group; this is likely a reflection of an increased number of males and thus overall height 
in the SAI group.
216
5.3.7 Secondary adrenal insufficiency baseline biochemical data
The table below summarises the baseline biochemical and other characteristics of the SAI 
cohort.
Subject
Number
DHEAS
(mmol/1)
Testosterone
(nmol/1)
HSCRP
(mg/1)
Fasting
glucose
(mmol/1)
Fasting lipids
TC
(mmol/1)
HDL
(mmol/I)
LDL
(mmol/1)
TAG
(mmol/1)
201 0.1 0.7 10.8 4.7 3.9 1.0 2.3 1.4
202 3.3 21 0.68 5.6 6.9 1.0 4.8 2.4
203 0.9 0.7 22.2 4.9 6.0 1.2 4.3 1.2
204 0.1 20 0.77 5.9 4.8 0.8 3.0 2.2
205 0.1 6.4 0.88 5.3 5.0 1.3 3.2 1.2
206 0.5 0.7 8.24 4.7 5.1 1 2.8 2.8
207 0.4 8.4 9.0 6.8 3.8 0.9 2.3 1.4
208 0.4 33.9 3.33 5.4 4.7 1.4 2.9 0.8
209 0.1 5.9 7.7 4.5 6.4 1 4.5 2
210 nd nd Nd nd nd nd nd nd
211 0.1 0.7 7.44 4.3 5.6 1.4 3.8 0.9
212 0.6 7.4 Nd 11.3 5.1 0.7 3.1 3
213 0.3 27.3 0.5 4.7 4.5 0.7 3.2 1.3
214 0.2 10.4 0.67 5.1 4.6 1.3 2.6 1.6
215 0.4 25.7 1.0 4.6 5.6 1.1 4.2 0.6
216 0.4 32 0.24 5.4 4.5 1.0 3.0 1.2
217 0.9 0.7 2.23 4.8 7.3 1.7 5.2 0.8
218 0.2 0.7 1.3 4.3 3.6 0.9 1.5 2.7
219 0.2 0.7 3.91 7.6 4.8 1.2 2.1 3.4
220 0.2 0.7 0.93 5.0 7.4 1.5 5.2 1.5
MEAN 0.49 6  16.5 
$ 0.70
4.55 5.52 5.24 1.11 337 1.71
Table 5.8 Baseline biochemical data collected in study subjects with SAI (nd -  not done)
Based on the IDF 2005 criteria 55% of this study population met the diagnostic criteria 
for the metabolic syndrome (see chapter 3); this is over double what would be expected in 
the background population (www.idf.org) and is slightly greater than that demonstrated in 
the PAI group.
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5.3.8 Secondary adrenal insufficiency baseline data correlations
As in the analysis of the PAI baseline data the number of cases is small (n=20) and must 
be considered when interpreting the correlation data. However a number of parameters 
demonstrated significant correlations (Pearson’s correlation).
Significant correlations (Pearson’s) in metabolic syndrome parameters in study subjects
with SAI at baseline
Age Sex BMI •/•fat wc dia
BP
Cdia
BP
Insulin HSCRP HOMA HDL LDL aPWV Ai
Age - - - 0.03 - - - - - - - 0.001 0.024
Sex . - - - - - - - - - - 0.006 -
BMI - - - - - - - 0.013 - - - - -
%fat - - . - - - - 0.024 - - - 0.034 -
wc 0.03 - - - 0.048 0.032 0.013 - 0.008 0.032 0.021 - -
diaBP - - - - 0.048 - - - - - - - -
CdiaBP - - - - 0.032 - - - - - - - 0.035
Insulin - - - - 0.013 - - - - - - - -
HSCRP - - 0.013 0.024 - - - - - - - - -
HOMA - - - - 0.008 - - - - - - - -
HDL - - - - 0.032 - - - - - - - -
LDL - - - - 0.021 - - - - - - - -
aPWV 0.001 0.006 - 0.034 - - - - - - - - -
Ai 0.024 - - - - - 0.035 - - - - - -
Table 5.9 Significant baseline data correlations (Pearson’s correlation) expressed as
p-values in study subjects with SAI
Waist circumference (wc), as a measure of central (visceral) adiposity correlates 
positively with age, peripheral and central diastolic blood pressure, insulin and insulin 
resistance and negatively with HDL (Fig 5.4 shows graphical examples).
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Fig 5.4 Correlations (Pearson’s) with waist circumference at baseline in study subjects 
with SAI (wc -  waist circumference, HDL -  high density lipoprotein)
Fat percentage also correlated with HSCRP and as anticipated, measures of arterial 
stiffness (aPWV) correlated positively with age and sex though negatively correlation
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with fat percentage. Again, further statistical exploration of the inter-dependence of these 
variables was not undertaken in view of the small numbers.
5.4 Statistical rationale
Gaussian distributional form was checked for each variable by means of a histogram and 
Q-Q (quantile-quantile) plot for the data at the baseline visit. The Q-Q plot gives a more 
sensitive assessment of Gaussian distribution as for a perfect Gaussian distribution the 
points plotted would coincide with the diagonal line of identity. Log transformation was 
performed for non-Gaussian variables.
The total study population comprised 40 individuals, half of whom had PAI and half SAI. 
The effect of treatment could well be different for these two. While this was considered 
in its own right, a preliminary check was performed by assessing whether the variable 
being considered differed significantly at baseline between the two groups, using the 
Mann-Whitney test. If there were clear differences evident at baseline, this suggested that 
analyses were likely to require to be considered separately for the two groups; if there 
were not, then an analysis based on 40 subjects has clear advantages in terms of power. 
Similarly, many of the variables considered are either known to be grossly gender- 
dependent in the general population, or else show signs of gender differences in the study 
population. This would suggest splitting by gender also but analyses split by group and 
gender simultaneously would have grossly inadequate power. To decide for each variable 
whether to split by group and/or gender, we took into account both the evidence from the 
study data and our prior knowledge concerning the variable in question.
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5.5 Effects on primary end points - vascular parameters
A summary of the vascular outcomes of the entire cohort is given in Table 5.10. From 
these results it is clear that DHEA therapy did not improve any measure of arterial 
stiffness or endothelial function, although results for both brachial pulse wave velocity 
and Tr (time of travel of the reflected wave) almost reached significance with p-values of 
0.07 and 95% confidence intervals which just include the null hypothesis value of zero. If 
confirmed in larger trials, an increase in Tr and reduced bPWV would both be consistent 
with reduced regional arterial stiffness in the brachial tree. However, the absence of any 
change in Ai suggests that wave reflection is not significantly affected. Furthermore, 
carotid-femoral pulse wave velocity (aPWV), which has the greatest amount of 
epidemiological evidence for its predictive value for cardiovascular events, did not 
change following DHEA treatment. There were no changes in peripheral or central 
systolic or diastolic blood pressure. Furthermore, the magnitude of reduction in Ai post- 
GTN, a direct endothelium-independent smooth muscle vasodilator, was unaffected by 
DHEA compared with placebo. Similarly, there were no changes following salbutamol in 
this parameter, suggesting that endothelial function was not affected by DHEA treatment.
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Vascular outcomes of the entire study cohort
Variable Mean difference 95% Cl 
for the difference
p-value
Tr (milliseconds) +3.7 -0.25 to +7.61 0.066
bP WV (metres/ second) -0.37 -0.72 to +0.01 0.068
aPWV (metres/second) +0.48 -0.33 to -0.24 0.753
Ai (%) +0.16 -2.55 to +2.86 0.907
Peripheral systolic BP (mmHg) +0.22 -3.64 to +4.08 0.909
Peripheral diastolic BP (mmHg) +0.43 -2.13 to +3.0 0.734
Central systolic BP (mmHg) +0.52 -4.6 to +2.68 0.594
Central diastolic BP (mmHg) -0.19 -2.91 to +2.52 0.886
Ai post-GTN (%) +0.83 -1.6 to +3.26 0.493
Ai post-salbutamol (%) -1.8 -4.86 to +1.25 0.239
Table 5.10. Entire cohort vascular data. Tr, time of travel of the reflected wave; bPWV, 
brachial pulse wave velocity; aPWV, aortic pulse wave velocity; Ai, augmentation index. 
Data shown are for mean difference, 95% confidence interval for the difference (Cl) and
p-value
Stratification of the data by study group did not show any differences in baseline values 
between subjects with PAI and SAI for Tr (p = 0.33), aPWV (p = 0.83), systolic 
peripheral blood pressure (p = 0.76), systolic diastolic blood pressure (p = 0.34), central 
systolic blood pressure (p = 0.99), central diastolic blood pressure (p = 0.38), Ai post- 
GTN (p = 0.07) or Ai post salbutamol (p = 0.2). However there was evidence for a 
difference between groups for bPWV (p = 0.009) and for Ai (p = 0.02). Nevertheless, 
analyses of these and other vascular end points stratified by study group (Table 5.11) did 
not show any changes in vascular outcome with DHEA therapy apart from minor changes 
in peripheral and central systolic blood pressure (Fig 5.5). However, the reduction seen in 
peripheral systolic blood pressure and central systolic blood pressure with DHEA in the 
SAI group and increase in peripheral systolic blood pressure in subjects with Addison’s 
disease should be interpreted with caution given the wide confidence intervals evident.
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Furthermore, because peripheral systolic blood pressure is a major input variable in 
calculation of central systolic blood pressure, it is clear that change in peripheral blood 
pressure would appear to be the principal driver of the reduced central systolic BP given 
that Ai did not change.
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Change in vascular outcomes stratified by group
Variable Mean difference 95% Cl 
for the difference
p-value
Tr (milliseconds) 
PAI +2.75 -3.35 to +8.85 0.352
SAI +4.42 -0.83 to 9.67 0.093
bP WV(metres/second) 
PAI -0.42 -1.08. to +0.24 0.199
SAI -0.31 -0.74 to +0.12 0.139
aPWV (metres/second) 
PAI +0.02 -0.4 to +0.45 0.906
SAI -0.07 -0.47 to +0.32 0.689
Ai (%) 
PAI +1.75 -2.19 to +5.68 0.357
SAI -1.39 -5.38 to 2.59 0.467
Peripheral systolic BP (mmHg) 
PAI +6.34 +0.84 to +11.58 0.027
SAI -6.08 -10.63 to -1.52 0.012
Peripheral diastolic BP (mmHg) 
PAI +3.27 -0.3 to 6.85 0.07
SAI -2.23 -5.7 to 1.23 0.184
Central systolic BP (mmHg) 
PAI +4.65 -0.85 to +10.15 0.089
SAI -6.66 -10.74 to -2.59 0.003
Central diastolic BP (mmHg) 
PAI +2.27 -1.8 to +6.35 0.256
SAI -2.66 -6.42 to +1.09 0.151
Ai post-GTN (%) 
PAI +1.6 -2.43 to +5.63 0.402
SAI -0.08 -3.99 to 3.84 0.967
Ai post-salbutamol (%) 
PAI -2.28 -7.98 to +3.41 0.407
SAI -1.47 -4.91 to +1.98 0.369
Table 5.11 Vascular data stratified by study group. Tr, time of travel of the reflected 
wave; bPWV, brachial pulse wave velocity; aPWV, aortic pulse wave velocity; Ai, 
augmentation index. Data shown are for mean difference, 95% confidence interval (Cl)
for the difference and p-value
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Stratification of the data by gender did not show any differences in baseline values 
between male and female subjects for bPWV (p = 0.35), or Ai post-GTN (p = 0.89). 
However there was evidence for a difference between genders for Tr (p = 0.02) aPWV 
(p = 0.02) Ai (p = 0.04), peripheral systolic blood pressure (p = 0.004) peripheral 
diastolic blood pressure (p = 0.02), central systolic blood pressure (p = 0.02) central 
diastolic blood pressure (p = 0.02), and Ai post salbutamol (p = 0.003). Nevertheless, 
analyses of these and the other vascular end points stratified by gender (Table 5.12) did 
not show any changes in vascular outcome with DHEA therapy.
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Change in vascular parameters stratified by gender
Variable Mean difference 95% Cl 
for the difference
p-value
Tr (milliseconds) 
Male +5.69 -1.28 to +12.66 0.096
Female +2.62 -4.66 to 9.9 0.442
bPWV(metres/second)
Male -0.14 -0.64 to +0.36 0.538
Female -0.64 -1.32 to +0.03 0.061
aPWV (metres/second) 
Male +0.24 -0.72 to +0.24 0.301
Female +0.19 -0.19 to +0.57 0.28
Ai (%) 
Male -0.6 -7.23 to +6.02 0.835
Female +0.3 -2.83 to +3.43 0.842
Peripheral Systolic BP (mmHg) 
Male -1.17 -7.34 to +5.01 0.687
Female +2.39 -4.88 to +9.67 0.472
Peripheral Diastolic BP (mmHg) 
Male +0.79 -4.4 to +5.98 0.733
Female +0.26 -3.69 to +4.2 0.891
Systolic central BP (mmHg) 
Male -2.33 -8.24 to +3.58 0.411
Female +0.55 -6.31 to +7.42 0.855
Diastolic central BP (mmHg) 
Male +0.88 -4.46 to +6.21 0.713
Female -1.52 -6.1 to +3.05 0.48
Ai post-GTN (%) 
Male -0.56 -2.93 to +1.8 0.621
Female +2.39 -2.39 to +7.17 0.294
Ai post-salbutamol (%) 
Male -1.9 -7.2 to +3.6 0.345
Female -1.8 -7.9 to +4.2 0.522
Table 5.12 Vascular data stratified by gender. Tr, time of travel of the reflected wave;
bPWV, brachial pulse wave velocity; aPWV, aortic pulse wave velocity; Ai, 
augmentation index. Data shown are for mean difference, 95% confidence interval (Cl)
for the difference and p-value
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Effects of supplementing DHEA on central systolic blood pressure in PAI and SAI 
study: Primery attend failire study: Secondary adrenal failure
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Fig 5.5 Change in central systolic blood pressure following 12 weeks of DHEA/placebo
treatment in PAI and SAI.
5.6 Effects on secondary end points
5.6.1 Body composition
A summary of the effects on body composition for the entire cohort is given in Table
5.13. From these results it is clear that DHEA therapy did not affect weight, body mass
index, fat percentage, waist circumference or hip circumference. Stratification of the data 
by study group did not show any differences in baseline values between subjects with 
PAI and SAI for body mass index (p= 0.16) or hip circumference (p = 0.19). However 
there was evidence for a difference between groups for weight (p = 0.003) fat percentage 
(p = 0.003) and waist circumference (p = 0.006). Nevertheless, analyses of these and all 
other body composition end points stratified by study group (Table 5.14) did not show 
any effects of DHEA therapy on any of these variables.
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p=0.003
Change in body composition for the entire cohort
Variable Mean difference 95% Cl 
for the difference
p-value
Weight (kg) -0.24 -1.11 to +0.63 0.58
BMI (kg/m2) -0.09 -0.4 to +0.22 0.551
Fat percentage (%) -0.23 -0.77 to -0.3 0.383
Waist circumference (cm) +0.68 -1.05 to +2.41 0.423
Hip circumference (cm) -0.16 -1.66 to +1.34 0.828
Table 5.13 Effects on body composition in entire cohort. Data shown are for mean 
difference, 95% confidence interval (Cl) for the difference and p-value
Change in body composition stratified by group
Variable Mean difference 95% Cl 
for the difference
p-value
Weight (kg) 
PAI +0.32 -0.67 to +1.13 0.498
SAI -0.91 -2.66 to +0.84 0.267
BMI (kg/m2) 
PAI +0.12 -0.24 to +0.47 0.498
SAI -0.34 -0.95 to +0.27 0.233
Fat percentage (%) 
PAI -0.1 -0.9 to +0.7 0.786
SAI -0.38 -1.19 to +0.44 0.337
Waist circumference (cm) 
PAI +1.82 -0.85 to +4.49 0.161
SAI -0.58 -3.04 to +1.89 0.61
Hip circumference (cm) 
PAI +0.83 -1.23 to +2.9 0.407
SAI -1.08 -3.58 to +1.43 0.362
Table 5.14 Changes in body composition stratified by group. Data shown are for mean 
difference, 95% confidence interval (Cl) for the difference and p-value
Stratification of the data by gender did not show any differences in baseline values 
between male and female subjects for BMI (p = 0.44) or hip circumference (p = 0.75). 
However, there was evidence for a difference between genders at baseline for weight (p =
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0.002), fat percentage (p = 0.002) and waist circumference (p = 0.02). Nevertheless, 
analyses of all body composition end points stratified by gender (Table 5.15) did not 
show any changes following DHEA treatment.
Change in body composition stratified by gender
Variable Mean difference 95% Cl 
for the difference
p-value
Weight (kg) 
Male +0.13 -1 to +1.26 0.807
Female +0.54 -1.31 to +0.99 0.77
BMI (kg/m2) 
Male +0.02 -0.31 to +0.36 0.883
Female -0.05 -0.48 to +0.37 0.798
Fat percentage (%) 
Male +0.5 -0.28 to +1.28 0.18
Female -0.59 -1.23 to +0.04 0.065
Waist circumference (cm) 
Male +2.58 -1.12 to +6.29 0.136
Female +0.02 -2.13 to +2.16 0.986
Hip circumference (cm) 
Male +1.58 -0.38 to +3.54 0.105
Female -0.86 -2.48 to +0.77 0.28
Table 5.15 Changes in body composition stratified by gender. Data shown are for mean 
difference, 95% confidence interval (Cl) for the difference and p-value
5.6.2 Serum Androgens
Table 5.16 summarises the change in DHEAS, androstenedione and testosterone levels 
for the total cohort. As expected supplementation of DHEA significantly increased serum 
DHEAS levels (Fig 5.6). Androstenedione concentrations were also increased 
significantly with mean concentrations marginally above the reference range (Fig 5.8). 
Unsurprisingly testosterone concentration was not altered in the total cohort.
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Stratification by study group (table 5.17) did not show any differences in baseline values 
between subjects with PAI and SAI for DHEAS (p = 0.73) androstenedione (p = 0.41) or 
testosterone (p = 0.34). Analysis of the data stratified by study group showed that the 
increases in DHEAS and androstenedione levels following DHEA treatment were 
maintained in both groups although again testosterone levels did not change. 
Stratification of the data by gender showed clear differences at baseline between male 
and female subjects for both androstenedione (p = 0.002) and testosterone (p<0.001). 
DHEAS levels were not different between males and females at baseline (p = 0.41). 
DHEAS levels increased following DHEA supplementation in both males and females as 
did androstenedione levels (Table 5.18). Table 5.18 also shows that testosterone 
increased in women but was unaffected in men (Fig 5.7), which is not surprising as 
testicular Leydig cells are the major source of testosterone in men and all males with 
hypopituitarism were optimally replaced with testosterone therapy.
Change in DHEAS, androstenedione and testosterone levels for the total cohort
Variable Mean difference 95% Cl 
for the difference
p-value
DHEAS (pmol/1) +12.94 +10.68 to +15.18 <0.001
Androstenedione (nmol/1) +13.86 +11.24 to +16.47 <0.001
Testosterone (nmol/1) +1 -1.83 to +3.38 0.447
Table 5.16 Change in DHEAS, androstenedione and testosterone levels for the total 
cohort. Data shown are for mean difference, 95% confidence interval (Cl) for the
difference and p-value
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Change in DHEAS, androstenedione and testosterone levels stratified by group
Variable Mean difference 95% Cl 
for the difference
p-value
DHEAS (pmol/1) 
PAI +14.42 +10.99 to +17.85 <0.001
SAI +11.16 +7.52 to 14.81 <0.0001
Androstenedione (nmol/1) 
PAI +14.46 +9.86 to +19.06 <0.001
SAI +12.99 +9.29 to +16.69 <0.001
Testosterone (nmol/1) 
PAI +0.5 -0.45 to +1.44 0.267
SAI +1.3 -5.04 to 7.63 0.667
Table 5.17 Change in DHEAS, androstenedione and testosterone levels stratified by 
group. Data shown are for mean difference, 95% confidence interval (Cl) for the
difference and p-value
Change in DHEAS, androstenedione and testosterone levels stratified by gender
Variable Mean difference 95% Cl 
for the difference
p-value
DHEAS (pmol/1) 
Male +12.29 +10.12 to +14.47 <0.001
Female +14.31 +10.03 to 18.59 <0.0001
Androstenedione (nmol/1) 
Male +12.3 +8.1 to +16.5 <0.001
Female +15.41 +9.82 to +21 <0.001
Testosterone (nmol/1) 
Male +0.74 -7.59 to +9.1 0.84
Female +0.45 +0.24 to 0.69 0.002
Table 5.18 Change in DHEAS, androstenedione and testosterone levels stratified by 
gender. Data shown are for mean difference, 95% confidence interval (Cl) for the
difference and p-value
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Effect of DHEA replacement on serum Effect of DHEA replacement on serum
DHEAS concentrations in the entire cohort androstenedione concentrations in the entire
cohort
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Fig 5.6 Serum DHEAS and androstenedione concentrations following 12 weeks of 
treatment with DHEA/placebo in PAI and SAI.
Effect of DHEA replacement on testosterones concentrations according to gender
Sex: Male Sex: Female
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Fig 5.7 Serum testosterone concentrations following 12 weeks of treatment with 
DHEA/placebo in males and females
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5.6.3 Metabolic Biochemistry
Table 5.19 provides a summary of the effects of DHEA on serum metabolic markers for 
the entire cohort. DHEA caused a small reduction in HDL cholesterol (p = 0.007) but 
other serum lipids, adiponectin, HSCRP and HOMA-IR were unaffected. Stratification of 
the data by study group did not show any differences in baseline values between subjects 
with PAI and SAI for adiponectin (p = 0.55), HSCRP (p = 0.57), total cholesterol (p = 
0.31), LDL cholesterol (p = 0.78), triglycerides (p = 0.43) or HOMA-IR (p = 0.34). 
However there was evidence for a difference between groups for HDL cholesterol (p = 
0.008). Analysis of the serum metabolic markers stratified by study group (Table 5.20) 
did not show any changes with DHEA therapy apart from a small increase in HSCRP in 
patients with SAI and a small reduction in HDL cholesterol in subjects with PAI. 
However, neither of these quite met the level of statistical stringency (1% level of 
significance) required for a secondary endpoint. A small reduction in total cholesterol 
was observed in patients with PAI following DHEA therapy and also in HOMA-IR in 
this group; however these did not quite achieve statistical significance with p values of 
0.08 and 95% confidence intervals which just included the null hypothesis value of zero.
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Summary o f the effects o f DHEA on serum metabolic markers for the entire cohort
Variable Mean difference 95% Cl 
for the difference
p-value
Adiponectin (pg/ml) +7.3 -46.65 to +61.25 0.785
HSCRP (mg/1) +0.23 -0.06 to + 0.52 0.117
Insulin (mU/1) -1.71 -5.07 to +1.65 0.308
Glucose (mmol/1) -0.05 -0.56 to +0.45 0.824
HOMA-IR -0.58 -1.42 to +0.26 0.166
HDL (mmol/1) -0.08 -0.13 to -0.02 0.007
LDL (mmol/1) -0.07 -0.25 to +0.1 0.4
TAG (mmol/1) +0.05 -0.21 to +0.31 0.709
TC (mmol/1) -0.13 -0.34 to 0.09 0.232
IGF-1 (ng/ml) (SAI only) -0.75 -3.53 to +2.03 0.555
Table 5.19 Effects of DHEA on serum metabolic markers for the entire cohort. Data 
shown are for mean difference, 95% confidence interval (Cl) for the difference and p- 
value (HSCRP -  high sensitivity c-reactive protein, HOMA-IR -  homeostatic model of 
insulin resistance, HDL -  high density lipoprotein cholesterol, LDL -  low density 
lipoprotein cholesterol, TAG -  triacylglycerides, TC -  total cholesterol, IGF-1 -  Insulin­
like growth factor-1)
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Change in serum metabolic markers stratified by group
Variable Mean difference 95% Cl 
for the difference
p-value
Adiponectin (pg/ml) 
PAI +11.27 -93.34 to +115.87 0.823
SAI +6.51 -33.84 to +46.86 0.735
HSCRP (mg/1) 
PAI +0.12 -0.33 to +0.58 0.575
SAI +0.38 +0.01 to +0.75 0.043
Insulin (mU/1) 
PAI -2.62 -7.05 to +1.81 0.215
SAI -1.16 -7.6 to +5.27 0.7
Glucose (mmol/1) 
PAI +0.17 -0.05 to +0.39 0.119
SAI -0.33 -1.57 to +0.92 0.559
HOMA-IR
PAI -0.7 -0.15 to +0.1 0.08
SAI -0.56 -2.41 to +1.28 0.506
HDL (mmol/1) 
PAI -0.13 -0.23 to -0.03 0.011
SAI -0.02 -0.07 to +0.03 0.345
LDL (mmol/1) 
PAI -0.1 -0.3 to +0.11 0.339
SAI -0.04 -0.39 to 0.31 0.81
TAG (mmol/1) 
PAI -0.02 -0.43 to +0.39 0.919
SAI +0.1 -0.25 to 0.45 0.54
TC (mmol/1) 
PAI -0.25 -0.52 to 0.03 0.076
SAI -0.001 -0.37 to +0.37 0.994
Table 5.20 Effects of DHEA on serum metabolic markers stratified by group. Data shown 
are for mean difference, 95% confidence interval (Cl) for the difference and p-value 
(HSCRP -  high sensitivity c-reactive protein, HOMA-IR -  homeostatic model of insulin 
resistance, HDL -  high density lipoprotein cholesterol, LDL -  low density lipoprotein 
cholesterol, TAG -  triacylglycerides, TC -  total cholesterol)
Stratification of the data by gender (Table 5.21) did not show any differences in baseline 
values between male and female subjects for adiponectin (p = 0.39), total cholesterol (p =
0.11), LDL cholesterol (p = 0.7), triacylglycerides (p = 0.73) or HOMA-IR (p=0.18).
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However, HDL cholesterol did show a gender difference at baseline (p = 0.004) and 
HSCRP also showed a gender difference at baseline of borderline statistical significance 
(p = 0.05). Analysis of metabolic outcomes stratified by gender showed no effects of 
DHEA therapy on any of the variables examined apart from confirmation of HDL 
cholesterol lowering in females, with mild reduction in HDL cholesterol and increase in 
HSCRP in males almost reaching significance with p-values of 0.06 and 0.08 
respectively.
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Effects o f DHEA on serum metabolic markers stratified by gender
Variable Mean difference 95% Cl 
for the difference
p-value
Adiponectin (pg/ml) 
Male +15.84 -65.43 to +97.12 0.675
Female -11.62 -107.14 to +83.91 0.795
HSCRP (mg/1) 
Male +0.34 -0.05 to +0.73 0.082
Female +0.19 -0.18 to +0.55 0.297
Insulin (mU/1) 
Male -0.76 -3.92 to +2.4 0.615
Female -2.77 -9.9 to +4.4 0.41
Glucose (mmol/1) 
Male +0.12 -0.22 to +0.46 0.437
Female -0.1 -0.88 to +0.69 0.795
HOMA-IR
Male -0.25 -1 to +0.51 0.493
Female -0.97 -2.43 to +0.5 0.18
HDL (mmol/1) 
Male -0.05 -0.11 to +0.002 0.056
Female -0.12 -0.23 to -0.01 0.032
LDL (mmol/1) 
Male +0.03 -0.19 to +0.25 0.742
Female -0.13 -0.41 to 0.15 0.325
TAG (mmol/1) 
Male +0.08 -0.33 to +0.49 0.662
Female +0.03 -0.31 to 0.38 0.836
TC (mmol/1) 
Male +0.01 -0.24 to 0.26 0.915
Female -0.23 -0.55 to +0.09 0.147
Table 5.20 Effects of DHEA on serum metabolic markers stratified by gender. Data 
shown are for mean difference, 95% confidence interval (Cl) for the difference and p- 
value (HSCRP -  high sensitivity c-reactive protein, HOMA-IR -  homeostatic model of 
insulin resistance, HDL -  high density lipoprotein cholesterol, LDL -  low density 
lipoprotein cholesterol, TAG -  triacylglycerides, TC -  total cholesterol)
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5.7 Discussion
To my knowledge, this is only the second clinical trial to report on the effects of DHEA 
supplementation on vascular function in subjects with Addison’s disease and the first of 
its kind in subjects with optimally treated panhypopituitarism. The study failed to 
demonstrate any clear benefits, or risks, of short-term physiological DHEA 
supplementation on endothelial function or arterial stiffness in these patient groups, 
although results for both brachial pulse wave velocity and Tr almost reached significance 
with p-values of 0.07 and 95% confidence intervals which just included the null 
hypothesis value of zero. If confirmed, an increase in Tr and reduced brachial PWV 
would both be consistent with reduced regional arterial stiffness in the brachial tree, and 
would corroborate Fukui and colleagues’ observation of an independent, inverse 
correlation of serum DHEAS levels with brachial-ankle PWV in men with type 2 diabetes 
[318]. However, the absence of any change in Ai suggests that wave reflection is not 
significantly influenced by DHEA. Furthermore, aortic pulse wave velocity, which has 
the greatest amount of epidemiological evidence for its predictive value for 
cardiovascular mortality [198-200], did not change.
A cross-over design was employed for this study because a substantial within-subject 
correlation is anticipated, such that smaller sample sizes are required to detect significant 
differences. Care was taken to minimise the potential for a carry-over effect, which was 
not evident in the study, by using a washout period of 8 weeks. The sample size 
calculations indicated that the study had more than adequate power to detect any 
clinically relevant changes in endothelial function if present, especially when both study
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populations were combined. Furthermore, any disadvantages of reduced precision using 
augmentation index compared with FMD to assess endothelial function [319] should have 
been outweighed by the within-subject correlation. It was felt important to recruit both 
males and females to redress an imbalance in the literature which has predominantly 
focused on females with Addison’s disease. Moreover, interventional studies of DHEA 
supplementation in other conditions have shown benefits on vascular risk in both sexes 
[180, 187].
Many previous studies in this area support the contention that DHEA has important 
actions on the vasculature. The epidemiological data, which have demonstrated either an 
inverse [8, 320] or no [321] relationship between cardiovascular mortality and circulating 
DHEAS levels in men, are controversial but animal studies [210, 219, 322, 323] and in 
vitro experiments [187, 211, 212, 324-329] have both shown the potential for anti- 
atherosclerotic actions of DHEA. Indeed, the in vitro data support both a direct and non- 
genomic action of DHEA on the endothelium, conclusions based on the rapidity of action 
on endothelial nitric oxide synthase and failure to block endothelial cell activation with 
selective oestrogen or testosterone receptor antagonists [187, 211, 325]. Recent studies 
have extended these observations to demonstrate roles for DHEA in vascular endothelial 
cell survival [327], proliferation/angiogenesis [328], and activation, including 
transcriptional regulation of endothelin-1 [329]. Studies in rodents [322] and other 
mammals [210, 219, 323] have also demonstrated many vascular benefits of DHEA, 
although the validity of a number of these findings must be questioned in view of the
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often supraphysiological DHEA doses used and the low circulating DHEAS levels 
present in lower order mammals.
Despite the compelling evidence for vasculoprotective actions of DHEA from in vitro 
and animal studies, human clinical trials of DHEA replacement on metabolic and 
vascular function have shown conflicting results, partly because interpretation of these 
trials is difficult due to significant heterogeneity in study design, including major 
differences in DHEA dose (ranging from 25 to 1600mg), treatment duration (ranging 
from 4 to 52 weeks) and underlying condition (healthy volunteers, hypercholesterolaemic 
men, postmenopausal women, obesity and adrenal insufficiency) [147]. Nevertheless, 
Kawano and colleagues were able to show improved endothelial function with low doses 
of DHEA (25mg daily) in middle-aged hypercholesterolaemic men [180], an observation 
later substantiated in post-menopausal women [187], albeit using high DHEA doses 
(lOOmg/day). However, our findings are largely in keeping with the only other clinical 
trial of DHEA action on vascular function in adrenal insufficiency [241]. In this report, 
Christiansen et al examined magnetic resonance cardiac output, endothelial function 
(FMD), echocardiography, 24 hour ambulatory blood pressure and maximal oxygen 
consumption in 10 women with Addison’s disease or isolated ACTH deficiency. They 
did not find any effects of DHEA therapy on these parameters but the comparatively 
small subject number may have left their study underpowered to detect any minor 
changes.
Recognising that the effects of DHEA replacement might well be different for subjects 
with primary adrenal failure and hypopituitarism we repeated our analyses with the data
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stratified by study group. These analyses demonstrated discordant effects of DHEA on 
systolic blood pressure, with an increase in peripheral systolic blood pressure in subjects 
with Addison’s disease and a reduction in peripheral and central systolic blood pressure 
in subjects with hypopituitarism, the latter driven largely by reduced peripheral systolic 
pressure as Ai did not change. These discrepancies are not easily resolved but the 
confidence intervals are wide, and the changes may simply represent type I errors. A 
previous study has shown a beneficial action of growth hormone replacement on central 
systolic blood pressure in subjects with hypopituitarism [330]. Given that DHEA has 
been shown to reduce growth hormone dose requirements in hypopituitarism [83] we 
hypothesised that the reduction in central systolic blood pressure might be attributable to 
improved GH sensitivity; however, IGF-I levels did not change with treatment.
Further analyses were undertaken to determine whether any of the effects of DHEA in the 
study populations were dependent on gender. Other than the anticipated increase in serum 
testosterone in women but not men, DHEA did not seem to affect any of the vascular or 
metabolic endpoints in a gender-dependent manner, although it is conceded that the study 
had very limited power to support either these analyses or the logically preferable 
interaction analyses.
DHEA did not affect any of the anthropometric variables studied (weight, body mass 
index, fat percentage, waist circumference or hip circumference). This is perhaps not 
surprising given the physiological replacement dose chosen and the comparatively short 
timeframe of treatment. Nevertheless, direct, non-genomic, inhibitory actions of DHEA
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on preadipocyte cell proliferation and adipogenesis have been previously reported in vitro 
[139, 289] and some interventional studies in humans [152, 331] in which adipose mass 
is reduced with DHEA therapy. However, most other studies, including a recent long­
term clinical trial of physiological DHEA replacement in adrenal insufficiency [240], do 
not support a significant effect of DHEA on fat mass. Given that measures of fat mass did 
not change with DHEA treatment, it is perhaps not surprising that adiponectin 
concentrations were also unaffected, although increases in adiponectin mRNA expression 
have previously been reported in white adipose tissue of DHEA-treated rats [332].
In agreement with some studies a small reduction in HDL cholesterol was observed, 
notably in women, an observation that others have attributed to androgenic conversion of 
DHEA [12, 152, 177], with consequent increased hepatic lipase activity [230] and/or 
increased HDL uptake by scavenger receptor B1 and so augmenting reverse cholesterol 
transport [229]. However, the magnitude of fall is modest and of the same order as that 
observed with low dose testosterone replacement. Although these changes might be 
considered proatherogenic, it is important to note that the antiatherogenic effect of HDL 
cholesterol is largely attributable to changes in HDL cholesterol metabolism rather than 
concentration per se [333]; HDL subclass analysis was not undertaken in this study.
I utilised fasting insulin and glucose measurements to determine insulin resistance 
(HOMA-IR) and noted that changes in this parameter almost reached statistical 
significance in the PAI group (p=0.08). A previous study by Dhataryia et al [10] has 
shown improvements in insulin sensitivity in this patient group using a more robust
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method (hyperinsulinaemic euglycaemic clamp). My study was limited in only using a 
single fasting value of glucose and insulin to calculate HOMA-IR, in contrast to 
recommendations which employ the triple fasting insulin measurement (5 minutes apart) 
[297]. Hence, a more robust measurement protocol incorporating the mean of 3 measures 
might have compensated more adequately for variation in insulin pulsatility, and might 
have resulted in statistically significant changes in HOMA-IR.
I acknowledge the heterogeneous nature of my study population whereby males and 
females were recruited from a wide age range, in addition to subjects with both primary 
and secondary adrenal failure (of varying disease duration), and oestrogen replete and 
deplete females. This is a limitation of my study and a more focused study group may 
well have generated different results to those observed. Indeed, Kawano’s study, which 
demonstrated improved endothelial function following DHEA treatment, confined 
recruitment to middle aged men with hypercholesterolaemia [180], in line with similar 
benefits in postmenopausal women [187]. I had originally planned to determine whether 
any improvements in vascular function might be confined to either gender but 
acknowledge that the study had limited power to address this question.
In conclusion, these data do not support a major action of short-term DHEA on vascular 
risk reduction in subjects with Addison’s disease or hypopituitarism, and suggest that 
pathological DHEA/DHEAS deficiency does not provide a unifying explanation for the 
increased cardiovascular mortality reported in these conditions [239, 244, 245, 247]. 
Based on these findings, routine DHEA replacement in Addison’s disease or 
hypopituitarism for vascular protection cannot presently be recommended and its use in
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the clinic should continue to be restricted to individuals with significantly impaired 
quality of life and/or reduced libido.
Chapter 6
GENERAL DISCUSSION
6.1 Overview
The in vitro studies generated in this thesis have yielded some results that are novel and 
others that are in support of previous findings. Previous investigators have demonstrated 
inhibition of preadipocyte proliferation by DHEA [139] as well as possible pro-BAT 
[334] effects and an inability of adipose tissue to sulphate DHEA [87]. The major novel 
findings are:
1. The differential effect of DHEA on adipogenesis of primary human omental 
(inhibited) and subcutaneous (neutral effect) preadipocytes, and
2. The cell cycle blockade observed following DHEA treatment in cell line 
preadipocytes.
These novel data therefore represent potential advancements in this area of biochemical 
endocrinology. More recent studies continue to demonstrate beneficial anthropometric 
and metabolic effects following DHEA treatment. A recent study has shown 
improvements in insulin sensitivity in ageing rats [335] following DHEA treatment and 
also reductions in measures of body fat and adiponectin levels in aged rats [336]. A 
further study has linked low DHEAS levels with the more severe types of non-alcoholic 
fatty liver disease, a condition associated with insulin resistance and the metabolic 
syndrome [337]. Furthermore a paper by Hemandez-Morante and colleagues showed 
gender-specific effects on lipolysis of adipose tissue ex vivo, with DHEAS stimulating 
lipolysis in subcutaneous adipose tissue in females but in visceral adipose tissue in males 
[316].
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The clinical trial reported in this thesis was conducted to a high standard with 
comprehensive ethical, statistical and regulatory body review both at pre-initiation and 
study completion. It therefore represents the first comprehensive trial of DHEA 
supplementation on vascular risk in hypopituitarism and Addison’s disease. However, I 
was unable to confirm my hypothesis that DHEA, through its action on adipose tissue, 
has a beneficial effect on vascular health in pathological states of DHEA deficiency. 
Nevertheless, the study has generated some interesting results within sub-groups which 
might warrant further analysis in the future. A number of more recent studies analysing 
the potential influence that DHEA may have on vascular health in vivo have been 
performed during the course of this body of work, and these continue to be inconclusive. 
Once more these various studies have tended to focus on physiological DHEA deficiency 
or specific disease states rather than pathological DHEA deficiency. In a study by Fukui 
and colleagues [318], using similar methods of evaluating arterial stiffness to those used 
in this study, a significant inverse correlation was noted between serum DHEAS and 
brachial pulse wave velocity in men with Type II diabetes, one of the core features of the 
metabolic syndrome. However, a similar independent correlation was also seen with 
serum testosterone. A placebo controlled therapeutic trial of DHEA supplementation in 
the elderly (75 mg in men and 50 mg in women) for two years (mean age in the treatment 
arms 68.4 years for both men and women) failed to demonstrate any improvements in 
insulin sensitivity [338]. A further observational study failed to identify any association 
between serum DHEAS and the presence or severity of coronary angiography -  identified 
cardiovascular disease in 502 men [339]. Serum DHEAS was, however, found to be 
inversely associated with atherosclerosis in diabetic post-menopausal women [317] and
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endothelial function in post-menopausal women with coronary risk factors [340]. A 
further myocardial infarction study in women (predominantly post menopausal), 
however, showed a positive, albeit modest, association between DHEA and DHEAS and 
risk of myocardial infarction [341], although another study by Kawano et al demonstrated 
significantly lower DHEAS levels in cases of congestive cardiac failure [342]. It is 
therefore clear that most reports in this field are focused on observational studies, which 
do not necessarily imply causation nor tell us about the directionality of effects.
Moreover, as previously discussed, positive inverse associations of serum DHEAS with 
any of the above outcome measures may merely represent an epiphenomenon, perhaps 
reflecting a stress-induced decrease in DHEAS to cortisol ratio. The question as to 
whether DHEA should be routinely supplemented in pathological DHEA deficiency 
remains unanswered, but I believe the various studies undertaken within this body of 
work will positively influence this area of uncertainty.
6.2 In vitro and ex vivo studies
It appears clear that DHEA can negatively influence both cell line and primary 
preadipocyte biology in agreement with some previous studies [139, 258, 289]. 
Proliferation is inhibited in cell line and primary culture preadipocytes and I have been 
able to demonstrate that this is due, at least in part, to cell cycle blockade. The inhibition 
of proliferation in isolation could be either inhibitory or stimulatory to adipogenesis.
Since termination of proliferation is a prerequisite for preadipocyte differentiation, the 
induced cell cycle arrest could promote differentiation. However, the reduced number of 
precursors could result in a smaller adipose tissue depot. The differential effect on
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adipogenesis in omental- and subcutaneous-derived preadipocytes is a novel finding and 
would tend to support the initial hypothesis. The extent to which this effect may influence 
fat depots in vivo is, however, unclear, since the extent to which latent precursor fat cell 
maturation influences human adult adiposity is not known. A recent study using the novel 
carbon-14 dating method suggested that adipocyte number does not increase in 
association with the development of obesity after adolescence, such that an increase in fat 
cell size causes the enlargement of adipose depots and fat cell number is therefore 
determined before the onset of adulthood [343]. This conclusion is drawn from 
observations that fat cell turnover remains constant irrespective of BMI, and adipocyte 
age is no different in thin and obese individuals despite the presence of more adipocytes 
in the obese individuals [343]. Data from patients with phaeochromocytomas would tend 
to counter this argument and suggest that under certain circumstances precursor cell 
adipogenesis can, and does affect adipocyte depot mass. In this situation there is a 
demonstrable increase in BAT secondary to exaggerated adrenergic stimulus [89], even 
though there is likely to be only very little BAT in human adults despite a previous study 
having identified functioning BAT in adult humans using positron emission tomography 
[344]. The development of obesity is therefore likely to be secondary to a combination of 
these factors, although the relative contribution of adipogenesis from latent precursors is 
likely to be significantly less than the simple, widespread increase in adipocyte 
accumulation of triglyceride and overall cell diameter. What is potentially more 
interesting still is that DHEA may promote adipogenesis in BAT. The caveats to these 
data are discussed in Chapter 3 relating to the high Ct values observed following QPCR. 
This observation may explain why DHEA is so avidly generated by the foetal adrenal
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gland and also why this falls away soon after birth. Furthermore, these data are supported 
by a previous study that demonstrated an increase in UCP-1 in genetically obese rats 
following DHEA treatment [334]. Studies concerning modulation of BAT are particularly 
emotive as any agent promoting BAT over WAT is effectively causing a change in 
function of adipose tissue shifting the focus from energy storage to one of energy 
dissipation. Such agents could have enormous implications considering the world wide 
health burden of obesity. Intra-adipose tissue DHEA concentration is a further area of 
uncertainty. The study by Feher [85] suggests that DHEA in adipose tissue is present in 
much higher concentrations than that found in the circulation and also that this increases 
further with obesity. These issues make the decision of which concentrations to base 
one’s estimation of physiologically relevant effects difficult. It is clear that mouse 
adipocytes would not be exposed to the concentrations that are utilised in the study, but 
the human primary culture experiments are likely to reflect conditions that are close to 
physiology, particularly in the obese.
The primary culture experiments were, however, affected by difficulties that often beset 
such studies. The cells were slow growing, could be prone to infection and the omental 
samples contained significant numbers of mesothelial cells that demonstrated a greater 
proliferation potential than the preadipocytes. Furthermore, RNA yield from these 
experiments tended to be low, despite various measures to augment this; RNA quality 
was, however, most often preserved. These various factors lead to smaller numbers of 
samples suitable for final analysis and certainly more extensive in vitro studies would be 
required to confirm these findings.
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A further area of discussion is that this study has demonstrated, as suggested by others 
[87], that adipocytes do not have the capacity to sulphate DHEA and thus generate 
DHEAS; hence there is a tendency to generate down-stream metabolites as opposed to 
adding to the serum DHEAS pool. The implications that this may have are not 
immediately obvious although obesity in males is known to be associated with central 
hypogonadism and adipose tissue primed for the conversion of androgenic precursors 
could represent part of the compensatory mechanism. This would, however, be against 
the gender-dependent tendency to produce oestrogen in males and testosterone in females 
[51-53], as confirmed by this work.
6.3 In vivo studies
The clinical trial did not demonstrate any significant improvement in body composition 
following active treatment although it is conceded that it was not powered to do so. This 
is corroborated by other studies [240], although most studies in this area have evaluated 
effects in primary and not secondary adrenal insufficiency. The lack of effect may be 
secondary to the relatively short treatment phase duration or to a reduced potency on 
adipose tissue when exposed in vivo, and at physiological concentration, to counter 
regulatory substances. Furthermore, even if DHEA does impact upon adipogenesis, the 
effect on mature adipocytes may be minimal if at all. It is clear that adipocytes have the 
ability to metabolise DHEA and it is conceivable that mature cells have a greater 
metabolic capacity than the precursors such that the metabolite conversation occurs 
before any anti-growth effects can be triggered. The preparation of DHEA and the doses 
used in the clinical trial generated circulating concentrations that tended to be marginally
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above established reference ranges and this counters data from some previous studies, 
although a more recent study reported similar findings [240].
I hypothesised that a link between adipose tissue and the vasculature might be mediated 
by changes in the adipocytokine profile. Obesity causes alterations in the adipocytokine 
profile (as discussed in Chapter 1) with resultant effects on insulin sensitivity, 
inflammation and satiety. Many of these factors have been implicated in the development 
of the derangements apparent in the metabolic syndrome. This study was not able to 
confirm this hypothesis although I chose to focus solely on adiponectin and it is 
conceivable that DHEA might alter other adipokines. It was perhaps not surprising that 
adiponectin levels did not change given that there was no reduction in measures of 
adiposity. However, the ELISA kits used to assay the serum were designed for the 
analysis of conditioned culture medium from in vitro cultures in which relatively low 
concentrations of adiponectin may be detectable when compared to patient serum. It was 
therefore necessary to dilute the serum significantly to allow for ELISA detection. Serial 
1 in 10 dilutions were performed in order to reduce the possibility of any pipetting error; 
however the results generated revealed wide variations. Although the major contributing 
factor to the variability observed here is likely to be a consequence of the great degree of 
heterogeneity in the differentiating potential of the preadipocytes cultured, minor 
experimental errors remain a possibility.
Although the characteristics of the subjects in both groups were largely representative of 
patients in the general population with Addison’s disease and hypopituitarism, the
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patients recruited into this clinical trial, as indeed in many clinical trials, tended to have 
certain characteristics that may have influenced some of the data generated. Overall they 
tended to be educated, professional (or retired professional) and health aware. I observed 
a small non-significant reduction in body weight, especially in subjects with 
hypopituitarism, even with placebo therapy which is likely a reflection of increased 
motivation as a result of participation in a clinical trial. This may have diluted any 
differences compared with active treatment. Many individuals who enrolled in the study 
were also retired. This likely relates to the fact that individuals at this time are more likely 
to have fewer commitments and are more available to participate in such endeavours.
The numbers studied were too small to allow comparisons based on age, but an 
interesting area for future research might be to examine the effects of DHEA stratified by 
age.
The trial was adequately powered for the vascular primary end points, yet failed to 
demonstrate a benefit on arterial compliance or endothelial function. Nevertheless, the 
data for the entire cohort suggest that DHEA might improve arterial stiffness in the 
brachial tree but this fell just short of statistical significance. Even so, the magnitude of 
effect was not marked, and an increased Tr of 3.7 ms and reduced bPWV of 0.35 m/s, if 
confirmed in other studies, would only be of marginal clinical relevance. This, taken also 
in the context of no changes in Ai or aPWV, suggests that DHEA does not markedly 
affect vascular risk in vivo, at least in the short-term and in physiological replacement 
doses.
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The methods used to determine arterial stiffness in this study appear to be relatively 
robust with little in the way of intra/inter-subject or investigator variability. However, I 
felt that the method of assessing endothelial function using the SphygmoCor system 
demonstrated excessive variability, which is in agreement with more recent comparisons 
of methods for measuring endothelial function [319]. The cause for this was unclear as I 
performed all but two of the endothelial function assessments, the medication used (GTN 
and salbutamol) was within use-by dates and identical equipment was used to both 
capture and analyse the data. Subjects were exposed to the same dose of medication 
although the salbutamol inhalation technique could conceivably have differed. 
Furthermore, the study subjects attended at the same or near same time at each visit and 
were asked to fast overnight; smokers were asked to refrain from smoking on the 
morning of the study visit. These numerous factors will have generated, as far as possible, 
standardised study visit conditions. The variations observed, however, may well have 
prevented the detection of any potential differences in endothelial function following 
DHEA therapy and, were the study to be repeated, a more robust method of determining 
endothelial function such as FMD should, I believe, be sought.
6.4 DHEA Therapy, Safety and Tolerability
Overall the study population tolerated the DHEA supplementation well. There were a few 
cases of the anticipated androgenic side effects experienced in females, although this only 
culminated in one withdrawal from the study. No male participants experienced drug- 
related side effects, although the only adverse event defined as serious occurred in a male 
subject, who coincidentally developed a viral upper respiratory tract infection. No issues
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concerning the safety of DHEA were raised in this study and no alteration in liver 
function tests were observed during the course of the study. There are, however, no long­
term safety data available on DHEA replacement, with the longest trials reporting follow- 
up periods of only two years. Nevertheless, it is possible to conclude that DHEA 
replacement, in the short term at least, is safe to use in this patient group. The potential 
for exacerbating hormone-dependent tumours remains and so its use cannot be advocated 
in cases of confirmed or suspected breast or prostate carcinoma. Furthermore, it might be 
prudent to undertake annual blood tests for prostate specific antigen (males over fifty 
years), liver function tests and full blood count on any one initiated on therapy.
6.5 Mortality and adrenal insufficiency -  possible causes and further implications
The increased cardiovascular mortality observed in both primary and secondary adrenal 
insufficiency is, as far as my study can ascertain, not attributable to DHEA deficiency, 
although the blood pressure effects in the hypopituitarism group may warrant further 
investigation. Possible causes for the adverse mortality rates are discussed in Chapter 2 
and include supraphysiological glucocorticoid replacement and associated illness.
Further analysis of this area of vascular risk and adrenal insufficiency becomes more 
important when one considers the potential ramifications for the 1-3% of the wider 
general population with adrenal insufficiency secondary to chronic glucocorticoid 
therapy. It may therefore be the case that DHEA/DHEAS deficiency is also important in 
patients taking long term steroids, although dissecting DHEA-related from 
glucocorticoid- or condition-related health effects would clearly be difficult.
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6.6 Future in vitro studies
Further studies, particularly assessing the impact on primary culture preadipoctyes would, 
I feel be important though cell line work using more human cell lines would also be 
useful (e.g. CHUB S7 see chapter 2). Preadipocyte extraction optimization could lead to 
greater experimental yield by reducing the possibility of mesothelial cell contamination 
and identify those cells with high differentiating potential. The isolation of PREF-1 
positive preadipocytes would effectively generate an enriched cell population with higher 
and potentially more predicable levels of adipogenic potential though this would require 
larger fat samples.
Assessing the effect of DHEA on mature adipose tissue ex vivo is another area of 
important work that is more readily transferable to the human model and should ideally 
be included in any future planned in vivo/ex vivo studies.
As discussed in chapter 3 many individuals consenting for adipose tissue retrieval had the 
diagnosis of cancer and although these individuals were all having potentially curative 
procedures with no sign of distant metastasis it is possible that this diagnosis in itself had 
an adipose tissue effect. Cachexia is a well recognised feature of advanced cancer but 
there is the possibility of lesser, clinically unapparent effects with small tumour loads. 
Therefore further studies should ideally use adipose tissue samples retrieved from 
individuals undergoing surgical procedures for non-malignant reasons. Due to increased 
use of endoscopic abdominal surgery it is likely that in order for this to be achieved fat 
retrieval via this method will need to be investigated. Fat removal methods for cosmetic 
purposes (liposuction) is another possible source of adipose tissue for experimentation 
but would only provide subcutaneous samples. Bariatric surgery would provide a further
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source of potential primary adipose tissue without the potential confounding factor of 
malignancy.
The possibility that DHEA may be involved in the modulation of BAT is also something 
I feel warrants further evaluation for reasons mentioned previously and positron emission 
tomography could provide an ideal, if expensive tool, with which to do this.
6.7 Future in vivo studies
Most of the data in relation to DHEA in vascular function have been acquired from 
observational, in vitro, or animal model sources. Given the limitations of each of these 
approaches, definitive conclusions on the role of DHEA in vascular protection and 
adrenal failure must rely on well conducted clinical trials. In this context the literature is 
currently sparse and my clinical trial has hopefully helped address this deficiency. The 
trial was conducted to ‘gold standard’ methodology and seemingly had more than 
adequate power to show an effect on arterial stiffness and endothelial function if present. 
Therefore, the failure to demonstrate any positive, or negative, effects of DHEA on 
vascular function is in itself important, and improves the evidence base considerably.
Any future in vivo studies might wish to focus specifically either on subjects with 
hypopituitarism, where we observed some reduction in central systolic blood pressure, or 
females where the reduction in bPWV almost reached significance. However, 
comparatively large numbers of patients would need to included, even with a cross-over 
design and its obvious advantages in terms of statistical power. Given the relative rarity 
of these conditions this might well require multi-centre involvement.
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Finally, refinements in methodology to improve precision should be considered, 
especially in relation to measurement of endothelial function e.g. flow mediated 
dilatation, body composition, visceral fat area by CT or MRI and other cardiovascular 
variables (e.g. echocardiography and carotid intima-media thickness).
6.8 Personal Conclusion
It is my opinion that DHEA replacement in Addison’s disease and hypopituitarism can 
have beneficial anthropometric and vascular effects but these actions are likely to be 
subtle, at least in the short-term. It is conceivable that the individuals that may benefit the 
most are those with the worst metabolic and anthropometric profile at baseline but my 
studies did not have the power to formally test this. Nevertheless, at the current time I do 
not anticipate that my clinical practice will change significantly as a result of this body of 
work; however, this is an area of clinical and biochemical endocrinology that 
undoubtedly requires further inspection.
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Appendices
Appendix chapter II
FRTL-5 cell culture medium
DMEM/Hams F12 (ratio 1:1) (86+86 mLs)
5% calf serum (lOmLs)
1.5% sodium bicarbonate (3mLs)
Pyruvate 2mLs
lOOu/mL Penicillin and lOOpg/mL Streptomycin (4mLs)
TSH 2mLs/Transferrin 2mLs/Insulin 2mLs/ascorbic acid 2mLs/hydrocortisone 2uLs
HACAT cell culture medium
DMEM/Hams F12 (ratio 1:1)
10% foetal calf serum
Loading buffer
10% SDS 2mL 
Glycerol lmL 
0.5M Tris (pH 6.8) lmL 
Distilled water 0.8mL 
0.2% Pyronin Y O.lmL 
(3-mercaptoethanol O.lmL
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Stacking gel (4%)
30% acrylamide 1.3mL 
Distilled water 6.lmL 
0.5M Tris (pH6.8) 2.5mL 
10% SDS lOOuL 
10% APS lOOuL 
TEMED lOuL
10% acrylamide (running) gel
30% acrylamide 3.3mL 
Distilled water 2.92mL 
1M Tris (pH 8.8) 3.75mL 
10% SDS lOOuL 
10% APS lOOuL 
TEMED 5uL
Running buffer
Tris 15g 
Glycine 72g 
SDS 5g
Make up to 1 litre with distilled water
Blotting buffer
0.025M Tris 3.025g
0.182M Glycine 13.66g
Methanol 200mL
Distilled water 800mL
Cool at -20 for 1 hour prior to use
TBS (lOx)
Tris 24.2g
Sodium Chloride 80g
(adjust to pH 7.6 with hydrochloric acid)
Make up to 1 litre with distilled water
TBS-T
TBS (lOx) lOOmL 
Distilled water 900mL 
Tween 20 lmL
Blocking buffer
TBS-T lOOmL
Marvel (powdered milk) 5g
Stripping buffer
0.5M Tris (pH 6.8) 6.25mL 
10% SDS lOmL 
Mercaptoethanol 0.35mL 
Distilled water 33.5mL
Appendix chapter III 
Adipose tissue study Patient information sheet
PATIENT INFORM ATION SHEET Version 2
May 2006
1. Title of study
Physiological and pharmacological modulation of adipose/connective tissue remodelling.
2. Introduction
You are being invited to take part in a research study. Before you decide whether you 
wish to become involved it is important that you understand why the research is being 
done and what it will involve. Please take time to read the following information 
carefully and discuss it with others if you wish.
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.
3. What is the purpose of this study?
A number of hormones can change the amount of fat that is stored in the body. Our 
research group is interested in studying the effects of some of these hormones, including 
thyroid hormones, growth hormone and a hormone called DHEA which is made in the 
adrenal gland, on the function of fat cells in the laboratory. Not all fat reacts in the same 
way. In some parts of the body hormones may cause fat to build up while in others it may 
break down.
In order for us to fully understand how these hormones affect fat cells, we are asking 
people to donate a small sample of their fat to us for our research studies. This sample 
will be obtained during your planned operation. We will measure how the cells grow and 
work in response to treatment with hormones.
We are also interested in studying whether changes in genes controlling growth hormone 
levels and function can have an effect on fat cells. In order for us to test this we will also 
ask you to donate a blood sample for us to analyse your growth hormone genes.
4. Why have I been chosen?
You have been chosen for this study as your surgeon has identified you as someone who 
will be undergoing an operation soon. A total of 100 patients will be studied.
5. Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to 
withdraw at any time and without giving a reason. A decision to withdraw at any time, or 
a decision not to take part, will not affect the standard of care you receive. If you 
withdraw your permission after we have obtained your samples, any stored blood or 
tissue samples that can still be identified as yours will be destroyed if you wish.
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6. What will happen to me if I take part?
A sample, about the size of one sugar cube, will be taken from the fat under your skin 
during your planned surgery. If you are having abdominal surgery we would also plan to 
remove a further sample of fat of the same size from the fat tissue that sits around your 
bowel (called omental or visceral fat). This procedure will not affect your operation scar. 
The fat samples would be used in laboratory experiments for further study. During these 
we would break up the fat and separate it into different cell types. We will measure how 
the cells grow and work in response to treatment with hormones.
The tests to examine your growth hormone genes (called GH1 and GHR) would involve 
us taking an extra sample of blood (equivalent to roughly two tablespoons). We would 
plan to take this sample while you are under anaesthetic during your operation so that you 
do not feel any discomfort.
7. What do I have to do?
There are no lifestyle or dietary restrictions and you can continue your daily activities 
normally. There will be no changes to the way in which you need to prepare for your 
operation and your surgical team will fully instruct you on this as normal. With your 
permission we will check with you and in your records on your previous medical health 
in case you have a medical condition or are taking any medication which may affect our 
ability to analyse your fat cells.
8. What are the possible disdvantages of taking part?
Occasionally patients may experience discomfort (temporary pain, swelling, bruising and 
rarely infection) caused by the collection of blood. Removing a small sample of fat from 
under the skin or from around the bowel is unlikely to cause any additional complications 
to those which could be expected from your type of operation.
The genetic blood sampling will test for variation in your growth hormone genes. These 
changes occur extremely commonly in the general population and can be seen as a 
variation of normal. The samples will be fully anonymised and the results of these genetic 
tests will have no implications for you in terms of inherited risk, reproductive decisions 
or insurance status.
9. What are the possible benefits of taking part?
The study may provide us with important information in identifying how hormones affect 
fat cell function. While there are unlikely to be any direct benefits to you, we hope that 
the results of these studies may help in the future treatment of patients with weight- 
related conditions such as obesity and diabetes.
10. What if there is a problem?
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions (Dr Aled Rees 02920 
745002). If you remain unhappy and wish to complain formally, you can do this through 
the NHS Complaints Procedure. Details can be obtained from the hospital.
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You are unlikely to be harmed as a result of taking part in this research project, but if you 
are you should be aware that there are no special compensation arrangements. If you are 
harmed due to someone’s negligence, then you may have grounds for a legal action but 
you may have to pay your legal costs. Regardless of this, if you wish to complain, or have 
any concerns about any aspect of the way you have been approached or treated during the 
course of this study, the normal National Health Service complaints mechanisms should 
be available to you.
11. Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be 
kept strictly confidential. Any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it.
With your permission your GP will be informed of your participation in this study.
If you join the study, some parts of your medical records and the data collected for the 
study may be looked at by the research team, by representatives of regulatory authorities 
and by authorised people from the Cardiff and Vale NHS Trust to check that the study is 
being carried out correctly. All will have a duty of confidentiality to you as a research 
participant and nothing that could reveal your identity will be disclosed outside the 
research site. Our procedures for handling, processing, storage and destruction of data 
are compliant with the Data Protection Act 1998.
12. What will happen to any samples I give?
After the sample of fat has been obtained at surgery the research doctors will immediately 
freeze this sample and store it for later analysis, or break it up and grow the fat cells in 
the laboratory. The blood samples will be used to test your growth hormone genes. Both 
the fat and blood samples will be stored securely in the Section of Endocrinology at the 
University Hospital of Wales (Room 168, 2nd Floor). The research investigators, Dr Aled 
Rees and Dr Marian Ludgate, will act as the day-to-day custodians for these samples. 
Only Dr Rees and Dr Ludgate, and immediate members of their research team will have 
access to the use of these samples. In addition, all the samples will be coded and 
anonymised such that your personal details will not be identifiable. We propose to store 
the fat and genetic samples for up to 15 years. After this time the samples will be 
destroyed by incineration.
It is possible that we may wish to use your fat sample for future studies looking at how 
other hormone systems could affect fat cell function. If this is the case then a further 
application will be made to the Research Ethics Committee for consideration. Similarly, 
we may wish to conduct genetic studies on genes other than the growth hormone system 
in the future. If this is the case then this will also be submitted to an Ethics Committee for 
consideration. The results of these tests done for research purposes are unlikely to have 
any direct clinical implications for you. It is possible that these studies may be carried out 
by researchers other than Dr Rees or Dr Ludgate, including researchers working for 
commercial companies.
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There is little prospect that the current studies will have any commercial significance but 
if future information from our research using your tissue samples shows any likelihood of 
commercial benefit, such as the development of a new treatment or medical test, then you 
would not benefit financially.
13. What will happen to the results of the research study?
The results of the research study will be prepared for publication in appropriate medical 
journals together with presentation at medical conferences. Patients participating in the 
study will be able to obtain a copy of the results after they have been published in the 
relevant joumal(s). Patients will not be identified in any report/publication.
14. Who is organising and funding the research?
The study is being organised by Dr Aled Rees and Dr Marian Ludgate in the Section of 
Endocrinology. Funding for the study is provided from the Section of Endocrinology and 
the doctors conducting the research are not being paid for including and looking after 
patients in the study, nor will they be able to sell for profit any samples that are collected.
15. Who has reviewed the study?
The study has been reviewed by the Cardiff and Vale NHS Trust Research and 
Development Office and by the South East Wales Local Research Ethics Committee.
16. Contact for further information
Should you have any further questions or queries regarding this research study, then 
please do not hesitate to contact me on 029 20745002. I can also be contacted via email 
(reesda@cf. ac. uk).
Thank you for considering taking part and taking time to read this sheet.
Aled Rees
Principal Investigator/Senior Lecturer in Endocrinology
You will be given a copy of this Patient Information Sheet and a signed consent form to 
keep
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Adipose tissue study consent from
CONSENT FORM
Version 2, May 2006.
Thank you for reading the information about our research project. If you would like 
to take part, please read and sign this form.
Patient Identification Number for this study:
Title of project: Physiological and pharmacological modulation of adipose/connective 
tissue remodelling
Name of researchers: Dr Aled Rees and Dr Marian Ludgate
Contact details for research team: Centre for Endocrine and Diabetes Sciences, 
University Hospital of Wales, Heath Park, Cardiff CF14 4XN. Telephone: 02920 742182.
Please 
initial boxes
1 .1 have read the attached information sheet on this project, dated May 
2006 (version 2), and have been given a copy to keep. I have been able to ask 
questions about the project and I understand why the research is being done 
and any risks involved.
2 .1 agree to give a sample of fat for research in this project. I understand 
how the sample will be collected, that giving a sample for this research is 
voluntary and that I am free to withdraw my approval for use of the sample 
at any time without giving a reason and without my medical treatment or 
legal rights being affected.
3 .1 give permission for someone from the research team to look at my 
medical records to get information on my previous medical health. I 
understand that the information will be kept confidential.
4 .1 understand that I will not benefit financially if this research leads to the 
development of a new treatment or medical test.
5 .1 know how to contact the research team if I need to, and how to get 
information about the results of the research.
6 .1 consent to my GP being informed of my participation in the study.
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7. Consent for storage and use in possible future research projects
I agree that the sample I have given and the information gathered about 
me can be stored by Dr Aled Rees/Dr Marian Ludgate at the Centre for 
Endocrine and Diabetes Sciences, School of Medicine, Cardiff University for 
possible use in future projects, as described in the attached information sheet. 
I understand that some of these projects may be carried out by researchers 
other than Dr Aled Rees/Dr Marian Ludgate who ran the first project, 
including researchers working for commercial companies.
8. Consent for genetic research
A. I give permission for growth hormone 1 (GH1) and growth hormone 
receptor (GHR) genotyping to be carried out on the samples I give, as part of 
this project
B. I understand that the project/future research using the samples I give 
may include genetic research aimed at understanding the genetic influences 
on fat cell regulation but that the results of these investigations are unlikely 
to have any implications for me personally.
Name of patient Date Signature
(BLOCK CAPITALS)
Name of person taking consent Date Signature
(if different from researcher)
Name of Researcher Date Signature
Would you like to be sent information about the progress of the project?
□ □
Yes No
Thank you for agreeing to participate in this research
s
1 copy for patient; 1 for researcher; 1 to be kept with hospital note
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Appendix chapter IV
DHEA study Patient information sheet
Adrenal insufficiency and vascular dysfunction.
PATIENT INFORMATION SHEET 
Version 4, September 2005.
1. Title of study
A randomised, double blind, placebo-controlled, cross-over study of the effects of 
dehydroepiandrosterone replacement on vascular function in patients with primary and 
secondary adrenal insufficiency.
2. Introduction
You are being invited to take part in a clinical research study. Before you decide whether 
you wish to become involved it is important that you understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully and discuss it with others if you wish. Please do not hesitate to ask us if there is 
anything that is not clear or if you would like more information. Take time to consider 
whether or not you would wish to take part.
Thank you for reading this.
3. What is the purpose of this study?
Adrenal insufficiency or failure is a condition resulting in low or absent steroid hormone 
production by the adrenal glands. This can arise as a result of a problem in the adrenal 
glands themselves where it is termed primary adrenal insufficiency (often called 
Addison’s disease), or from a failure of the pituitary glands where it is called secondary 
adrenal insufficiency. Treatment of these conditions requires replacement of steroid 
hormones, such as hydrocortisone or prednisolone, and, on occasions, a class of 
hormones called mineralocorticoids, such as fludrocortisone. However, recent studies 
have shown that replacing a third hormone called dehydroepiandrosterone (or DHEA in 
short) can have positive effects on mood and well-being. There have been no studies 
though on the effects of replacing DHEA on the function of blood vessels in adrenal 
failure. This may be an important area to study as research in elderly and middle-aged 
people without adrenal disease has shown that low levels of DHEA may increase the risk 
of heart disease. Another study recently has shown that treating healthy middle-aged men 
with DHEA improves the function of their blood vessels.
We wish to study the effects of replacing DHEA in adrenal insufficiency on blood vessel 
function. This study will involve four visits to the Endocrinology department at the Heath 
hospital and will last for a total of 32 weeks.
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4. Why have I been chosen?
You have been chosen for this study as your doctor has identified you as having either 
Addison’s disease (primary adrenal insufficiency) or pituitary disease causing secondary 
adrenal insufficiency, and you have been on stable hormone replacement treatment for 
some time. A total of 40 patients will be studied, 20 of whom will have primary adrenal 
insufficiency and 20 will have secondary adrenal insufficiency.
5. Do I have to take part?
It is up to you to decide whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive.
6. What will happen to me if I take part?
The study will last for a total of 32 weeks and you will be asked to attend the 
Endocrinology Investigation unit on 4 separate occasions. Each of these visits will last 
approximately 2 hours.
In order to know whether DHEA changes blood vessel function we need to make 
comparisons. DHEA will be compared in this study with a placebo tablet. A placebo is a 
dummy treatment such as a pill which looks like the real thing but is not. It contains no 
active ingredient.
People will be put into two groups and then compared. The groups are selected by a 
computer which has no information about the individual i.e. by chance (or randomised). 
Half the patients will be put into group A and will receive DHEA treatment for 12 weeks. 
The other half will be put into group B and will receive placebo treatment. These groups 
will be compared.
Neither you nor your doctor will know in which treatment group you are (although your 
doctor is able to find out if he/she needs to do so). This is to make sure that the results 
cannot be influenced in any way.
At the end of 12 weeks of treatment you will have a break of 8 weeks before taking the 
other treatment for a further 12 weeks (placebo treatment if you received DHEA for the 
first part of the study and DHEA if you received placebo initially). The break of 8 weeks 
between treatments will ensure that the first drug is cleared from your body before you 
start the new treatment.
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A summary of what will happen and when the study visits will take place is shown in the 
following flowchart:
--------------------------------------------------►H------------------------- ►U----------------------------------------------------------- ►
First treatment Wash-out Second treatment
Group A
DHEA DHEA
PlaceboGroup B Placebo
12 weeks 8 weeks 12 weeks
Visit 2 Visit 4Visit 1 Visit 3
On each visit the measurements performed are designed to measure the stiffness of your 
blood vessels. This is known as Pulse Wave Analysis. The techniques that we use are 
completely painless and ‘non-invasive’. The main equipment we use is called a 
“Sphygmocor” machine. This consists of a small pencil-like probe placed over the wrist, 
which measures the pulse’s waveform. During the measurements you will also be asked 
to take a puff of a salbutamol inhaler (like that used in asthma) and a GTN tablet under 
your tongue (like that used in angina). Both these drugs act to change the shape of the 
pulse waveform that we measure. Both drugs are safe and are unlikely to produce any 
side effects although you may experience a slight headache after the GTN. We would 
then use the “Sphygmocor” machine to measure something called Pulse Wave Velocity. 
This looks at how fast your pulse travels along blood vessels. It is done in the same way 
by putting a pencil-like probe on the skin. This time it is put on the skin over three 
different arteries, at the wrist (the radial artery), in the neck (the carotid artery) and at the 
top of the leg (the femoral artery). Whilst this is being done you are put an ECG machine 
so that we can time the pulse with your heart beat.
During each visit we will also take blood samples (approximately three tablespoons) to 
check your hormones, cholesterol, insulin, clotting factors and CRP (a non-specific 
marker of inflammation in the body). Your height, weight and blood pressure will also be 
measured at each visit as well as something called Bioimpedance. This is measured using 
a specialised weighing scale and measures levels of body fat and body muscle.
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7. What do I have to do?
It is important that you take your regular medication in the normal way without altering 
the dose or timing of these during the course of the study, though you will be permitted to 
increase the dose of your steroid tablets for a short while if you developed an illness 
coincidentally. You should inform us of any dose adjustments.
You will be asked to take the study medication regularly for the duration of the study.
The tablets will be taken once a day.
There is no lifestyle or dietary restrictions and you can continue your daily activities 
normally. We request that you report any illnesses to us as they may influence the timing 
of the test visits.
For women, you should inform us immediately if you become pregnant.
For each of the study visits, we ask that you attend the Endocrine Investigation unit at 9 
o’clock in the morning having fasted from midnight the previous night. You can drink 
water freely.
8. What is the drug that is being tested?
DHEA is a naturally occurring hormone that is produced by the adrenal glands and many 
patients with adrenal insufficiency are now taking this treatment on a regular basis. A 
dose of 50 mg is being used in this study as this is the dose that restores the levels of 
DHEA in the blood to normal. The drug comes in tablet form and we will provide you 
with a card to carry explaining the details of this trial. You should carry this with you at 
all times.
9. What are the side effects of DHEA?
DHEA is a naturally occurring hormone and is a safe, established treatment in adrenal 
insufficiency. No major side effects have been reported with this treatment. However, a 
small number of women have experienced minor acne in some studies and we will ask 
you to report any side effects to us at each study visit. There have been very rare cases of 
minor abnormal liver tests also reported and we will be monitoring these. You will be 
told if any new side effect is found as a result of this study or any other studies using 
DHEA.
If you become in any way concerned you should contact Dr Sam Rice on telephone 
number 02920 746357 or 07866 741 543.
10. What are the possible disadvantages and risks of taking part?
DHEA can cause some minor acne in women and abnormal liver tests have been 
recorded rarely in patients taking DHEA. Other than possible discomfort (temporary pain, 
swelling, bruising and rarely infection) caused by the collection of blood, no other side 
effects are anticipated from the study procedures.
The risks to an unborn human foetus or a breastfed child from DHEA are not known. 
Women who are pregnant or breastfeeding a child may therefore not participate in this 
trial, neither should women who plan to become pregnant during the study. Women who 
are at risk of pregnancy will have a pregnancy test before taking part in the_study.
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Women who could become pregnant must use an effective contraceptive during the 
course of this study. Any woman who finds that she has become pregnant while taking 
part in the study should immediately tell her research doctor.
11. What are the potential benefits of taking part?
Some patients may experience improved mood and well-being. However, this cannot be 
guaranteed. The information we get from this study may help us to treat future patients 
with adrenal insufficiency better.
12. What if new information becomes available?
Sometimes during the course of a research project, new information becomes available 
about the drug that is being studied. If this happens, your research doctor will tell you 
about it and discuss with you whether you want to continue in the study. If you decide to 
withdraw, your research doctor will make arrangements for your care to continue. If you 
decide to continue in the study you will be asked to sign an updated consent form.
Also, on receiving new information your research doctor might consider it to be in your 
best interests to withdraw you from the study. He/she will explain the reasons and arrange 
for your care to continue.
13. What happens when the research study stops?
If you feel you would wish to continue DHEA therapy at the end of the study you will be 
able to discuss this with your Endocrinologist.
14. What if something goes wrong?
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it. Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms should be available to you.
15. Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be 
kept strictly confidential. Any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it.
With your permission your GP will be informed of your participation in this study.
16. What will happen to the results of the research study?
The results of the research study will be prepared for publication in appropriate medical 
journals together with presentation at medical conferences. Patients participating in the 
study will be able to obtain a copy of the results after they have been published in the 
relevant joumal(s). Patients will not be identified in any report/publication.
Patients will be able to discover which arm of the study they were in if they so wish, but 
only after the study has been completed in its entirety.
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17. Who is organising and funding the research?
The study is being organised by Dr Aled Rees in the Section of Endocrinology (the 
Principal Investigator) and Dr Sam Rice (Clinical Research Fellow). Funding for the 
study is provided from the Section of Endocrinology and the doctors conducting the 
research are not being paid for including and looking after patients in the study.
18. Who has reviewed the study?
The study has been reviewed by the Cardiff and Vale NHS Trust Research and 
Development Office and by the South East Wales Local Research Ethics Committee.
19. Contact for further information
Should you have any further questions or queries regarding this research study, then 
please do not hesitate to contact Dr Aled Rees on 029 20745002 or Dr Sam Rice on 029 
20746357 . If an emergency should arise during the study Dr Rice can be contacted on 
07866 741 543.
Thank you for taking part in this study.
Dr Aled Rees
Lecturer in Endocrinology
You will be given a copy of this Patient Information Sheet and a signed consent form to 
keep.
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DHEA study consent form
Adrenal insufficiency and vascular dysfunction.
Patient Identification Number for this trial:
CONSENT FORM
Version 4, September 2005.
Title of project: A randomised, double blind, placebo-controlled, cross-over study of the 
effects of dehydroepiandrosterone replacement on vascular function in patients with 
primary and secondary adrenal insufficiency
Name of Researchers: Dr Aled Rees, Dr Sam Rice
Please initial box
1.1 confirm that I have read and understood the information sheet dated 
September 2005 (version 4) for the above study and have had the 
opportunity to ask questions.
2 .1 understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected
3 .1 understand that sections of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to 
my taking part in research. I give permission for these individuals to have 
access to my records.
4. Do you consent to your GP being informed of your participation in the 
Study.
5. If I am at risk of pregnancy I consent to a pregnancy test.
6 .1 agree to take part in the above study.
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Name of patient Date Signature
Name of person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
1 copy for patient; 1 for researcher; 1 to be kept with hospital notes
Endothelial function assessment protocol 
Run in
Time Augmentation 
index a
Augmentation 
index b
+ 5 minutes Blood pressure
Heart rate
+ 7 minutes Augmentation
Index
+ 15 minutes Blood pressure
Heart Rate
+17 minutes Augmentation
index
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PART B (GTN -  endothelial independent vasodilation)
A 500mcg GTN tablet is placed under the tongue and the stopwatch is started
Time Augmentation 
index a
Augmentation 
index b
+1 minute Blood pressure
Heart rate
+3 minutes 
REMOVE GTN
Augmentation
Index
+5 minutes Augmentation
Index
+7 minutes Blood pressure
Heart rate
+10 minutes Augmentation
Index
+12 minutes Blood pressure
Heart rate
+15 minutes Augmentation
Index
+17 minutes Blood pressure
Heart rate
+20 minutes Augmentation
Index
+25 minutes Blood pressure
Heart rate
+28 minutes Augmentation
Index
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PART C (SALBUTAMOL -endothelial independent vasodilation)
Patient practices breathing in and holding breath using spacer device. 2 puffs of 
salbutamol are delivered into device, patient takes inhales maximally and holds 
breath for 10 seconds then exhales, a further 2 puffs of salbutmol are delivered and 
the breathing manoeuvres are repeated a second time. The stopwatch is started
following the final exhalation.
Time Augmentation 
index a
Augmentation 
index b
+2 minutes Blood pressure
Heart rate
+5 minutes Augmentation
Index
+7 minutes Blood pressure
Heart rate
+10 minutes Augmentation
Index
+12 minutes Blood pressure
Heart rate
+15 minutes Augmentation
Index
+17 minutes Blood pressure
Heart rate
+20 minutes Augmentation
Index
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